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ABSTRACT OF DISSERTATION

DIET-INDUCED OBESITY:
DOPAMINERGIC AND BEHAVIORAL MECHANISMS
AS OUTCOMES AND PREDICTORS

Obesity and drug abuse share common neural circuitries including the
mesocoticolimbic and striatal dopamine reward system. In the current study, a rat model
of diet-induced obesity (DIO) was used to determine striatal dopamine function,
impulsivity and motivation as neurobehavioral outcomes and predictors of obesity. For
the outcome study, rats were randomly assigned a high-fat (HF) or a low-fat (LF) diet for
8 wk. Following the 8-wk HF-diet exposure, rats were segregated into obesity-prone and
obesity-resistant groups based on maximum and minimum body weight gain,
respectively, and neurobehavioral outcomes were evaluated. For the predictor study,
neurobehavioral antecedents were evaluated prior to an 8-wk high-fat diet exposure and
were correlated with subsequent body weight gain. Striatal D2 receptor density was
determined by in vitro kinetic analysis of [3H]raclopride binding. DAT function was
determined using in vitro kinetic analysis of [3H]dopamine uptake, methamphetamineevoked [3H]dopamine overflow and no net flux in vivo microdialysis. DAT cell-surface
expression was determined using biotinylation and Western blotting. Impulsivity and
food-motivated behavior were determined using a delay discounting task and
progressive ratio schedule for food-reinforcers, respectively. Relative to obesityresistant, obesity-prone rats exhibited 18% greater body weight, 42% lower striatal D2
receptor density, 30% lower total DAT expression, 40% lower in vitro and in vivo DAT
function, 45% greater extracellular dopamine concentration, and 2-fold greater
methamphetamine-evoked [3H]dopamine overflow. Obesity-prone rats exhibited higher
motivation for food, but were less impulsive relative to obesity-resistant rats.
Neurobehavioral antecedents of DIO included greater motivation for high-fat reinforcers
in rats subsequently shown to be obesity-prone relative to obesity-resistant. Impulsivity,
DAT function and extracellular dopamine concentration did not predict the DIOphenotype. Thus, motivation for food is linked to both initiation and maintenance of
obesity. Importantly, obesity results in decreased striatal DAT function, which may
underlie the maintenance of compulsive food intake in obesity.

KEYWORDS: Diet-induced obesity, dopamine transporter, impulsivity, motivation,
striatum
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Chapter One
Overall Introduction

I.

Obesity: A global epidemic

Obesity is a complex medical condition that is characterized by excessive,
abnormal fat accumulation as a result of increased intake of energy-dense foods
and decreased physical activity (World health organization (WHO) factsheet N0
311). Body mass index (BMI), a proportion of body weight to height, is commonly
employed to classify overweight and obese individuals and has been considered
as a reliable indicator of body fat (Mei et al., 2002; Flegal et al., 2009). Individuals
with BMI greater than or equal to 25 are classified as overweight and those with
BMI greater than 30 are classified as obese.

Over the past two decades, the prevalence of obesity has increased in the
United States (US) and worldwide and has contributed to serious health and
economic consequences. The dramatic rise in obesity has been attributed to
genetic susceptibility and environmental factors that include availability of highenergy dense foods and sedentary life style that lacks adequate physical activity.
The prevalence of obesity in the US during 2009-2010 was 35.5% among adult
men, 35.8% among adult women, and approximately 17% among children and
adolescents, as evidenced by reports from the National Health and Examination
Survey (NHANES). Furthermore, reports from the Center for Disease Control and
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Prevention’s Behavioral Risk Factor Surveillance System (BRFSS) indicate that
in 2012, all states in the US had a prevalence of obesity greater than 20%, and
12 states (including Kentucky) had a prevalence of more than 30%. The current
trends in obesity in the US have led to the estimation that total healthcare costs
attributable to obesity could reach $861 to $957 billion by 2030, which would
account for 16-18% of total US health expenditures. Obesity was previously
recognized as a health problem only in developed countries. However, the
prevalence of overweight and obesity is evident in developing countries as well.
Importantly, WHO reports indicate that in 2010, around 43 million children were
overweight, out of which approximately 35 million overweight children lived in
developing countries. Based on the current trends, WHO predicts that by 2015,
about 2.3 billion adults will be overweight and over 700 million people will be
classified as obese.

Metabolic syndrome is a constellation of metabolic abnormalities that
increases the risk for cardiovascular diseases and other severe health problems
including type-2 diabetes and stroke (Eckel et al., 2005). Obesity significantly
contributes to the metabolic syndrome. Specifically, abdominal adiposity is
known to result in metabolic abnormalities that include; hyperglycemia,
dyslipidemia and hypertension (Mokdad et al., 2001; Bloomgarden, 2002;
Montani et al., 2002; Grundy et al., 2005). Compared to non-obese women,
obese women exhibit a greater probability (~ 60-fold) of being diagnosed with
type-2 diabetes (Colditz et al., 1990). Further, overweight and obese men were
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shown to exhibit increased risk for ischemic and hemorrhagic stroke (Kurth et al.,
2002).

In addition to the metabolic syndrome, obesity is also shown to increase
the risk for certain types of cancer. The National Cancer Institute (NCI)
Surveillance, Epidemiology, and End Results data in 2007 estimated that in the
US, about 4% of cancer cases in men and 7% in women were due to obesity.
Importantly, the contribution of obesity to cancer was as high as 40% for cancers
like, endometrial and esophageal adenocarcinoma (NCI, 2012). The current
trend in obesity is estimated to lead to an additional 500,000 cases of cancer in
the US by 2030. Thus, there is compelling evidence that demonstrates metabolic,
cardiovascular and cancer-related risks associated with obesity. The escalating
rates of obesity and associated co-morbidities necessitate effective long term
pharmacotherapy to treat this complex medical condition.

II.

Homoeostatic regulation of energy balance

Obesity results from a long-term positive energy balance such that there is
increased food intake and decreased energy expenditure (Spiegelman and Flier,
2001). Homeostasis involves the maintenance of equilibrium by adjusting
physiological processes. Importantly, homeostatic energy balance involves
mechanisms that adjust food intake and energy expenditure to maintain a body
weight set point. Regulation of appetite and body weight involves a complex
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interaction between multiple neural systems, peripheral energy stores and
external cues that influence food availability and palatability. A fundamental
overview of both homeostatic and higher brain reward centers that regulate food
intake and metabolism is provided in sections II, III and IV of this chapter.

II a. Peripheral signals: Satiety, hunger and adiposity

Maintenance of energy balance involves extensive coordination between
brain and peripheral mechanisms. In order to establish energy balance,
homeostatic neuronal circuits in the central nervous system (CNS) integrates two
major peripheral factors that are triggered upon food ingestion. These include: a)
satiety and hunger; b) adiposity. These peripheral factors can be further
classified into episodic and tonic factors (Halford and Blundell, 2000). Episodic
factors are triggered upon recent food consumption and constitute both satiety
and hunger factors. Tonic factors include adiposity factors that arise from tissue
stores to indicate the depletion or repletion of energy stores and thereby regulate
food intake based on the state of body’s energy stores.

Satiety. Satiety is a state of being full after eating such that hunger and
eating behaviors are consequently inhibited (Blundell, 1991). Satiety factors that
inhibit appetite include pre-absorptive stomach distension and post absorptive
fuel metabolism (Harrold et al., 2012). Chemicals released by the gastrointestinal
tract during the process of food digestion also contribute towards satiety signals.
Peripheral hormones that regulate satiety include; cholecystokinin (CCK),
4

glucagon-like peptide-1 (GLP-1), peptide YY (PYY) and amylin. CCK is a peptide
hormone released from the I-cells of the proximal intestinal tract following
detection of fat and protein in the gut (Liddle et al., 1985). CCK is derived from
the pro-CCK gene through post-translational modification which creates a
number of biologically active peptides that differ in the length of amino acids (4 to
83 amino acids), the predominant molecular form being CCK-58 (Rehfeld et al.,
2001). CCK-induced satiety signaling is mediated via CCK receptors expressed
in the intestinal tract, brain stem and the hypothalamus (Ballinger et al., 1995;
Blevins et al., 2000; Degen et al., 2001). GLP-1 is a peptide hormone that is
synthesized by the L-cells of distal small intestine and is released in response to
carbohydrate and fat digestion (Lavin et al., 1998; Thomsen et al., 1999). Two
forms of GLP-1 that are found in the circulatory system include; GLP-1(7–36)
amide and GLP-1(7–37) amide, the predominant variant being GLP-1(7–36)
(Marks et al., 1991). GLP-1 is known to mediate appetite control via insulin
release, glucagon inhibition, absorption and metabolism of macronutrients
(Naslund et al., 1999; Flint et al., 2001). GLP-1 receptors are widely expressed in
the CNS and peripheral tissues (Bullock et al., 1995; Gutzwiller et al., 2004). PYY
is a 36-amino acid peptide hormone released from the L-cells of distal small
intestine in response to the detection of fatty acids, fibers and bile in the gut
(Onaga et al., 2002). PYY receptors are widely expressed in the CNS. In addition
to appetite control, PYY is also shown to increase energy expenditure (Sloth et
al., 2007). Amylin is a 37-amino acid peptide hormone that is released along with
insulin by the pancreatic β-cells in response to high-blood glucose levels and is
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shown to reduce both food intake and body weight via actions at the level of the
brain stem (Rushing et al., 2001).

Hunger. Hunger is a physiological response to the orosensory effects of
food stimuli, as well as to the decline in blood glucose levels that involves the
motivation to seek and consume food (Melanson et al., 1999; Harrold et al.,
2012). Importantly, glucose availability is known to influence the expression of
orexigenic and anorexigenic peptides, thereby regulating food intake (Levin,
2006). Ghrelin is a 28-amino acid appetite-stimulating peptide hormone that is
found in the highest concentrations in the gut (Korbonits and Grossman, 2004).
Additionally, hypothalamic neurons are shown to secrete ghrelin. Ghrelin crosses
the blood brain barrier and initiates feeding via ghrelin receptors expressed in the
hypothalamus (Cummings, 2006; Harrold et al., 2008). Ghrelin levels are
dependent on nutritional status such that peak ghrelin concentrations are found
prior to meal initiation (Cummings et al., 2001). Ghrelin levels decrease upon
food consumption and the postprandial ghrelin suppression is shown to be
proportional to ingested caloric load (Callahan et al., 2004). Compared to lean
control, obese individuals are more sensitive to the appetite-stimulating effects of
ghrelin (Druce et al., 2005).

Adiposity. Three major adiposity factors that serve as feedback signals
and are modulated by food intake and adipose tissue mass include; leptin, insulin
and adiponectin. Leptin, a product of leptin gene (Lep(ob)), is a protein of
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molecular weight 18,000, that contains a signal sequence which is cleaved to
produce the mature leptin hormone of molecular weight 16,000 (Zhang et al.,
1994). Leptin is secreted by adipocytes in proportion to fat mass and is known to
decrease food intake and increase energy expenditure by acting via neuronal
leptin receptors in multiple brain regions (Maffei et al., 1995; Porte et al., 2002).
Leptin-induced decreases in food intake and body weight are predominantly
mediated by hypothalamic leptin receptors (Fei et al., 1997; Elmquist et al., 1998;
Myers et al., 2008). Insulin, a metabolic hormone synthesized in the pancreas by
the β-cells of the islets of Langerhans, also increases proportionally with
adiposity (Woods et al., 1974). Insulin is a polypeptide hormone that is composed
of two peptide chains of 21 (A) and 30 (B) amino acids, which are linked by two
disulfide bonds (Brange and Langkjoer, 1993). Similar to leptin, insulin is also
shown to decrease food intake and body weight via insulin receptors in the
hypothalamus (Menendez and Atrens 1991). Adiponectin, a 244-amino acid long
polypeptide, is another adipocyte-derived protein that is shown to decrease body
weight and lipid levels and facilitate insulin action (increases insulin sensitization)
(Berg et al., 2001; Qi et al., 2004; Kadowaki and Yamauchi, 2005).

Collectively, energy homeostasis involves the central integration of
peripheral hormonal signals that include; short-term, meal-related afferent satiety
and hunger signals from the gut (CCK, GLP-1, PYY, amylin and ghrelin) and
longer-term afferent signals from the adipocytes (leptin and adiponectin) and the
pancreatic β-cells (insulin).
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II b. Brain circuits involved in homoeostatic regulation

Energy homeostasis is known to be regulated by neuronal circuits in the
hypothalamus and the brain stem. Importantly, these brain circuits integrate
signals from circulating hormones, sensory factors that include smell, taste and
sight of food; as well as peripheral factors that are governed by ingestion of food,
absorption and metabolism.

Hypothalamus. Multiple neuronal circuits within the hypothalamus are
implicated in the primary regulation of energy homeostasis (Wynne et al., 2005;
Morrison and Berthoud, 2007). Specifically, the arcuate nucleus of the
hypopthalamus (ARH) is known to stimulate and inhibit food intake via two
distinct neuronal populations. A sub population of neurons within the ARH
expresses orexigenic peptides, neuropeptide Y (NPY) and agouti-related protein
(AgRP). Activation of the NPY/AgrP neurons increases food intake and
decreases energy expenditure, as evidenced by brain infusion studies conducted
in rats (Broberger et al., 1998, Hahn et al., 1998). NPY infusion into the
hypothalamus was shown to increase feeding and delay the onset of satiety
(Stanley and Libowitz, 1985). Central infusion of AgRP increased food intake and
body weight and also reversed leptin-induced inhibition of food intake and body
weight (Ebihara et al., 1999).
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In contrast, pro-opiomelanocortin (POMC) neurons in the ARH produce
anorexigenic peptides, α- melanocyte stimulating hormone (α-MSH) and cocaine
and amphetamine related transcript (CART). α-MSH, a 13-amino acid peptide, is
generated from the precursor hormone, POMC (Eipper and Mains, 1980). CART
is a neuropeptide that also serves as a neurotransmitter (Lambert et al., 1997). In
particular, CART peptides (55–102 aminoacids) have been implicated in the
regulation of energy homeostasis (Murphy, 2005). Activation of POMC neurons
inhibits food intake and increases energy expenditure, as demonstrated by brain
infusion and knockout studies in rodents (Elias et al., 1998a; Kristensen et al.,
1998). The anorexigenic effects of α-MSH are mediated via MC3R and MC4R
receptors expressed in the lateral ARH (Watson and Akil, 1979). MC4R null mice
exhibit hyperphagia and are obese (Huszar et al., 1997). MC3R null mice are
shown to develop obesity regardless of increases in food intake, suggesting the
role of MC3R in fat metabolism (Chen et al., 2000). Interestingly, AgRP is known
to selectively antagonize MC3R and MC4R (Ollmann et al., 1997). Mutations of
MC3R/MC4R are shown to be associated with morbid obesity in humans (Krude
et al., 1998; Yeo et al., 1998). In rats, central administration of CART and antiCART antibodies is shown to decrease and increase food intake, respectively
(Lambert et al., 1997). Also, CART knockout mice exhibit increased body weight
when fed a high-fat (HF) diet (Asnicar et al., 2001).

Extensive reciprocal connections exists between the ARH and other
hypothalamic regions including the paraventricular nucleus (PVN), dorsomedial
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hypothalamus (DMH), lateral hypothalamus (LHA), perifornical area and ventral
medial hypothalamus (VMH) (Elias et al., 1998b; Kalra et al., 1999). These brain
regions receive projections from NPY/AgRP neurons and POMC neurons in the
ARH and also comprise of second-order neurons that express neuropeptides
involved in energy homeostasis. Orexigenic peptides, termed as orexins or
hypocretins (orexin-A (33 amino acid residues) and orexin-B (28 amino acid
residues)), are excitatory neuropeptides that are synthesized in the
LHA/perifornical area and are implicated in feeding behavior (De Lecea et al.,
1998; Sakurai et al., 1998). Acute central administration of orexins is shown to
promote hyperphagia and delay the onset of satiety in rats (Rodgers et al., 2002).
Further, orexin knockout mice exhibit narcolepsy, implicating the role of orexins
in arousal (Chemelli et al., 1999). Cell bodies within the LHA consist of another
potent orexigenic peptide, melanin-concentrating hormone (MCH). Chronic
central infusion of MCH was shown to increase food intake and body weight in
rats (Qu et al., 1996). Neurons of the PVN express anorexigenic peptides that
include; thyrotropin-releasing hormone (TRH), corticotrophin-releasing hormone
(CRH) and brain derived neurotrophic factor (BDNF). TRH is a tripeptidal
hormone whereas CRH is a 41-amino acid peptide hormone and
neurotransmitter (Fekete et al, 2000; Sarkar and Lechan, 2003). The role of brain
BDNF in energy homeostasis comes from genetic mutation studies in which
BDNF conditional mutant mice exhibited increased body weight and increased
food intake compared to control (Rios et al., 2001). Further, BDNF infusion into
the VMH of mice with deficient MC4R signaling suppressed hyperphagia and
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excessive weight gain in response to a HF-diet (Xu et al., 2003). This result lead
to the interpretation that BDNF may regulate energy balance downstream of
MC4R.

Brain stem. The nucleus of the solitary tract/area postrema (NST/AP) in
the medulla of the brain stem is also involved in integrating afferent signals and
relaying them further to other regulatory centers in the CNS including the ARH
(Harrold et al., 2012). Peripheral gustatory signals that include gastric distension
as well as signals (CCK) involved in meal termination are integrated in the NST
via receptors on the vagal nerve (Berthoud et al., 2002). Further, destruction of
NST is shown to result in elevated consumption of palatable foods (Hyde and
Miselis, 1983). Receptors for leptin, ghrelin, amylin and NPY and for components
of the melanocortin system have also been identified in the brainstem (Fodor et
al., 1994; Mountjoy et al., 1994; Dumont et al., 1998; Berthoud, 2002; Grill and
Kaplan, 2002).

Monoamine neurotransmitters that regulate food intake and that are
synthesized in brain stem areas include; norepinephrine and serotonin (5HT)
(Schwartz et al., 2000). Norepinephrine is synthesized predominantly in the
dorsal vagal complex and the locus coeruleus. Norepinephrine synthesizing
neurons project to the spinal cord, hypothalamus, thalamus and cortex.
Importantly, increased norepinephrine in the PVN and LHA is shown to promote
hyperphagia and body weight gain in rats (Oltmans, 1983; Leibowitz et al., 1984).
The 5HT system consists of cell bodies in the caudal brainstem that project
11

widely throughout the brain. 5HT-receptor signaling is shown to suppress food
intake (Leibowitz et al., 1988). There are seven families of 5HT receptors (5-HT 17 ),

comprising at least 14 distinct receptor subtypes out of which 5HT 1B R,

5HT 2C R and 5HT 6 R subtypes are shown to be the principal mediators of
anorectic effects in rodents (Garfield and Heisler, 2009). Overall, brain stem
mechanisms appear to be important in the regulation of energy balance.

Taken together, both the hypothalamus and the brain stem consist of
distinct neuronal circuits, signaling molecules and reciprocal connections that
regulate energy homeostasis. Additionally, peripheral satiety, hunger and
adiposity signals are also integrated within the hypothalamic and brainstem
circuits to regulate feeding and metabolism.

III.

Non-homeostatic regulation of energy balance: The brain reward

system

The brain reward system consists of neural circuits that regulate a)
reward/saliency, b) motivation, c) learning/conditioning and, d) inhibitory control
and executive function (Wise, 2006; Volkow et al., 2008, Kenny, 2011).
Reward/saliency is mediated through nucleus accumbens (NAc), ventral
pallidum, medial orbitorfrontal cortex (OFC) and hypothalamus; motivation is
mediated through dorsal striatum; inhibitory control and executive function is
mediated through cingulated gyrus, dorsolateral prefrontal cortex (DLPFC) and
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lateral OFC and, learning/conditioning is mediated through hippocampus,
amygdala and dorsal striatum (Volkow et al., 2008).

Increased ease of access to palatable foods and overconsumption is
responsible for the increasing prevalence of obesity (Volkow and Wise, 2005;
Swinburn et al., 2009). Importantly, the rewarding and pleasurable properties of
palatable foods trigger excessive consumption, despite having met the energy
requirements. The metabolic consequences of food are regulated by homeostatic
functions; however, the reinforcing and hedonic consequences of food are
regulated by the reward system (Lutter and Nestler, 2009; Berthoud et al., 2011).
In obesity, the brain reward system appears to override the homeostatic control
of appetite, such that feeding behavior is regulated by hedonic rather than
physiological needs (Flier, 2004; Palmiter, 2007; Shomaker et al., 2010).

Orosensory and post-ingestive consequences of palatable foods engender
greater preference compared to less palatable foods, and promote excessive
food consumption (Warwick and Weingarten, 1995; Sclafani, 2001; Macht and
Mueller, 2007). Consumption of palatable foods is also associated with sensory
reward processing of food and food-related cues that regulate preference and
hedonic value of certain diets (Rolls, 2011). The role of the brain reward system
in hedonic food consumption is evident from human imaging studies that
employed the blood-oxygen level dependent (BOLD) functional magnetic
resonance imaging fMRI technique. In these studies, compared to lean
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individuals, obese humans exhibited enhanced baseline resting activity in the
somatosensory cortex as well as greater activation of insula and midbrain areas
upon tasting palatable foods (Wang et al., 2002a). These results suggest that
obesity is associated with increased sensitivity to the rewarding properties of
food. Human imaging studies have also demonstrated activation of brain reward
relevant regions in response to palatable food-related visual and olfactory cues.
Compared with non-food objects, viewing photographs of fattening foods resulted
in significantly greater activation in the brainstem, hypothalamus, amygdala,
DLPFC, OFC, insular cortex, dorsal striatum and NAc of healthy, non-obese
women (Schur et al., 2009). In another study, obese women exhibited greater
activation of the hippocampus in response to palatable food related odors,
compared to lean control (Bragulat et al., 2010). Palatable food related odors
elicited greater BOLD responses in the ventral tegmental area (VTA), NAc and
medial prefrontal cortex (mPFC), compared to nonappetitive odors, when
responses were collapsed across obese and control groups (Bragulat et al.,
2010). Immediate early gene-expression (c-fos) studies conducted in rats
following exposure to palatable foods demonstrated increased activation of
reward-related brain regions that include; striatum, NAc, amygdala and limbic
structures, consistent with human findings (Angeles-Castellanos et al., 2007).
Recent animal studies also indicate the role of habenula in hedonic food intake.
Deep brain stimulation of the later habenula was shown to decrease sucrose
self-administration in rats (Friedman et al., 2011). Furthermore, lesioning of the
lateral habenula resulted in delayed extinction response despite substitution of
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sucrose with water, indicating increased sucrose-seeking behavior. Collectively,
nonhomeostatic feeding behavior appears to be regulated by brain regions
implicated in learning, reward processing and motivation.

Dopamine, one of the major neurotransmitters of the reward system, is
known to facilitate conditioning to food stimuli as well as to regulate appetitive
and food-motivated behaviors (Mark et al., 1994; Martel and Fantino, 1996;
Wang et al., 2002b). The reinforcing properties of food are predominantly
mediated by dopaminergic activation of the reward circuits (Epstein and Leddy,
2006). Ingestion of palatable foods results in dopamine release in the NAc and
dorsal striatum, brain regions that mediate primary reward and motivation,
respectively (Martel and Fantino, 1996; Small et al., 2003; Kelley, 2004).

In addition to dopamine, NAc-mediated signaling of opioids, gamma amino
butyric acid (GABA), and glutamate have also been implicated in food reward.
Opioid signaling in the NAc shell is shown to modulate food palatability and
nonhomeostatic feeding (Peciña and Berridge, 2005). Intra-accumbens infusion
of μ-opioid receptor agonist, D-Ala2, N, Me-Phe4, Gly-ol5-enkephalin, in satiated
rats resulted in increased consumption of palatable foods and also greater
preference for HF- compared to high-carbohydrate diets (Zhang et al., 1998).
Opioid-mediated stimulatory effects on palatable food ingestion was blocked by
systemic administration of a non-selective opioid receptor antagonist, naltrexone.
Stimulation of inhibitory GABA system and blockade of excitatory glutamate
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system in the NAc shell is shown to produce increases in food intake (Kelley et
al., 2005). Intra-accumbens shell injections of muscimol and baclofen, selective
GABA-A and GABA-B agonists, respectively, increased feeding in satiated rats
(Stratford and Kelley, 1997). Glutamatergic signaling in the NAc is shown to
negatively regulate feeding behavior, as evidenced by stimulation of food intake
upon blockade of AMPA/kainate glutamate receptors in the NAc shell
(Maldonado-Irizarry et al., 1995; Reynolds and Berridge, 2003). The amygdala is
another important component of the brain reward system that is known to
regulate reward-mediated food intake. Importantly, reciprocal connections
between the central nucleus of the amygdala and the NAc as well as the
basolateral amygdala and forebrain regions have been suggested in the
involvement of opioid-mediated eating and assessment of food palatability (Kim
et al., 2004).

IV.

Interaction between homeostatic and reward mechanisms

Emerging evidence demonstrates functional interaction between
homeostatic and reward circuits that regulate food intake. Reciprocal connections
have been reported between the NAc and the LHA (Stratford and Kelley, 1999).
Importantly, peripheral hormones that include leptin, insulin and ghrelin are
shown to module feeding behavior independent of their actions in the
hypothalamus (Palmiter, 2007). Ghrelin levels rise upon fasting, and leptin and
insulin levels increase with corresponding increases in fat and glucose levels,
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resulting in activation of respective hypothalamic receptors to regulate food
intake and increase energy expenditure. In addition to widespread distribution in
the hypothalamus, leptin, insulin and ghrelin receptors are also shown to be colocalized with tyrosine hydroxylase, a marker of dopamine neurons and rate
limiting enzyme of dopamine synthesis of (Figlewicz et al., 2003; Abizaid et al.,
2006). Leptin inhibits dopamine neuron firing rate and decreases extracellular
dopamine in the NAc (Krugel et al., 2003; Hommel et al., 2006). On the other
hand, ghrelin activates dopamine neuron firing; however, the stimulatory action is
shown to be dependent on glutamate signaling (Abizaid et al., 2006). Insulin is
shown to increase dopamine transporter (DAT) mRNA, suggesting a reduction in
dopamine signaling (Figlewicz et al., 1994; 2003).

Further, adiposity hormones are shown to influence food reward
(Tzschentke, 2007). Rewarding effects of food can be measured using selfadministration (operant procedures) and conditioned place preference (CPP).
During operant procedures, animals are food deprived and trained to lever-press
for food pellets in operant conditioning chambers. CPP is a behavioral
conditioning paradigm using compartmentalised test chambers in which the
animal is presented with a positive reinforcer (e.g., food) that is paired with
distinct environmental cues (Bardo and Bevins, 2000). Preference for the
compartment previously associated with the positive reinforcer provides an
indicator of preference for that reinforcer. Decreased sucrose self-administration,
decreased CPP for sucrose pellets and reversal of CPP for HF food was
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demonstrated following intracerebroventricular infusions of insulin and leptin
(Figlewicz et al., 2003, 2004, 2006). Leptin and insulin exert catabolic actions by
decreasing food intake and increasing energy expenditure (Woods et al., 1996;
Barzilai et al., 1997). While obesity is associated with increased leptin and insulin
levels, decreased central leptin and insulin signaling in obesity results in reduced
sensitivity to central catabolic effects (Levin and Dunn-Meynell, 2002; Levin et
al., 2004; Clegg et al., 2005). Following leptin injections, obesity-prone rats
exhibited decreased leptin-induced immunoreactive phosphorylated signal
transducer and activator of transcription 3 (pSTAT3) expression in the
hypothalamic arcuate, ventromedial, and dorsomedial nuclei, respectively (Levin
et al., 2004). Intracerebroventricular injections of insulin were shown to decrease
food intake in obesity-resistant rats; however, no such effect was found in the
obesity-prone rats (Clegg et al., 2005). Thus, defective hypothalamic signaling of
adiposity hormones leads to disruption in energy homeostasis. Also, defective
leptin- and insulin-signaling in the dopamine reward pathway may result in
disinhibition of dopamine neurons, thereby leading to increased dopamine
signaling and food-motivated behavior.

Leptin regulation of the dopamine reward pathway is evident from studies
conducted in leptin deficient ob/ob mice. Compared to wild type, ob/ob mice
exhibited decreased levels of tyrosine hydroxylase in midbrain dopamine
neurons, reduced evoked dopamine release in NAc, decreased somatodendritic
vesicular stores of dopamine in the VTA and substantia nigra, and decreased
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striatal D2 receptors (Fulton et al., 2006; Roseberry et al., 2007; Pfaffly et al.,
2010). Importantly, peripheral leptin treatment ameliorated the prior existing
dopaminergic deficiencies in ob/ob mice (Fulton et al., 2006; Pfaffly et al., 2010).
Furthermore, leptin receptor-expressing neurons in the LHA are shown to
innervate the VTA (Leinninger et al., 2009). Also, leptin action on hypothalamic
neurons is shown to restore tyrosine hyroxylase and mesolimbic dopamine levels
in leptin-deficient mice (Leinninger et al., 2009). Diet-induced obese (DIO) rats
exhibit leptin resistance in the VTA as evidenced by impaired leptin-stimulated
phosphorylation of signal transducers and activators of transcription 3 (STAT3)
(Matheny et al., 2011). In addition to the inhibitory effect of leptin signaling on
striatal dopaminergic transmission, an effect of D2 receptors (D2R) on leptin
signaling is suggested by decreases in circulating leptin levels following
administration of D2R agonist, bromocriptine (Doknic et al., 2002; Kok et al.,
2006). Thus, leptin and D2R signaling appear to act in a reciprocal manner to
regulate homeostatic and hedonic aspects of feeding behavior. Taken together,
energy balance appears to involve a complex crosstalk and functional interaction
between homeostatic and reward mechanisms.

V.

Role of macronutrients in food addiction

The increasing prevalence of obesity has been attributed to the ease of
availability and excessive consumption of energy-dense foods as well as a
sedentary lifestyle that lacks adequate physical activity (Drewnowski and
Specter, 2004; Rolls, 2009). Compared to non-obese individuals, obese
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indiviuals consume diets higher in energy density, as evidenced by a crosssectional survey of food intake (Ledikwe et al., 2006). Importantly, energy density
of fat is twice as high as that of protein and carbohydrates (Bray et al., 2004). In
addition to increased energy density, sensory preferences for fat as well as levels
of body fat are shown to positively correlate with amount of dietary fat (Dreon et
al., 1988; Mela and Sacchetti, 1991). HF-diets are shown to produce greater
weight gain than high-carbohydrate diets, as evidenced by both human and
animal studies (Warwick and Schiffman, 1992). Further, HF-diets are shown to
induce increases in body weight gain even if caloric intake does not exceed that
of high-carbohydrate diet-fed controls (Warwick et al., 2002). Overall, dietary fat
appears to be an important factor that regulates the development of obesity.

V a. Dietary preference and effects

Energy intake is influenced by internal episodic factors that include;
hunger and satiety signals, as well as external factors such as availability and
food properties. Measures of food preference serve as sensitive predictors of
food consumption (Blundell and Hill, 1988). Preference for specific food types are
modulated by orosensory properties and macronutrient composition (Drewnowksi
et al., 1992; Sclafani, 2001). Importantly, proteins, fats and carbohydrates differ
in energy density and generate distinct physiological responses that influence
meal size and post-ingestive inhibition (Blundell and King, 1996).

20

Controversy exists regarding macronutrient-preference in obesity. While
some human studies report increased preference and consumption of
carbohydrates in obese compared to non-obese individuals, other studies
suggest a major role of dietary fat in human obesity (Wurtman and Wurtman,
1984; Heraief et al., 1985; Lieberman et al., 1986). Obese women preferred
sensory stimuli that are relatively low in sugar, but rich in fat, as evidenced by
taste preference studies using sugar/fat mixtures (Drewnowski, 1985). In another
study, obese women were shown to consume more fat calories than lean women
(Romieu et al., 1988). Preferences for typical American foods that are major
sources of carbohydrate, protein and fat calories were determined in obese men
and women (Drewnowski et al., 1992). Obese men preferred protein/fat mixtures
while obese women preferred carbohydrate/fat mixtures. Also, carbohydrates
were listed less frequently, and only if they were also major sources of fat, or
were sweet. Consistent with human findings, animal studies also demonstrate
increased fat preference in obesity, as evidenced by a macronutrient choice
procedure (Okada et al., 1992). Relative to inbred obesity-resistant (S5B\PI) rats,
inbred obesity-prone (Osborne–Mendel) rats exhibited increased choice for fat
compared to carbohydrate and protein diets. Generally, these studies suggest
that obesity is associated with increased preference for foods that are a major
source of fat.

Orosensory properties and post-ingestive effects of HF-diets engender
greater preference and overeating (Kern et al., 1993; Warwick and Weingarten,
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1995; Gaillard et al., 2008). The significance of flavor and the influence of
postingestive nutrient effects on food choice and intake have been investigated
using self-regulated intragastric feeding techniques. Enhancing the flavor of a
solution paired with intra-gastric carbohydrate infusions significantly increased
carbohydrate selection and total energy intake (Ackroff and Sclafani, 2006).
Further, when the flavors were equalized, infusions of a HF-diet stimulated
greater overeating compared to infusions of an isocaloric high-carbohydrate diet
(Warwick and Weingarten, 1995; Lucas et al., 1998). Thus, alterations in nutrient
composition (fat-carbohydrate ratio) of the intra-gastric infusions appear to
influence energy intake. Importantly, flavor and post-ingestive nutrient effects are
not independent since nutrient feedback is known to influence flavor preferences
and food consumption (Sclafani, 2001).

Recent studies have revealed a link between increased consumption of
high-fructose corn syrup (HFCS) and the prevalence of obesity (Bray, 2008).
Despite lack of differences in the number of total calories consumed, rats with
access to HFCS for 12 h daily for 8 wk gained significantly greater body weight
than rats with access to 10% sucrose for an equivalent duration of time (Bocarsly
et al., 2010). Further, following long-term exposure to HFCS for 6-7 months, rats
exhibited increased weight gain and fat deposition and also increased circulating
triglyceride levels. HFCS contains a greater proportion of fructose compared to
sucrose. Importantly, fructose molecules are transformed into glycerol and fatty
acids, which are eventually taken up by adipose tissue, leading to increased
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adiposity (Hallfrisch, 1990). Insulin released by dietary sucrose increases leptin
release and thereby inhibits food intake (Saad et al., 1998). On the contrary,
HFCS decreases circulating insulin and leptin levels (Teff et al., 2004). Thus,
unlike sucrose, intake of fructose delays satiety thereby contributing to increased
food intake and body weight. Taken together, long term consumption of HFCS
appears to induce obesity-related parameters in animals; however, comparisons
between HFCS and HF-diets are yet to be investigated.

Excessive intake of palatable foods that contain high-levels of fat and
sugar has been attributed to the physiological effects of these diets on hunger
and satiety peptides (Charlotte Erlanson-Albertsson, 2005). Rats fed a diet rich in
unsaturated fat demonstrate elevated levels of the satiety hormone POMC,
whereas no effects of saturated fat on POMC levels were found (Dziedzic et al.,
2007). When infused into the ileum of healthy humans, triacylglycerols with
unsaturated fatty acids increased CCK levels whereas triacylglycerols with
saturated fatty acids did not (Maljaars et al., 2009). On the other hand, sucrose is
shown to increase levels of hunger peptide NPY and satiety peptide α- MSH.
Thus, differential expression of appetite regulating peptides may govern intake of
specific food types.

The reward system has been implicated also in the hedonic consumption
of high-energy dense foods (Blundell and King, 1996). Involvement of the opioid
system in palatable food consumption is supported by increases in hypothalamic
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expression of opioid peptides and opioid receptors upon ingestion of palatable
foods (Kim et al., 1996; Welch et al., 1996). Further, consumption of palatable
foods is shown also to activate the opioid system in the NAc (Zhang et al., 2003).
Intracerebroventricular injection of opioids is shown to stimulate intake of sucrose
and fat (Ookuma et al., 1997; Zhang and Kelley, 2002). Compared to lesspalatable foods, ingestion of high-palatable foods is shown to induce greater
dopamine release in NAc and striatum (Martel and Fantino, 1996; Small et al.,
2003). These results suggest that sensory properties influence the rewarding
effects of food. Nonetheless, the effect of specific macronutrients (HF, highcarbohydrate) on dopamine release is yet to be determined.

In contrast to dopamine, 5HT produces satiety that is suggested to be
mediated by hypothalamic inhibition of NPY expression (Lawton et al., 1995;
Halford and Blundell, 2000). Importantly, brain 5HT levels are shown to be
affected by circulating levels of tryptophan and certain macronutrients (Halford
and Blundell, 2000). Depressed patients exhibit deficieny in 5HT
neurotransmission and therefore tend to compensate by overeating highcarbohydrate diets that increase brain serotonin turnover (Wurtman and
Wurtman, 1995). Fenfluramine, an anorexic agent, which is believed to release
5HT as well as inhibit 5HT reuptake has been shown to specifically reduce fat
intake (Lawton et al. 1995; Bray, 2001). Enterostatin, an anorexigenic peptide,
produced by proteolytic cleavage of pancreatic procolipase in the gut has been
shown to inhibit fat intake in rats (Erlanson-Albertsson, 1981; Erlanson-
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Albertsson and York, 1997). Importantly, this inhibitory response is known to be
mediated by both 5HT and opioidergic systems. Overall, the reinforcing effects of
palatable foods appear to be regulated by vital neurotransmitters of the reward
system that include dopamine, opioids and 5HT.

VI.

Striatal dopaminergic system in obesity

Dopamine is a critical monoamine neurotransmitter that is known to
regulate food intake by modulating appetitive motivational processes via the
reward pathway (Wise, 2006). Ingestion of food results in dopamine release in
the NAc, the primary reward center of the brain (Koob and Bloom, 1988;
Bassareo and Di Chiara, 1999; Kelley, 2004). Importantly, dopaminergic
activation of the reward pathway is dependent on the sensory and rewarding
properties of food such that high-palatable foods induce greater dopamine
release in the NAc compared to less-palatable foods (Martel and Fantino, 1996).
Repeated stimulation of the dopaminergic system upon excessive consumption
of palatable foods is believed to trigger neurobiological adaptations that may
result in compulsive hedonic food intake (Volkow et al., 2008).

Dopaminergic activation in the NAc is critical for primary reward processes
associated with food palatability (Szczypka et al., 2001; Wise, 2006).
Nonetheless, the involvement of dopamine in the dorsal striatum appears to be
critical for motivational process involved in general food consumption for survival
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(Sotak et al., 2005; Palmiter, 2008). Furthermore, striatal dopamine involvement
in obesity is suggested by reductions in preference of palatable foods as well as
general food consumption following tyrosine hydroxylase gene inactivation. While
gene rescue in the NAc and striatum restored preference, only striatal rescue
restored general consumption (Szczypka et al., 2001). Striatal dopamine
involvement in motivation for food is supported also by high progressive ratio
(PR) breakpoints in rats over-expressing striatal delta Fos B, a transcription
factor that is believed to be expressed in response to sustained dopamine
signaling (Olausson et al., 2006).

Dysfunction of the dopamine reward system has been implicated in
obesity. Obese humans exhibit decreased striatal D2-receptor density and
decreased striatal activity (BOLD signals), compared to non-obese individuals
(Wang et al., 2001; Stice et al., 2008). TaqIA restriction fragment length
polymorphism is downstream from the D2R gene and individuals carrying the A1
allele of the polymorphism exhibit 30–40% decreased striatal D2 receptor levels
compared to those lacking the A1 allele (Jönsson et al., 1999; Ritchie and Noble,
2003). Similar to drug addiction, the TaqIA A1 allele of the DRD2 gene also is
suggested to influence susceptibility to obesity (Comings and Blum, 2000).
Importantly, individuals with the A1 allele exhibit a strong inverse relationship
between striatal response to food receipt and BMI (Stice et al., 2008). Also, A1
allele carriers’ exhibit decreased glucose metabolism in striatal and cortical brain
areas that regulate hedonic responses to food (Jönsson et al., 1999).
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Collectively, striatal D2 receptor function appears to regulate response to
palatable foods, and diminished D2 receptor signaling may increase vulnerability
to obesity.

Consistent with obese humans, decreased striatal D2 receptor levels were
found in obese rats (Johnson and Kenny, 2010). Furthermore, lentivirusmediated knockdown of striatal D2 receptors resulted in increased thresholds for
electrical brain stimulation reward in rats with extended access to a palatable
cafeteria diet, compared to lenti-control rats (Johnson and Kenny, 2010).
Furthermore, striatal D2-knockdown was shown to induce compulsive foodseeking behavior in rats with extended access to a cafeteria diet, as evidenced
by increased resistance to aversive stimuli-induced disruption of food
consumption (Johnson and Kenny, 2010). Taken together, overconsumption of
palatable foods and the development of obesity appear to trigger addiction-like
neuroadaptive responses in the striatal dopamine system that may contribute to
the development of compulsive eating.

VII.

Dopamine neurochemistry

Dopaminergic pathways arise from projections originating from different
brain regions that synthesize dopamine. The major dopamine pathways include:
the mesolimbic, mesocortical, nigrostriatal and tuberofundibular pathways (Fig.
1). The mesolimbic pathways orginates from the midbrain VTA and innervates
the NAc (ventral striatum), amygdala and olfactory tubercle and parts of the
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limbic system and is known to mediate reward and motivation (Koob and Bloom,
1988; Koob, 1992; Kelley, 2004). The mesocortical pathway consists of
dopaminergic projections from the VTA to different regions of the frontal cortex
that influence learning, memory and inhibitory control (Moal and Simon, 1991;
Koob and Volkow, 2010). The tuberoinfundibular pathways arises from dopamine
synthesizing cells in the PVN and ARH and innervates the median eminence of
the hypothalamus and the anterior pituitary gland where dopamine inhibits the
release of prolactin hormone (Feldman et al., 1997; Vallone et al., 2000).

The nigrostriatal pathway consists of dopaminergic projections from the
substantia nigra compacta which innervates the dorsal striatum (caudateputamen). While dopamine function in the dorsal striatum is primarily involved in
motor control, emerging evidence demonstrates the role of striatal in motivation
and habit formation (Ito et al., 2002; Yin et al., 2005; Everitt and Robbins, 2005;
Olausson et al., 2006). The involvement of striatum in motivation for food is
supported by findings that rats over-expressing striatal delta Fos B (transcription
factor expressed in response to sustained dopaminergic activation) exhibit
increased progressive ratio (PR) responding for food. During PR responding, rats
are trained to respond on a lever to obtain food reinforcers and the number of
responses required to obtain a single food reinforcer is increased progressively
within a behavioral session. The response ratio at which the rat ceases to
respond is called the PR breakpoint, indicative of motivation (Richardson and
Roberts, 1996). Habitual behavior is indicated by operant performance for reward
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that is insensitive to post-training changes in the value of the outcome (Yin et al.,
2005). The development of a stimulus-response habit involving the dorsolateral
striatum was demonstrated using the outcome devaluation procedure in rats with
lesions in the dorsolateral striatum and sham control rats (Yin et al., 2005). Rats
were trained to press a lever for sucrose reward delivered on an interval
schedule. The sucrose was then devalued by pairing its consumption with illness
induced by an injection of lithium chloride before the effect of this treatment was
assessed in an extinction test (lever-press did not result in sucrose
reinforcement). In contrast to sham operated controls, rats with dorsolateral
striatum lesions reduced their lever performance upon devaluation of the
outcome. These results indicate that operant performance in the rats with
dorsolateral lesions was controlled by goal expectancy, such that devaluation of
the goal decreased subsequent performance (Yin et al., 2005). Furthermore,
microdialysis studies demonstrate that prolonged cocaine-seeking increases
dopamine release in the dorsal striatum but not ventral striatum, suggesting the
role of striatal dopamine in habitual behaviors (Ito et al., 2002). Additionally,
autoradiographic studies demonstrate reductions in dopamine D2 receptors in
the dorsal striatum following chronic, but not acute cocaine self-administration in
monkeys, emphasizing the role of striatum in habit formation (Nader et al.,
2002).

Dopamine is a catecholamine neurotransmitter synthesized in
dopaminergic neurons that constitutes about 80% of the catecholamine content
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in the brain (Feldman et al., 1997; Vallone et al., 2000). The synthesis, release
and uptake mechanisms that regulate dopamine function are illustrated in Fig. 2.
Dopamine is synthesized from the precursor aromatic amino acid L-tyrosine
(Cooper et al., 2003). L-tyrosine undergoes hydroxylation into L-3, 4dihyroxyphenylalanine (L-DOPA) in the presence of a rate-limiting catalytic
enzyme, tyrosine hydroxylase and its cofactors, including Fe2+, O 2 and
tetrahydropteridine (Cooper et al., 2003). Further, L-DOPA undergoes
decarboxylation to form dopamine. Decarboxylation occurs in the presence of the
catalytic enzyme, aromatic L-amino acid decarboxylase (AADC) and cofactor,
pyridoxal phosphate (vitamin B6). The synthesized dopamine is stored in
synaptic vesicles of presynaptic terminals until release into the extracellular
space.

Under the influence of an action potential at the nerve terminal, the
synaptic membrane undergoes depolarization resulting in influx of calcium into
the nerve terminal (Blaustein et al., 1978; Bean and Roth, 1991). Subsequently,
calcium-dependent dopamine release into the extracellular space occurs as a
result of fusion of the synaptic vesicles with the membrane. Extracellular
dopamine binds to dopamine D1-like and D2-like receptors. Importantly,
dopamine release is also modulated by presynaptic D2 autoreceptors such that
D2 agonists inhibit and D2 antagonists enhance evoked release of dopamine
(Roth, 1984; Dwoskin and Zahniser, 1986; Boyar and Altar 1987; Westerink and
De Vries, 1989). Autoreceptors are shown to be localized at the soma, dendrites
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and nerve terminals of dopaminergic neurons (Sesack et al., 1994). Stimulation
of D2 autoreceptors in the somatodendritic region slows the firing rate of
dopaminergic neurons, whereas stimulation of autoreceptors located on
dopamine nerve terminals results in inhibition of dopamine synthesis and release
(Wolf and Roth, 1990). In order to terminate dopamine signaling, dopamine is
transported from the extracellular space back into the nerve terminal by the
membrane dopamine transporter (DAT). Once in the cytosol, dopamine is
packaged back into synaptic vesicles by the vesicular monoamine transporter-2
(VMAT2) for storage and subsequent release into the extracellular space.
Cytosolic dopamine is metabolized into dihydroxyphenylacetic acid (DOPAC), by
undergoing oxidative deamination in the presence of monoamine oxidase (MAO),
a mitochondrial outer membrane-bound flavoprotein (Edmondson et al., 2004).
Dopamine is also metabolized extraneuronally by catechol-O-methyl transferase
(COMT) into 3-methoxy-4-hydroxyphenylacetaldehyde which is further
metabolized into homovanillic acid by MAO (Grossman et al., 1992).

VII a. Dopamine receptors

Dopaminergic effects are mediated by specific dopamine membrane
receptors. Dopamine receptors belong to the family of 7-transmembrane domain,
G-protein coupled receptors (Gingrich and Caron, 1993). Following receptor
synthesis in the endoplasmic reticulum (ER) and oligosaccharide processing in
the Golgi appartus, dopamine receptors are targeted to the plasma membrane
(Missale et al., 1998; Drake et al., 2006). Activation of dopamine receptors
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results in G-protein coupling that governs subsequent receptor-mediated effects.
The agonist-occupied receptor is then internalized following phosphorylation by
G-protein receptor kinases and β-arrestin binding. Following internalization,
receptors either undergo recycling, trafficking back to the plasma membrane or
get sorted for lysosomal degradation. These events may be dependent on the
magnitude and duration of dopamine signaling. Desensitization (loss of activity)
of dopamine receptors may be a result of sustained agonist-stimulation
(Hausdorff et al., 1989).

On the basis of biochemical and pharmacological properties, dopamine
receptors are further classified into D1-like and D2-like receptors (Missale et al.,
1998). The D1-like receptor family includes D1 and D5 receptors, and the D2-like
receptor family includes D2, D3 and D4 receptors. D1-like receptor subtypes
couple to the G-protein Gs and activate adenylyl cyclase (Monsma et al., 1990).
The D2-like receptor subtypes couple to the G-protein Gi, inhibit adenylyl cyclase
and Ca2+ channels and activate K+ channels and arachidonic acid synthesis
(Piomelli, 1993; Jackson and Westlind-Danielsson, 1994; Missale et al., 1998).
While the D1-like receptors are exclusively postsynaptic, D2-like receptors are
also expressed presynaptically, in addition to their postsynaptic expression.
Specifically, the gene for the D2 receptor gives rise to two receptor isoforms, D2L
and D2S receptors, that differ in the presence and absence of a 29 amino-acid
segment in the third cytoplasmic loop, respectively (Missale et al., 1998). D2L
receptors are primarily postsynaptic. On the other hand, D2S receptors are
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located presynaptically and serve as autoreceptors. Importantly, autoreceptorstimulation exerts a negative feedback on dopamine neurotransmission by
inhibition of dopamine synthesis and release and increases in DAT function
(Dwoskin and Zahniser, 1986; Westerink and De Vries, 1989; Wolf and Roth,
1990; Meiergerd et al., 1993; Cass and Gerhardt, 1994).

D1 receptors are mainly expressed in the dorsal striatum, NAc, olfactory
tubercle, cerebral cortex, amygdala, island of Calleja and in the subthalamic
nucleus (Jackson and Westlind-Danielsson, 1994). In contrast to the widespread
expression of D1 receptors, D5 receptor expression is restricted to the
hippocampus, lateral mammilary nucleus and the parafascicular nucleus of the
thalamus. D2 receptors are predominantly expressed in the dorsal striatum, NAc
core, olfactory tubercle, prefrontal, cingulate, temporal and enthorinal cortices,
amygdala, hippocampus, hypothalamus, substantia nigra pars compacta and the
VTA. Importantly, D2 receptors are also located peripherally in the retina, kidney,
vascular system and pituitary gland (Jackson and Westlind-Danielsson, 1994).

D1-like receptors are shown to mediate gustatory learning and palatable
food preference (Fenu et al., 2001; Cooper and Al-Naser, 2006). A conditioned
taste aversion paradigm was employed to investigate the role of dopamine
receptors in gustatory learning. This paradigm is shown to demonstrate
Pavlovian learning induced by the association of the gustatory conditioned
stimulus (saccharin or sucorse) with the malaise-inducing unconditioned stimulus
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(lithium) (Yamamoto et al., 1994, Fenu et al., 2001). An unconditioned stimulus
automatically triggers a response. A conditioned stimulus is the stimulus that
over repeated exposure becomes associated with the unconditioned stimulus. D1
antagonist (SCH 23390) (12.5–50 μg/kg, s.c.), administered 5 min after the
conditioned stimulus (saccharin solution), impaired the acquisition of conditioned
taste aversion in a paradigm consisting of saccharin–lithium association. On the
contrary, administration of the specific D2/D3 antagonist raclopride (100 and 300
μg/kg, s.c.) failed to impair the acquisition of conditioned taste aversion,
indicating the specific role of D1 receptors in gustatory learning. Due to lack of a
selective ligand for D5 receptors, the independent role of D5 receptors in feeding
behavior is not clear. The role of D2 receptors in obesity is evidenced by
increased thresholds for electrical brain stimulation reward in rats with lentivirusmediated knockdown of striatal D2 receptors and extended access to a palatable
cafeteria diet, as compared to lenti-control rats (Johnson and Kenny, 2010).
Compulsivity is a behavior that persists despite negative health consequences
(Koob and Volkow, 2010). Increased resistance to aversive stimuli-induced
disruption of food consumption in striatal D2-knockdown rats indicates
compulsive food-seeking behavior in rats with extended access to a cafeteria diet
(Johnson and Kenny, 2010). Administration of SB-277011-A, a selective D3
receptor antagonist, is shown to attenuate sucrose-seeking behavior induced by
sucrose-associated cue reintroduction in rodents, suggesting the role of D3
receptors in relapse (Cervo et al., 2007). In depth study of the specific role of the
various dopamine receptor types in obesity is yet to be conducted.
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VII b. Monoamine transporters: DAT and VMAT2

Dopaminergic neurotransmission mediates a wide array of functions
including locomotor activity, cognition, reward mechanisms and motivated
behaviors (Iversen and Iversen, 2007; Palmiter, 2008). The intensity and duration
of dopamine signaling is dependent on the re-uptake of dopamine from the
extracellular space back into the nerve terminals by plasma membrane DAT
(Torres, 2006). Furthermore, cytosolic dopamine is transported back into the
vesicles for storage and subsequent release by VMAT2 (Erickson et al., 1992;
Schuldiner, 1994). Thus, both DAT and VMAT2 regulate extracellular dopamine
concentrations, and thereby, represent critical mechanisms in the termination of
dopaminergic effects at presynaptic and postsynaptic dopamine receptors.

i) DAT

DAT belongs to the family of Na+ and Cl- dependent transporters, which
includes transporters for other related monomines such as norepinephrine and
5HT as well as inhibitory neurotransmitters like GABA and glycine (Masson et.,
1999). DAT also is considered as a marker of dopaminergic neurons due to its
exclusive expression in dopamine-synthesizing neurons (Torres, 2006).
Translocation of dopamine into the nerve terminal by DAT is accompanied by cotransport of two Na+ ions and one Cl- ion (Reith et al., 1997; Rudnick, 1997). DAT
consists of 12 transmembrane domains (TMDs), a large glycosylated loop
between TMDs 3 and 4, and intracellular carboxy and amino terminal domains
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(Shimada et al., 1991). Synthesis and assembly of DAT occurs within the ER and
Golgi complex of neurons. Oligomerization of DAT has been suggested as an
important mechanism for the efficient exit of DAT from the ER (Sorkin et al.,
2003; Torres et al., 2003). Following proper folding and assembly within the ER,
DAT oligomers interact with components of the coat protein complex II, and this
interaction is known to regulate DAT transport from the ER to the Golgi complex
for glycosylation (Sucic et al., 2011). Although DATs are targeted to the plasma
membrane, they shuttle between the cell-surface and endosomal compartments.
An immunofluorescent study conducted in rat dopamine neuronal cultures
demonstrated predominant expression of DAT in the plasma membrane and
recycling endosomes of presynaptic structures (Rao et al., 2011). On the
contrary, in the somatodendritic compartments, DAT was detected in early, late
and recycling endosomal compartments suggesting differential pathways and/or
protein interactions regulating DAT trafficking mechanisms between cell-surface
and endosomal compartments (Rao et al., 2011; Sager and Torres, 2011).
Proteins that are known to regulate DAT degradation include clarithrin coat
accessory proteins and ubiquitin ligases (Sorkin et al., 2006). Nonetheless,
detailed molecular mechanisms associated with DAT degradation are not
completely understood.

Regulation of DAT function
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DAT-mediated clearance of extracellular dopamine requires effective
targeting of DAT to the cell-surface of dopaminergic neurons (Zahniser and
Sorkin, 2004). Importantly, DAT activity is regulated by a wide array of cellular
and exogenous factors that include; activation of intracellular second-messenger
systems (Gulley and Zahniser, 2003; Torres et al., 2003; Vaughan, 2004;
Ramamoorthy et al., 2011), presynaptic G-protein coupled receptors (Meigerd et
al., 1993; Cass and Gerhardt, 1994, Bolan et al., 2007; Zapata et al., 2007),
protein-protein interactions between DAT and other transmembrane or
cytoskeletal scaffolding proteins (Sager and Torres, 2011), and interaction with
DAT substrates and inhibitors (Saunders et al., 2000; Loder and Melikian, 2003).

Autoreceptor-mediated regulation of DAT. Activation of D2 and D3
autoreceptors modulate DAT function. In vitro kinetic analysis conducted in
striatal synaptosomes demonstrated increased V max of dopamine transport in the
presence of D2/D3 agonist, quinpirole (Meigerd et al., 1993). This finding was
further supported by in vivo electrochemical assays that reported inhibition of
DAT function upon localized intrastriatal application of raclopride, a selective D2
receptor antagonist (Cass and Gerhardt, 1994). Addition of D2/D3 receptor
agonist quinpirole to human embryonic kidney (HEK) cells co-expressing human
DAT (hDAT) and D2S revealed increased DAT function and cell-surface
expression (Bolan et al., 2007). Furthermore, D2S-mediated increase in DAT
function was shown to be dependent on extracellular signal-regulated kinases 1
and 2 (ERK1/2) and independent of phosphoinositide 3 kinase (PI3K).
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In vitro kinetic analysis and in vivo electrochemical studies revealed
increased NAc DAT function upon treatment with PD128907, a selective D3
agonist (Zapata and Shippenberg, 2002). Furthermore, D3 receptor-mediated
increases in DAT activity was also observed in HEK cells and mouse
neuroblastoma cells co-expressing hDAT and D3 receptors (Zapata et al., 2007).
In the same study, acute activation of D3 receptors was reported to enhance
DAT function. Also, the D3-mediate increase in DAT function was shown to be
PI3K and mitogen-activated protein kinase (MAPK) dependent, and was also
associated with increased DAT cell-surface expression. On the contrary,
sustained D3 receptor activation decreased DAT function and DAT cell-surface
expression (Zapata et al., 2007). Thus, D2- and D3-mediated regulation of DAT
function appears to occur via similar signaling mechanisms.

Second-messenger systems. Cellular signaling cascades that involve
phosphorylation are a critical regulator of DAT activity. Importantly, DAT
phosphorylation may result in alteration in intrinsic activity of the transporter,
alterations in affinity for ligands, as well as alterations in membrane distribution of
DAT (Mortensen and Amara, 2003). Protein kinases and phosphotases that
affect DAT function include protein kinase C (PKC), protein kinase A (PKA),
PI3K, protein tyrosine kinase, Ca2+/calmodulin kinase, protein phosphotase 1 and
MAPK families (Melikian, 2004; Vaughan, 2004; Foster et al., 2006; Hoover et
al., 2007). The role of phosphotases in the regulation of DAT has been studied
using a pharmacological inhibitor of PP1 and PP2A, okdaic acid (Vaughan et al.,
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1997). Dose-dependent increases in DAT phosphorylation and decreases in
dopamine uptake were found in striatal synaptosomes following okdaic acid
treatment (Vaughan et al., 1997). Insulin signaling via tyrosin kinase receptors is
critical for DAT function and expression (Doolen and Zahniser, 2001). Blockade
of insulin receptor-mediated signaling with tyrosine kinase inhibitors revealed
decreased dopamine clearance and decreased DAT expression (Doolen and
Zahniser, 2001). Furthermore, inhibition of downstream components of the
insulin signaling pathway that include PI3K and protein kinase B (Akt), have been
shown to result in decreased DAT function and surface expression (Carvelli et
al., 2002; Garcia et al., 2005).

PKC is the most extensively investigated kinase with respect to regulation
of DAT function. While PKC, PI3K and MAPK signaling pathways influence
phosphorylation of DAT serine and threonine residues, the regulatory effects of
PI3K and MAPK on DAT is opposite to that of PKC (Schmitt and Reith, 2010). In
contrast to PKC, activation of PI3K and MAPK results in upregulation of DAT
activity (Carvelli et al., 2002; Lin et al., 2003). As described previously, these
signaling cascades can be activated by GPCRs (D2 and D3 receptors). Further,
PI3K and MAPK pathways also are essential for tyrosine kinase-mediated
upregulation of DAT function and cell-surface expression (Hoover et al., 2007).
On the contrary, PKC activation results in decreased [3H]dopamine uptake and
[3H]mazindol (DAT ligand) binding to human DATs expressed in Xenopus
oocytes, thereby suggesting a role of phosphorylation in promoting internalization
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of plasmalemmal DAT (Zhu et al., 1997). Also, PKC-mediated DAT
internalization was postulated as a result of increased clarithrin-dependent
endocytosis and decreased recycling from endosomal compartments (Daniels
and Amara, 1999; Loder and Melikian, 2003; Sorkina et al., 2005). Unfortunately,
the relationship between PKC-mediated DAT phosphorylation at serine and
threonine residues and DAT membrane distribution remains unclear.
Nonetheless, it has been hypothesized that activation of PKC may result in
activation of DAT-associated scaffolding or skeletal proteins that in turn regulate
DAT trafficking (Vaughan, 2004; Foster et al., 2006). Taken together, distinct
intracellular signaling cascades differentially regulate DAT function.

Protein-protein interactions. DAT interacting proteins can be classified
as signaling molecules, GPCRs, presynaptic proteins and other miscellaneous
proteins. Signaling molecules include protein phosphotase 2A (PP2A), PKCβ,
cGMP-dependent protein kinase Iα and neuronal nitric oxide synthase.
Interaction of PP2A and PKCβ with DAT has been demonstrated by coimmunoprecipitation (Bauman et al., 2000; Johnson et al., 2005). Importantly,
PKCβ knockout mice exhibit decreased dopamine uptake by DAT and decreased
cell-surface DAT expression, thereby suggesting that PKCβ facilitates DAT
function (Chen et al., 2009). Other signaling molecules have been shown to coimmunoprecipate with DAT; however, their precise role is yet to be established.
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Functional regulation of DAT by GPCRs, namely D2 receptors, is
evidenced by experiments in which D2 receptor stimulation resulted in increased
DAT function and expression (Cass and Gerhardt, 1994; Bolan et al., 2007).
Direct interaction between D2 and DAT resulting in a functional protein complex
was revealed (Lee et al., 2007). The first 23 residues of the amino terminus of
DAT co-immunoprecipitated with the D2 receptors from striatal lysates and
conversely, residues 242-344 from the third intracellular loop of D2 receptors coimmunoprecipitated with DAT (Lee et al., 2007). Further, disruption of the D2DAT complex by a cell membrane permeable interfering peptide decreased DAT
function. An orphan GPCR, GPR37, has also been reported to coimmunoprecipitate with DAT. GPR37 null mice exhibit increased DAT function
and plasma membrane DAT levels in striatal synaptosomes (Marazitti et al.,
2004).

Presynaptic protein-α-synuclein has been shown to form a complex with
presynaptic hDAT in cotransfected HEK-293 cells through direct binding of the
non-A β amyloid component of α-synuclein to the carboxyl-terminal tail of hDAT
(Lee et al., 2001). Further, the α-synuclein-hDAT complex formation has been
shown to facilitate DAT trafficking to the membrane, thereby faciliating dopamine
uptake. On the otherhand, overexpression of syntaxin1A decreased DAT function
and cell-surface DAT expression in a non-neuronal LLCPK1 cell line (Cervinski et
al., 2010). Also, overexpression of other miscellaneous proteins like Hic-5, PDZ
domain containing protein interacting with C-kinase 1 (PICKI) and SCAMP2 in
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HEK-293 cells transfected with hDAT revealed decreased DAT function and
decreased cell-surface DAT expression (Torres et al., 200; Carneiro et al., 2002;
Muller et al., 2006). Futhermore, functional interaction between DAT and synaptic
vesicle protein, synaptogyrin-3 was revealed by studies in which overexpression
of synaptogyrin-3 in PC12 and MN9D cells demonstrated increased DAT function
without alterations in cell-surface DAT levels (Egana et al., 2009). Overall,
protein-protein interactions regulate DAT trafficking and function.

Regulation of DAT reverse transport

In addition to dopamine uptake, reverse transport of dopamine via DAT
occurs in the presence of pharmacological agents including amphetamines
(Sulzer et al., 2005). DAT reverse transport of dopamine involves distinct second
messenger systems and protein interactions. In both rat striatum and PC12 cells,
direct PKC activation by phorbol esters has been shown to enhance
amphetamine-induced dopamine efflux, whereas PKC inhibitors block this effect
(Gianbalvo, 1992; Kantor and Gnegy, 1998; Kantor et al., 2001). Furthermore,
PKC activation results in phosporylation of N-terminal serines in DAT (Foster et
al., 2002). Importantly, N-terminal phosphorylation of DAT has been shown to be
essential for amphetamine-mediated dopamine efflux (Khoshbouei et al., 2004).
Studies conducted using the patch-clamp technique in the whole cell
configuration demonstrated that amphetamine-induced DAT reverse transport
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requires intracellular Ca2+ that possibly activates PKC leading to DAT
phosphorylation and DAT-mediated dopamine efflux (Gnegy et al., 2004).

In addition to PKC, Ca2+/calmodulin-dependent protein kinase α (CaMKIIα)
is also a critical regulatory component of amphetamine-induced dopamine efflux
via DAT. Chronoamperometry measurements revealed decreased amphetamineinduced dopamine efflux in response to a CaMKIIα inhibitor, K93 (Fog et al.,
2006). Importantly, in the same study, a physical association between CaMKIIα
and DAT C-terminus was established and subsequent disruption of this
association resulted in a decrease in the amount of DAT-mediated dopamine
efflux evoked by amphetamine. CaMKIIα activation inhibits Akt, a central
component of the insulin signaling pathway (Wei et al., 2007). Therefore,
amphetamine-induced decreases in dopamine uptake and expression may
involve defective insulin signaling.

DAT association with syntaxin 1A also has been implicated in DAT
reverse transport. Syntaxin1A is a SNARE component (soluble N-ethylmaleimide
sensitive factor attachment protein receptor) that is critical for synaptic vesicular
release. Syntaxin 1A interaction with DAT increases amphetamine-induced
dopamine efflux (Binda et al., 2008). Furthermore, pharmacological inhibition of
CaMKII revealed that the syntaxin 1A-DAT association in response to
amphetamine requires CaMKII activity (Dipace et al., 2007). Based on these
findings, a model for amphetamine-induced DAT reverse transport has been
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formulated (Robertson et al., 2009). In the presence of amphetamine, CaMKIIα
binds to the C-terminus of DAT that result in subsequent N-terminal
phosphorylation facilitating syntaxin1A -DAT association. This series of events is
postulated to promote the shift of DAT from an outward to inward facing
conformation that facilitates dopamine efflux from the terminal into the
extracellular space.

In addition to promoting dopamine efflux, amphetamines also decrease
dopamine uptake function and cell-surface expression (Saunder et al., 2000).
PKC activation leads to decreased DAT cell-surface expression; however, DAT
residues required for PKC-induced DAT internalization are not required for
amphetamine-induced DAT trafficking from the cell membrane (Daniels and
Amara, 1999; Loder and Melikian, 2003; Boudanova et al., 2008). While PKC
plays a prominent role in amphetamine-induced dopamine efflux, it may not be
involved in amphetamine-induced DAT trafficking. Interestingly, in another study,
PKC-induced regulation of DAT was attributed to the membrane localization of
DAT (Foster et al., 2008). Briefly, within the membrane, DATs exist in two
subpopulations, namely the lipid-raft DATs and non-raft DATs. PKC-induced
phosphorylation of DAT was shown to occur to a greater extent in the lipid-raft
DATs compared to the non-raft DATs. These results suggest that the non-raft
population of DAT mediate amphetamine-induced DAT internalization, whereas
the lipid-raft population is responsible for amphetamine-mediated dopamine
efflux (Foster et al., 2008; Robertson and Galli, 2009).
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ii) VMAT2

VMATs translocate monoamines from the cytosol into synaptic vesicles
via a proton electrochemical gradient that is generated by the vacuolar type H+adenosine triphosphotase (Yelin and Schuldiner, 2002). VMAT1 and VMAT2 are
the two pharmacologically distinct VMAT isoforms and both contain 12 TMDs
with intracellular amino and carboxy termini (Erickson et al., 1992; Erickson and
Eiden, 1993). VMAT1 is expressed in chromaffin cells of the adrenal medulla and
enterochromafin cells of the intestinal tract and VMAT2 is expressed in
monoaminergic neurons and sympathetic postganglionic neurons (Weihe et al.,
1994; Peter et al., 1995; Erickson et al., 1996).

VMAT2 is solely responsible for dopamine transport from the cytosol into
synaptic vesicles for storage and subsequent release and is also reported to
have higher affinity for monamine substrates (Peter et al., 1994; Schuldiner,
1994). The proteins and pathways involved in VMAT2 synthesis, assembly and
trafficking still remains obscure (Sager and Torres, 2011). However, VMAT2 is
differentially localized to the synaptic vesicles in the nerve terminals and to the
tubulovesicular structures in the somatodendritic compartments (Nirenberg et al.,
1996, 1997). Hsc70, a chaperone protein was shown to colocalize with VMAT2 in
synaptic vesicles (Requena et al., 2009). Physical and functional coupling of
VMAT2 with tyrosine hyroxylase and AADC in the synaptic vesicles has been
reported (Cartier et al., 2010). Taken together, a model was proposed in which
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the chaperone protein Hsc70 was suggested to promote functional interaction
between VMAT2, tyrosine hydroxylase and AADC that would facilitate dopamine
synthesis in the synaptic vesicle membrane followed by loading into the vesicles
by VMAT2 (Sager and Torres, 2011). The proposed mechanism also suggests
minimization of intracellular dopamine diffusion, oxidation and toxicity. Thus,
VMAT2 plays an important role in dopamine homeostasis.

VIII.

Treatment options for obesity

Recent reports from the International Association for the Study of Obesity
(IASO) and International Obesity Task Force (IOTF) indicate that about 475
million adults and up to 50 million children in the world are obese (IASO, 2012).
Importantly, obesity leads to many serious diseases including dyslipidaemia,
hypertension, stroke, myocardial infarction, type-2 diabetes and certain cancers
(IASO, 2012). The increasing prevalence of obesity has resulted in several health
and financial problems. Thus, prevention and treatment of obesity has become a
major public health concern.

VIII a. Dietary intervention and exercise

Obesity is known to result from excessive consumption of high-energy
density foods and decreased physical activity (Rolls, 2009). A negative energy
balance induces weight loss and this can be achieved by decreasing intake of
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energy-dense foods and increasing energy expenditure by exercise. The
influence of energy density on weight loss was evident from a 1-year clinical trial
conducted in obese men and women in which individuals were food restricted
and different groups were provided foods with different energy density (Rolls et
al., 2005). The magnitude of weight loss was greater with low-energy foods
compared to that of high-energy foods. Decreased energy intake when
accompanied with exercise is proven to accelerate weight loss. Exercise
minimizes the loss of lean body mass and increases the metabolic rate thereby
facilitating weight loss (Despres and Lamarche, 1993). Importantly, exercise also
ameliorates the metabolic complications and co-morbidities of obesity that
include heart diseases and cancer (Ross et al., 2000, 2004; Sigal et al., 2006).

VIII b. Pharmacotherapeutic intervention

A healthy diet and lifestyle by itself have failed to ameliorate the obesity
epidemic, thereby necessitating the implementation of effective
pharmacotherapeutic strategies along with dietary and lifestyle modification. The
US FDA guidelines for registration of an anti-obesity therapy stipulate a weight
loss of 5% more than placebo after 1 year of treatment, and the guidelines in
Europe require a 10% weight loss from baseline, including effects of diet and
exercise (Cawthrone, 2007). Anti-obesity agents induce weight loss by one of the
following mechanisms that include increase in metabolism, increase in satiety,
decrease in appetite and decrease in fat absorption. Despite compliance with
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weight loss guidelines, the majority of the drugs launched for the treatment of
obesity over the last two decades have been withdrawn due to noncompliance,
safety profile and increased risk of cardiovascular and psychiatric complications.

The majority of past and current treatment options for obesity fall into two
categories that include appetite suppressants and gastrointestinal fat blockers
(Kordik and Reitz, 1999). Appetite suppressants that have been withdrawn
include; 1) Amphetamines that reverse monoamine transporters, thereby
increasing extracellular monoamine concentrations; 2) Fen-phen: A combination
of fenfluramine and dexfenfluramine that elevates extracellular 5HT levels by
stimulating 5HT release and inhibiting its reuptake; 3) Rimonabant, a
cannabinoid receptor (CB1) antagonist; 4) Sibutramine, a 5HT and
norepinephrine uptake inhibitor (Ioannides-Demos, 2011).

Currently approved medication for obesity

Orlistat. Orlistat ((S)-((S)-1-((2S, 3S)-3-hexyl-4-oxooxetan-2-yl)tridecan-2yl) 2-formamido-4-methylpentanoate) is the first lipase inhibitor for obesity that
was approved by the FDA in 1999 and currently has been granted an “over the
counter license” in the US and Europe (Heal et al., 2012). Importantly, orlistat is
the only available for long-term treatment for obesity such that it induces weight
loss and allows weight maintenance when used in conjunction with a reducedcalorie diet (Kushner, 2012). Orlistat is a gastrointestinal lipase inhibitor that
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blocks fat absorption from the gut (Mcneeley and Benfield, 1998; Lucas and
Kaplan-Machlis, 2001; Padwal and Majumdar, 2007).

The long-term efficacy of orlistat for weight loss has been demonstrated in
several randomized controlled trials that range from 2-4 years of therapy
(Hauptman et al., 2000; Heymsfield et al., 2000; Torgerson et al., 2004).
Moreover, orlistat is shown to produce improvements in blood pressure, insulin
resistance and serum lipid levels (Torgerson et al., 2004; Siebenhofer et al.,
2009). The most commonly experienced side-effects of orlistat are
gastrointestinal and include diarrhoea, flatulence, bloating, abdominal pain and
dyspepsia (Siebenhofer et al., 2009). The FDA received 32 reports of serious
liver injury in patients using orlistat between 1999 and October 2008, including 6
cases of liver failure (FDA drug safety communication, 2010). In May 2010 the
label for orlistat was revised and a warning of severe liver injury was included.
Cetilistat (2-(Hexadecyloxy)-6-methyl-4H-3, 1-benzoxazin-4-one) is another
gastric- and pancreatic-lipase inhibitor that is currently under development
Alizyme and Takeda Pharmaceuticals (Charmot, 2012). Importantly, this drug is
reported to exhibit fewer adverse effects compared to orlistat (Kopelman et al.,
2007, 2010).

Lorcaserin (Belviq®). The ability of fenfluramines to suppress appetite by
activation of 5HT receptors prompted the investigation of lorcaserin ((1R)-8Chloro-1-methyl-2, 3, 4, 5-tetrahydro-1H-3-benzazepine), a selective 5HT2C
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agonist, as a potential anti-obesity agent (Chakrabarti, 2009). Phase 3 clinical
trials of lorcaserin (10 mg twice a day) have demonstrated effective weight loss
compared to placebo, along with a good safety profile (Anderson et al., 2010;
Fidler et al., 2010; Smith et al., 2010). The most frequent adverse events
reported were headache, dizziness and nausea, but these were not significantly
different between treatment and placebo groups. Unlike fenfluramine, there was
no increase in the rate of cardiac valvulopathy following 2-year treatment with
lorcaserin (Smith et al., 2010). The FDA recently approved Belviq (lorcaserin
hydrochloride), as an addition to a reduced-calorie diet and exercise, for chronic
weight management (FDA News Release, 2012a)

Topiramate and phentermine (Qsymia®). Topiramate (2, 3: 4, 5-Bis-O(1-methylethylidene)-beta-D-fructopyranose sulfamate) is a GABA agonist and
an approved antiepileptic drug that has been evaluated in combination with
phentermine (2-Amino-2-methyl-1-phenylpropane) for the treatment of obesity.
Obese patients administered an extended release formulation of the combination
Qsymia (topiramate-7.5 mg and phentermine-46 mg) demonstrated greater
weight loss compared to those treated with either of the drug alone or placebo
(Kaplan, 2005). Since this combination is shown to increase heart rate, regular
monitoring of heart rate is recommended for all patients taking Qsymia (Pollack,
2010). The FDA recently approved Qsymia for obesity treatment (FDA News
Release, 2012b).
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Potential anti-obesity drugs under investigation: Monotherapy and
combination therapy candidates

Withdrawal of several centrally-acting appetite suppressants over the last
two decades has led to the development of novel pharmacotherapeutic options
that provide promising long-term results in the amelioration of obesity and
associated co-morbidities. In addition to the development of novel drugs, drugs
that are approved for other indications also are being evaluated currently for the
treatment of obesity (Gadde and Allison, 2009; Valentino et al., 2010). There are
also several combination drug therapies in phase 3 clinical trials that include
pramlintide and metreleptin, bupropion and naltrexone, bupropion and
zonisamide, and phentermine and topiramate.

Monotherapy

Tesofensine. Tesofensine (1R, 2R, 3S, 5S)-3-(3, 4-dichlorophenyl)-2(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane) is a novel potent, nonselective uptake inhibitor of dopamine, norepinephrine and 5HT. Tesofensine
was initially developed for the treatment of Alzheimer's and Parkinson's disease.
Efficacy was not found for the treatment of these neurological conditions (Astrup
et al., 2008a). Interestingly, meta-analysis of the results revealed that tesofensine
(0.125-1.0 mg once daily) produced dose-dependent weight loss and that
approximately 32% of obese patients achieved ≥5% weight reduction following
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14 wk of treatment (Astrup et al., 2008b). While no effects on blood pressure
were found, an increase in the dose of tesofensine produced increases in heart
rate. Also, psychiatric complications were evident at the highest dose of
tesofensine where 6.1% of obese subjects reported depressed mood compared
with 0% on placebo (Astrup et al., 2008b). Moreover, these adverse events
occurred in a patient group that had been pre-selected to exclude those with
known psychiatric disorders. While adverse effects were reported in human
obese patients, tesofensine revealed encouraging results in DIO rats. In addition
to tesofensine-induced weight loss, the obese rats also exhibited reductions in
abdominal and subcutaneous fat mass, reductions in plasma lipids and increased
insulin sensitivity (Hansen et al., 2010). The ability to decrease body weight and
improve various cardiometabolic risk factors in the DIO rat model supports its
clinical development as an anti-obesity drug. Overall, tesofensine appears to be
an impressive drug candidate for weight reduction; however, further development
is required to eliminate the psychiatric side-effects.

Pramlintide. Pramlintide was originally used for the treatment of type-2
diabetes and is currently under investigation for the treatment of obesity (Gadde
and Allison, 2009; Aronne et al., 2010). Pramlintide is a synthetic analog of the
pancreatic peptide hormone Amylin. In a 4 month study, subcutaneous injections
of pramlintide (120 µg three times a day and 360 µg twice a day) prior to meals,
in conjunction with lifestyle intervention, demonstrated significant weight loss,
reduced meal size and decreased food cravings in obese humans compared to
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placebo group (Smith et al., 2007). The proposed anti-obesity mechanism is via
decreases in appetite and increases in satiety through delayed gastrointestinal
motility. However, nausea was reported as a common side-effect in patients
treated with pramlintide. In another 16-wk phase 2 clinical trial employing obese
subjects with or without type-2 diabetes, pramlintide (240 µg, three time a day)
produced ≥5% weight loss compared to the placebo group (Aronne et al., 2007).
Importantly, the extent of weight loss was not different in pramlintide-treated
patients, either with or without nausea, indicating that the weight loss was not
mediated by nausea. Pramlintide is also being explored for potential combination
therapy as an anti-obesity agent.

Liraglutide and exenatide. Liraglutide and exenatide are GLP1 analogs
that were developed originally and approved for the treatment of type-2 diabetes
(Vilsbull et al., 2007). These analogs are known to exert their anti-obesity effect
via stimulation of leptin secretion and by delay of gastric emptying. While
liraglutide has entered phase 3 clinical trials, exenatide is currently being
evaluated in phase 2 clinical trials for the treatment of obesity (Meade, 2009).
Overweight patients treated with exenatide exhibited significant weight loss as
well as an improvement in glycemic control, compared to the placebo group
(Blonde, 2006). In addition to weight reduction, long-term use of liraglutide and
exenatide has been shown to decrease systolic blood pressure and levels of
glycosylated hemoglobin (Madsbad, 2009; Nauck et al., 2009).
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Combination therapy

Pramlintide combination therapy. A combination of pramlintide and
recombinant methyl human leptin, metreleptin, is being evaluated for the
treatment of obesity (Ravussin et al., 2009). In a 24-wk phase 2 clinical trial
conducted in obese patients, greater weight loss was demonstrated in patients
treated with the combination of pramlintide (360 µg twice a day) and metreleptin
(5 mg twice a day), compared to those treated with either one of the two drugs
alone. Currently, pramlintide is also being evaluated in combination (in pairs) with
sibutramine, phentermine and exenatide (Meade, 2009; Aronne et al., 2010).
Common side-effects reported with these combination treatments are nausea,
and increased heart rate and blood pressure (Aronne et al., 2010).

Bupropion and naltrexone (Contrave). Buproprion ((±)-2-(tertButylamino)-1-(3-chlorophenyly)propan-1-one), an inhibitor of dopamine and
norepniephrine transporters, is used to treat depression and nicotine addiction
(Dwoskin et al., 2006). Naltrexone (17-(cyclopropylmethyl)-4, 5α-epoxy-3, 14dihydroxymorphinan-6-one) is a selective opioid receptor antagonist used to treat
opiate and alcohol dependence (Heal et al., 2012). A combination of bupropion
and naltrexone was explored as a potential treatment option for obesity since
both these drugs are shown to activate POMC neurons and increase the release
of the α-MSH, an anorexigenic neuropeptide (Cone, 2005; Greenway et al.,
2009). An open-label 24 wk study using a sustained release formulation of
naltrexone (32 mg) and bupropion (360 mg) combination was conducted in
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overweight and obese women with depression (Mcelroy et al., 2010). In addition
to weight loss and decreased food intake, significant improvements in depressive
symptoms and glycemic control were achieved in the treatment group compared
to placebo. The proposed mechanism of action of the bupropion-naltrexone
combination is to inhibit the reinforcing and motivational aspects of food addiction
(Kushner, 2008). Nausea was the most commonly reported adverse event.

Bupropion and zonisamide. Weight-loss is a common side-effect of the
anti-convulsant drug, zonisamide, and this side-effect prompted the evaluation of
this drug as a potential treatment option for obesity (Gadde et al., 2003).
Zonisamide (1, 2-benzoxazol-3-ylmethanesulfonamide) is a potent inhibitor of
carbonic anhydrase isoenzymes and this pharmacological mechanism has been
proposed to mediate its weight-loss effect (De Simone et al., 2008). A 24 wk
phase 2 clinical trial of the bupropion (360 mg)-zonisamide (360 mg) combination
(sustained release formulation) demonstrated greater weight loss (9.2%) than
either drugs alone or placebo (Greenway et al., 2006, 2009).The most common
adverse events reported were headache, nausea and insomnia.

VIII c. Surgical treatment for obesity: Bariatric surgery

In 1991, the National Institutes of Health Consensus Development Panel
indicated that patients eligible for bariatric surgery include those with a BMI>40
kg/m2 and those who were well informed about the risks associated with surgical
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procedures (Greenway, 1996). The most recent guidelines of the American
Diabetes Association redefined the criteria for metabolic or bariatric surgery by
indicating that individuals with a BMI>35 kg/m2 and those with obesity-related comorbidities are eligible candidates for bariatric surgery (Kirkman et al., 2009).
Importantly, only obese individuals who are unable to achieve weight loss
throught diet, exercise and pharmacotherapy are recommended to opt for
surgical procedures. Bariatric procedures are broadly classified into two
categories that include restrictive procedures and diversionary procedures (Murr
et al., 2010). Restrictive procedures include laparoscopic adjustable gastric
banding (LAGB) and sleeve gastrectomy (SG), in which weight loss is
predominantly achieved due to the restriction of nutrient intake as a result of
reduction in stomach size (O’Brien et al., 2001; Karmali et al., 2010).
Diversionary procedures include roux-en-Y gastric bypass (RYGB) and
biliopancreatic diversion with a duodenal switch (BPD-DS), which restricts food
intake and also diverts nutrients from the stomach and duodenum (Murr et al.,
2010). In RYGB, a small stomach pouch is created with a stapler device, and
connected to the distal small intestine (Wickremesekara et al., 2005). BPD-DS is
a more complex bariatric surgery that includes removal of a large part of the
stomach, disconnection of the stomach from the duodenum, and connection to
the distal part of the small intestine (Buchwald et al., 2009).

Bariatric surgery is shown to successfully induce sustained weight loss
and reduce obesity-related complications including reduction in serum
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triglyceride and cholesterol levels, and improvement in hypertension (Foley et al.,
1992; Buchwald et al., 2005; Nugent et al., 2008). Side-effects of bariatric
procedures include bleeding, infection, leaks from the site where the intestines
are sewn together, diarrhea, blood clots as well as poor absortion of vitamins and
minerals (Murr et al., 2010). Bariatric surgery is contraindicated in patients with
depression, psychosis, binge eating disorders, current drug and alcohol abuse,
cardiac diseases, severe coagulopathy and those with major anesthesia-related
risks (Nandagopal et al., 2010). Success rates of bariatric surgery in children less
than 18 years of age remains controversial.

In summary, despite the prevalence of obesity, the current treatment
options are limited to bariatric surgery and a single approved anti-obesity
medication, orlistat. The scarcity of pharmacotherapeutic interventions and
withdrawal of several anti-obesity medications due to tolerance and safety issues
reveals the complexity of the regulation of appetite and body weight. Recent antiobesity approaches that include combination therapies targeted towards more
than one pharmacological target are postulated to exert greater and long-term
weight loss compared to monotherapies (Kushner, 2012). Overall, the most
efficacious treatment for obesity appears to be a combination of dietary
restriction, exercise and pharmacotherapy.

IX.

Rationale for employing a DIO model in the current study
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Obesity involves a complex interaction between central and peripheral
hormonal factors, in both homeostatic and reward systems. In addition to
increased high-caloric intake and decreased physical activity, the development of
obesity is also strongly influenced by genetics (Mutch and Clement, 2006).
Considering the complex etiology of obesity, the development and selection of
appropriate animal models that reflect human obesity is crucial to elucidate the
underlying physiological and molecular mechanisms and also for the evaluation
of potential pharmacotherapies.

An appropriate animal model ideally provides the majority of
pathophysiological characteristics associated with the disease under study,
thereby attributing optimum face and predictive validity (Heidbreder, 2011).
Research over the past two decades suggests rodents as the predominant model
of human obesity (Vickers et al., 2011). Importantly, several neuroanatomical and
functional similarities exist between rodents and humans, with respect to central
and peripheral regulation of energy homeostasis. Also, rodents have a well
developed orosensory and digestive system, enabling them to develop taste
preferences and consume a wide variety of foods. Rodent models of obesity can
be classified into two major categories, i.e, genetically-manipulated and
environmentally-induced obesity models (Kanasaki and Koya, 2011).
Additionally, obesity models have been generated by employing chemical and
surgical techniques whereby, localized lesions were produced in different regions
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of the hypothalamus including PVN, ARH and VMH (Nemeroff et al., 1978; Bray
et al., 1989; Tokunaga et al., 1989).

Genetic models of obesity. Single gene defects are shown to disrupt
function of the leptin-melanocortin pathway, thereby resulting in human obesity
(Farooqi and Rahilly, 2006). Extensive animal research has explored the genetic
basis of obesity enabling the generation of obesity rat models from the
propagation of specific rodent strains that exhibit spontaneous mutations of
genes, receptors or proteins (Tschop and Heiman, 2001). Abnormal functioning
of cellular enzymes may contribute to these spontaneous mutations resulting in
homeostatic imbalance. In contrast to animal models generated from
spontaneous mutants, genetically-engineered mutant models include transgenics
and knockouts that are generated by disruption or overexpression of a specific
gene, protein or receptor. Rodent models resulting from spontaneous or
engineered mutations may result in one or more of the following conditions;
hyperphagia, hypothermia, hyperglycemia, hyperinsulinemia, hormonal
deficiency, early or late onset of obesity. Obesity strains identified and
propagated based on spontaneous mutations are illustrated in Table 1. Mutant
obesity strains derived by transgenic gene overexpression and disruption are
illustrated in Table 2.

While genetically-engineered models have been extensively employed to
study the role of endogenous factors, physiological pathways and the mechanism
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of action of therapeutic compounds, interpretation of the results obtained from
these studies is complex (Tschop and Heiman, 2001). Deletion or alteration of
genes may trigger activation of compensatory mechanisms leading to
misinterpretation of the normal contribution of the gene per se (Nelson, 1997).
Importantly, gene products play active roles in different processes and pathways
such that genetic alteration may cause modifications in the associated processes
and pathways.

Environmentally-induced obesity: The DIO model. Geneticallyengineered animal models of obesity have been developed based on single gene
mutations identified in obese humans. However, owing to the polygenetic nature
of obesity, one must exercise caution while employing genetic animal models to
address questions regarding mechanisms involved in obesity (Korner et al.,
2008). In addition to internal genetic factors, the prevalence of obesity is
attributed to the increased ease of access to high-caloric palatable foods and
decreased physical activity (Rahilly and Farooqi, 2008). Thus, obesity involves a
complex polygenetic interaction with an obesogenic environment. Furthemore,
inter-individual differences exists with respect to susceptibility to obesity such
that some humans become obese and others resist the development of obesity
despite exposure to an obesogenic environment (Sims et al., 1968). Interestingly,
a similar differentiation into two distinct obesity-prone (OP) and obesity-resistant
(OR) phenotypes was found in rodents that were exposed to a HF-diet. Rat
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strains were shown to vary in their propensity to develop DIO (Schemmel et al.,
1970).

The rodent model of DIO has been extensively used to study factors that
underlie the development and maintenance of obesity, upon exposure to a highcaloric diet (Levin et al., 1997). Upon 90 days of exposure to a HF-diet, outbred
Sprague Dawley rats exhibited a bimodal weight gain pattern in which
approximately 50% of the rats employed developed obesity and the remaining
rats were obesity-resistant (Levin et al., 1987). Compared to OR rats, the DIO
OP rats exhibited hyperphagia, increased body weight and visceral adiposity,
increased levels of cholesterol and triglycerides, hyperinsulinemia,
hyperglycemia, defective leptin and insulin signaling as well as increased
concentrations of angiotensin peptides suggesting obesity-related metabolic and
cardiovascular complications (Levin et al., 1987, 1997, Dobrian et al., 2000;
Levin and Dunn-Meynell, 2002; Boustany et al., 2004; Clegg et al., 2005). Thus,
the DIO model mimics human obesity with respect to several neurohormonal
factors and cardio-metabolic conditions and represents polygenetic interactions
with an obesogenic environment (Madsen et al., 2010; Vickers et al., 2011).
Importantly, long-term metabolic and pharmacological characterization
demonstrates that the polygenetic DIO model efficiently simulates human obesity
conditions (Madsen et al., 2010; Vickers et al., 2011).
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The predicitve validity of genetic models is limited with respect to
screening of anti-obesity agents (Vickers et al., 2011). This drawback is
evidenced by failure of leptin-replacement therapy in normal obese patients.
While leptin-replacement therapy produced dramatic weight loss in leptindeficient monogenetic ob/ob mice and humans with congenital leptin deficiency,
similar weight loss results were not found in clinical trials conducted in normal
obese patients using recombinant leptin (Heymsfield et al., 1999; Farooqi and
O'Rahilly, 2009). This failure was attributed to the ploygenetic nature of obesity
which is associated with increased leptin-resistance in addition to increased
leptin levels (Correia and Haynes, 2007). In contrast to the genetic models, the
DIO model has been employed successfully to predict clinical efficiency of weight
loss drugs including, d-fenfluramine, sibutramine, orlistat and rimonabant
(Hauptman et al., 2000; Madsen et al., 2010).

Taken together, genetic models with spontaneous or engineered single
gene mutations are crucial in understanding the physiological role of specific
genes, receptors or hormones in the regulation of energy homeostasis (Tschop
and Heiman, 2001; Vickers et al., 2011). Moreover, these genetic techniques
provide an insight of novel-targets that can be explored for molecular
intervention. However, since obesity is polygenetic by nature, the
environmentally-induced obesity model appears to mimic human obesity to a
greater extent in comparison with genetic models. Thus, the DIO model appears
to be an appropriate animal model for the investigation of mechanisms
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underlying the development and maintenance of obesity in response to an
obesogenic environment.

X.

In vivo methodologies employed to assess dopamine function and

behavior in obesity

X a. No net flux microdialysis

Microdialysis is a widely used in vivo technique that enables the
monitoring and quantification of neurotransmitters, peptides and hormones in the
extracellular space (Smith et al., 1992; Chefer et al., 2006). Over the past few
decades, the microdialysis technique has advanced significantly facilitating the
analysis of monoamines, aminoacids, glucose and opioid peptides (Ungerstedt et
al., 1982; Imperato and Di Chiara, 1984; Zetterstrom et al., 1988; De Boer et al.,
1992; Bourdelais and Kalivas, 1992). Furthermore, microdialysis can be
conducted in various organ/tissue systems (eg., adipose tissue, brain, heart,
kidney) across species (eg., rats, dogs, rhesus monkey and rabbits) (Hallstrom et
al., 1989, Kuzmin et al., 1992; Linderoth et al., 1992; Saunders et al., 1993;
Wang and Sawchuck, 1995). The main principle underlying microdialysis is the
law of diffusion, such that substances diffuse along their concentration gradient,
from a region of higher concentration to a region of lower concentration, across
the microdialysis membrane (Friedman, 1986). The impact of osmotic and
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hydrostatic pressure differences across the membrane are considered to be
negligible during microdialysis (Benveniste, 1989; Bungay et al., 1990).

The microdialysis technique has been extensively employed to monitor
and quantify extracellular concentrations of neurotransmitters such as dopamine
(Smith et al., 1992; Justice, 1993; Acri et al., 2001). The principal device
employed in the microdialysis procedure is the probe that facilitates exchange of
substances between the extracellular space in the tissue of interest and the
perfusate. The microdialysis probe membrane is semi-permeable and typically
allows diffusion of substances with molecular mass < 20,000 Da. While
microdialysis is an invasive technique, experimental modifications over the years
have limited successfully the extent of tissue damage. As opposed to the surgical
implantation of the microdialysis probe itself, a sterile guide cannula is
stereotaxically implanted in the animal’s brain (Chefer et al., 2009). Following
recovery from surgery, a removable microdialysis probe is inserted into the
animal’s brain and artificial cerebrospinal fluid (aCSF) is infused into the probe at
a perfusion rate ranging from 0.3-3 µl/min. During continuous perfusion of aCSF
along the length of the microdialysis probe, diffusion of analytes occurs across
the probe membrane along the concentration gradient and the dialysate samples
are collected for subsequent quantification. The sensitivity of the analytical
technique employed for subsequent quantification governs the sample collection
volume and perfusion time. Typically, dialysate collection times range from 1 to
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20 min. A diagrammatic representation of microdialysis experimental set up and
microdiaslysis probe is provided in Fig. 3.

Brain microdialysis experiments can be categorized into two types that
include conventional microdialysis and the no net flux microdialysis technique.
During conventional microdialysis, aCSF devoid of the neurotransmitter is
perfused through the probe and the concentration of the neurotransmitter
diffused into the probe is determined. Extracellular neurotransmitter
concentration is governed by release, metabolism and uptake processes. Thus,
interpretation of the data derived from conventional microdialysis experiments is
limited such that the specific mechanism contributing to extracellular
neurotransmitter concentration is not known. In contrast, in no net flux
microdialysis, aCSF containing a range of concentrations of the neurotransmitter
is perfused through the probe and the concentration of the neurotransmitter
gained or lost by the probe is measured (Justice, 1993). The concentration range
of the neurotransmitter is based on the anticipated concentration of that
neurotransmitter in the extracellular space. The neurotransmitter concentration
lost or gained by the probe is plotted as a function of the concentration perfused
into the probe. Linear regression analysis of the no net flux plot yields the slope
which is called extraction fraction or in vivo probe recovery (E d ) and the Xintercept, which is the point of no net flux, represents the extracellular
neurotransmitter concentration.
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Alterations in E d are regulated by changes in diffusional resistance or
changes in flow rate (Chefer et al., 2009). Since the flow rate is held constant
during the experiment, E d values are majorly governed by diffusional resistance.
In comparison to the probe membrane and perfusate, the tissue offers maximum
diffusional resistance to the analyte (Bungay et al., 1990). Resistance
mechanisms in the tissue include tortuosity (diffusional path) and mechansims
that regulate analyte clearance (Bungay et al., 1990, 2003; Chefer et al., 2009).

Importantly, alterations in E d are shown to be dependent on changes in
monoamine uptake and independent of release and metabolism processes
(Smith and Justice, 1994; Bungay et al., 2003). Most importantly, studies have
demonstrated a relationship between E d and processes that control
neurotransmitter clearance. Pharmacological manipulations that inhibit synthesis,
release or metabolism of dopamine were shown to produce alterations in
extracellular NAc dopamine concentrations. However, only pharmacological
inhibition of dopamine uptake produced decreases in E d (Smith and Justice,
1994). Furthermore, electrochemical and radioligand uptake techniques have
demonstrated that alterations in E d provide a sensitive index of changes in
dopamine uptake (Chefer et al., 2000, 2005; Thompson et al., 2000). Another
study demonstrated reductions in E d for norepinephrine and serotonin upon
administration of the norepinephrine uptake inhibitor, desipramine, and serotonin
uptake inhibitor, paroxetine, respectively (Cosford et al., 1996).
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Thus, no net flux microdialysis appears to be a useful in vivo technique
that facilitates determination of extracellular neurotransmitter concentration as
well as neurotransmitter uptake mechanisms. Importantly, this technique was
employed in the current study to evaluate in vivo striatal DAT function and
extracellular dopamine levels.

X b. Operant behavioral procedures to assess impulsivity and
motivation

Obesity has been speculated to be a neurobehavioral disorder (Blum et
al., 2006; Volkow and O’Brien, 2007). The American Psychiatric Association’s
Diagnostic and Statistical Manual of Mental Disorders (DSM), list the diagnostic
criteria for behavioral disorders that include depression, substance abuse and
other personality disorders. Interestingly, the DSM-IV criteria for substance of
abuse dependence consist of symptoms that also correspond to behaviors in
obesity, few of which include persistent desire for food, maintenance of overeating
despite knowledge of adverse physical and psychological consequences caused
by excessive food consumption (Volkow and O’Brien, 2007). This striking
similarity in behaviors suggests that obesity may be considered as “food
addiction” and should be included as a mental disorder in DSM-V (Volkow and
O’Brien, 2007).
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The emerging neurobehavioral commonalities between obesity and drug
addiction have facilitated the implementation of operant behavioral paradigms in
obesity research. Operant conditioning procedures have been employed
extensively to evaluate the rewarding and motivational aspects of drugs of abuse
as well as food (Richardson and Roberts, 1996; Fleur et al., 2007; Hajnal et al.,
2007; Baladi and France, 2009). During operant conditioning, rats are trained to
perform an operant response to obtain reward (Lawrence and Illius, 1989).
Behaviors are measured in operant conditioning chambers that consist of
retractable levers for responding, hopper containing food pellet reinforcers, and a
food tray (Fig. 4; top). Food is a powerful positive reinforcer whereby the
rewarding effect of food increases the probability of a subsequent response
(Epstein and Leddy, 2006). During operant procedures, animals are food
restricted in order to increase hunger and decrease satiety, thereby facilitating
operant responding for food.

Motivation for food reinforcement and lack of inhibitory control has been
implicated in hedonic and nonhomeostatic intake of palatable foods (Volkow et
al., 2008; Appelhans et al., 2011). In the current study, impulsivity and motivation
were evaluated as behavioral mechanisms that may underlie DIO. Impulsivity
was determined using the delay discounting task and motivation for food was
evaluated using the PR schedule of reinforcement. Detailed information of these
behavioral assays is provided in chapter three. However, a brief introduction to
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the delay discounting task and PR schedule of reinforcement is provided in this
section.

Delay discounting task. Impulsivity is a multidimensional behavioral trait
that involves urgent actions, lack of premeditation and perseverance and
increased sensation seeking behaviors (Evenden, 1999; Whiteside and Lynam,
2001). Different behavioral tasks have been employed to address different
aspects of impulsivity that are dissociable at a neuroanatomical level (Winstanley
et al., 2004; Roesch and Bryden, 2011). Behavioral procedures that are
employed to evaluate impulsivity include go/no go task, stop-signal reaction time
task and five-choice serial reaction task, that measure impulsive action, and the
delay discounting procedure that measures impulsive choice (Winstanley et al.,
2006). Delay discounting is defined by the choice of a smaller, immediate reward
over a larger delayed reward and this choice of immediate reward is considered
to model impulsive behavior (Ainslie, 1975).

During the delay discounting task, rats undergo operant training sessions
that consist of forced trials and free trials (Evenden and Ryan, 1996). During the
forced trials, rats are provided access to one of the two levers for a specific
period of time during which the cue light above the extended lever remains
illuminated. Responses on the extended lever results in delivery of either one or
three food reinforcers. During the free trials, both levers are extended and both
stimulus lights are illuminated. While one lever delivers one food reinforcer
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immediately following a response, response on the other lever delivers three
reinforcers following a delay. The delay to obtain the larger reward is either
increased or decreased dependent on the choice of the lever that deliver three or
one food reinforcer, respectively. Impulsivity is defined as a behavior that lacks
inhibitory control (Whiteside and Lynam, 2001). With that perspective, greater
choice for the immediate, smaller reward compared to the larger delayed reward
is defined as an impulsive choice. Thus, the delay to discount the larger reward is
inversely proportional to impulsivity (Fig. 4; bottom-left).

PR schedule of reinforcement. Considerable evidence indicates that
alterations in the ratio of responses to rewards strongly influence operant
behavior (Collier, 1980). Motivation for reinforcement is evaluated using operant
procedures conducted using the fixed ratio (FR) and PR schedule of
reinforcement. In the FR schedule of reinforcement, rats are required to emit a
fixed number of responses to obtain a reinforcer (Lawrence et al., 1988). For
example, during an FR-1 schedule of reinforcement, 1 response yields one
reinforcer, during an FR-2 schedule, 2 responses yield one reinforcer and so on.
Thus, during the FR schedule, the number of responses required to obtain a
single reinforcer remains constant within an experimental session. During the PR
schedule of reinforcement, the number of responses required to obtain a single
reinforcer is increased progressively within an experimental session, whereby the
animal works harder for every successive reinforcer (Hudos, 1961; Lawrence and
Illius, 1989; Richardson and Roberts, 1996). Compared to FR, the PR schedule
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for reinforcement provides a sensitive measure of motivation (Kennedy and
Baldwin, 1972; Dantzer, 1976). The objective of conducting the PR schedule is to
escalate the response requirement to obtain the successive reinforcer until the
animal ceases to respond. The point at which the animal stops responding is
known as the PR breakpoint (Richardson and Roberts, 1996). The breakpoint is
also defined as the largest response ratio completed within an experimental
session (Shippenberg and Koob, 2002). The breakpoint represents maximum
effort expended to obtain reinforcement and hence is indicative of motivation for
reward (Richardson and Roberts, 1996; Fig 4; bottom-right).

XI.

Overall hypotheses and specific aims

Obesity is regulated by multiple neural networks that include the
homeostatic and reward system. In addition to hypothalamic mechanisms, the
elucidation of higher brain reward mechanisms in obesity is imperative for
identification of potential targets for pharmacological intervention. The overall
objective of the current dissertation research is to delineate neurobehavioral
mechanisms that underlie the development of DIO. A rat model of DIO was used
to investigate striatal dopamine function, impulsivity and motivation as
neurobehavioral outcomes and predictors of obesity. The current dissertation
research can be broadly classisied into the outcome study and the predictor
study.
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Outcome study. Striatal D2 receptor density, VMAT2 function, DAT
function and expression, extracellular dopamine, impulsivity and food-motivated
behavior were evaluated as neurobehavioral outcomes of DIO.
Hypothesis 1 (chapter two): DIO is associated with decreased striatal D2
receptors, increased VMAT2 function, decreased DAT function and expression,
and increased extracellular dopamine concentration. The specific aims
formulated to test the hypothesis were.
Specific aim 1. As an outcome of DIO, striatal D2 receptor density was
evaluated in vitro using [3H]raclopride saturation analysis in striatal membrane
preparations.
Specific aim 2. As an outcome of DIO, striatal VMAT2 and DAT function
were evaluated in vitro using saturation analysis of [3H]dopamine uptake into
striatal vesicular and synaptosomal preparations, respectively.
Specific aim 3. As an outcome of DIO, methamphetamine-induced reverse
transport of DAT was evaluated in vitro using superfused striatal slices.
Specific aim 4. As an outcome of DIO, striatal DAT cellular expression
was evaluated using biotinylation and Western blot assays.
Specific aim 5. As outcomes of DIO, striatal dopamine uptake and
extracellular dopamine concentration were evaluated in vivo using no net flux
microdialysis.
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Hypothesis 2 (chapter three): DIO is associated with increased impulsivity and
increased food-motivated behavior. The specific aims that were formulated to
test the proposed hypothesis follow.
Specific aim 1. As an outcome of DIO, impulsivity was evaluated using the
delay discounting task.
Specific aim 2. As outcomes of DIO, food-motivated behavior and
persistence of food-seeking behavior were evaluated using the PR schedule of
reinforcement and extinction procedures, respectively.

Predictor study. Impulsivity, motivation for HF-reinforcers, striatal DAT
function and extracellular dopamine concentration were evaluated as
neurobehavioral antecedents of DIO to determine whether these factors serve as
predictors of DIO.
Hypothesis 3 (chapter four): Pre-existing individual differences in the levels of
impulsivity, motivation, striatal DAT function and extracellular dopamine
concentration will predict the development of DIO in the rat model. The specific
aims formulated to test the proposed hypothesis follow.
Specific aim 1. As predictors of DIO, impulsivity and food-motivated
behavior were evaluated using the delay discounting task and PR schedule of
reinforcement, respectively.
Specific aim 2. As predictors of DIO, striatal DAT function and extracellular
dopamine concentration were evaluated in vivo using no net flux microdialysis.
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Table 1

Spontaneous mutant rodent strains

References

**Except the dw/dw and ZDF rat strains that develop obesity
in response to a HF-diet, remaining spontaneous mutant
strains develop obesity in response to a standard chow diet
ob/ob mice
Leptin gene mutation results in leptin hormone deficiency

Zhang et al.,
1994;
Campfield et al.,
1995

db/db mice
Leptin receptor mutation results in leptin resistance

Chen et al.,
1996

fa/fa mutation in Zucker, Koletsky and **Zucker Diabetic
Fatty (ZDF) rats
Leptin receptor mutation results in decreased surface
receptor expression

Takaya et al.,
1996; Friedman
et al., 1997

Carboxypeptidase E gene mutation in mice
Disruption in posttranslational processing and secretion of
pro-insulin and POMC

Naggert et al.,
1995; Cool et
al., 1997; Cool
and Loh, 1998

**Growth hormone-deficient dwarf (dw/dw) rat

Clark et al.,
1996

Yellow Avy/- Mouse
Ectopic expression of the agouti gene

Yen et al., 1994

Tubby mice
Tubby gene mutation; function not clear

Kleyn et al.,
1996
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Table 2
Genetically engineered mutant rodent strains

References

**Except for the MCH over expressing mice that
develop obesity in response to a HF-diet,
remaining mutant strains develop obesity in
response to a standard chow diet.
CRF overexpression in mice

Stenzel-Poore et al., 1994

AgRP overexpression in mice

Graham et al., 1997

Adipose tissue-specific glucose transporter
(GLUT4) overexpression in mice

Shepherd et al., 1993

**MCH overexpression in mice

Shimada et al., 1998

Melanocortin receptor knockout mice
(MC3 and MC4 )

Huszar et al., 1997; Chen
et al., 2000

5-HT 2C receptor knockout mice

Tecott et al., 1995

Neuropeptide Y receptor knockout; NPYR-Y 1 ,
NPYR-Y 2

Kushi et al., 1998
Naveilhan et al., 1999

Peroxisome proliferator-activated receptor alpha
(PPAR- ) knockout mice

Costet et al., 1998

Bombesin receptor 3 (BRS-3) knockout mice

Hamazaki et al., 1997

Brain specific, insulin receptor knockout mice

Bruning et al., 2000

Brown adipose tissue deficient mice

Lowell et al., 1993
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Figure 1
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Figure 1: Saggital rat brain section displaying major dopamine reward
pathways.

77

Figure 2
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Figure 2: Schematic representation of dopamine synthesis, release, uptake and
metabolism.
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Figure 3

80

Figure 3: Diagrammatic representation of in vivo brain microdialysis.
Microdialysis set up (top); microdialysis probe (bottom).
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Figure 4
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Figure 4: Operant chamber and behaviors evaluated. Impulsivity and foodmotivated behavior in rats were measured using behavioral procedures
conducted in operant chambers (top). Impulsivity was measured using a delay
discounting task in which rats were given a choice between an immediate small
food reward and a delayed larger food reward. Response on one lever delivered
one sucrose pellet immediately, whereas response on the other lever delivered
three pellets after an adjusted delay. The delay to obtain the larger reinforcer
served as the measure of impulsivity. The mean adjusted delay is inversely
proportional to impulsivity such that rats with low mean adjusted delay are
categorized as high-impulsive and vice-versa (bottom-left). Motivation for food
reinforcers was evaluated using a PR schedule in which the number of
responses required to obtain a single food reinforcer was increased progressively
within a session. As the number of responses required to obtain a single food
reinforcer is increased progressively, the response rate gradually declines. The
response ratio at the end of the session or the point at which the rat ceases to
respond is known as the PR breakpoint, indicative of motivation to obtain food
reward (bottom-right).

Copyright © Vidya Narayanaswami 2012
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Chapter Two
Evaluation of striatal D2 receptor density, VMAT2 function, DAT function
and expression, and extracellular dopamine levels as outcomes of DIO

I.

Introduction

Obesity is associated with greater preference for and non-homeostatic
overeating of palatable, HF-foods (Drewnowski et al., 1992; Lucas et al., 1998;
Sclafani, 2001; Gaillard et al., 2008). Both orosensory properties and nutritional
content confer rewarding properties to food (Warwick and Weingarten, 1995;
Martel and Fantino, 1996). A considerable body of evidence suggests that the
ability of palatable foods to establish and maintain response habits and
preference is mediated by dopamine function within the reward neurocircuitry
(Wang et al., 2001; Small et al., 2003; Wise, 2006). Importantly, ingestion of
palatable foods activates brain reward centers leading to dopamine release in the
NAc and striatum, associated with primary reward and habit formation,
respectively (Martel and Fantino, 1996; Small et al., 2003; Kelley, 2004). The
resulting dopaminergic activation is known to mediate the primary reinforcing
effects and incentive motivation for food, which further influence hedonic and
non-homeostatic food intake in obesity (Berthoud, 2002; Wise, 2006).

NAc dopamine mediates primary reward; however, a shift in control from
dopamine pathways in NAc to striatum is believed to occur coincident with the
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development of habitual behaviors (Di Chiara et al., 2004; Koob and Volkow,
2010). Inhibition of dopamine synthesis by inactivation of the tyrosine
hydroxylase gene results in reduced preference for palatable foods (Szczypka et
al., 2001). Gene rescue in NAc and/or striatum restores preference, whereas
only striatal rescue restores food consumption. Repeated dopaminergic
activation is known to cause expression of delta Fos B, a transcription factor that
is hypothesized to regulate behaviors and neuroadaptions associated with
dopaminergic signaling (Nestler et al., 2001). The involvement of striatum in
motivation for food is supported by findings that rats over-expressing striatal delta
Fos B exhibit high PR breakpoints (Olausson et al., 2006). Following extended
access to HF-food, obese rats exhibit increased thresholds for electrical brain
stimulation reward, increased resistance to aversive stimuli-induced disruption of
food consumption and decreased striatal D2 receptors (Johnson and Kenny,
2010). In obese humans, both D2-receptor density and neuronal activity in
striatum are decreased compared to non-obese individuals (Wang et al., 2001;
Stice et al., 2008). Thus, dysregulated striatal function may underlie excessive
food intake in obesity.

Extracellular dopamine concentrations are regulated by DAT and VMAT2,
which translocate dopamine across the plasmalemma from the extracellular
space into the cytosol, and from the cytosol into synaptic vesicles, respectively
(Sulzer et al., 2005). Inhibition of transporter function and/or reversal of these
striatal transporters by drugs of abuse increases extracellular dopamine
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concentrations, and the resulting dopaminergic stimulation is known to mediate
drug associated reward (Fleckenstein and Hanson, 2003; Kahlig and Galli, 2003;
Riddle et al., 2005). The role of VMAT2 in food intake and obesity has not been
studied; however, knockout studies and genetic analysis implicate the role for
DAT in food intake. DAT-deficient mice exhibit increased extracellular dopamine
concentration and greater food intake, compared to wildtype-mice (Pecina et al.,
2003). Genetic-linkage analysis reveals human DAT gene polymorphisms with a
greater frequency of short alleles (7 or 9 repeats) to be associated with reduced
DAT expression and binge eating (Heinz et al., 2000; Fuke et al., 2001;
Shinohara et al., 2004). Thus, DAT appears to play a prominent role in regulating
binge eating. Importantly, elevated extracellular dopamine concentration as a
result of dysregulated VMAT2 and DAT transporter function may contribute to
excessive food intake and the development of obesity.

The current study investigated striatal dopaminergic function following the
development of DIO. Striatal D2 receptor density, VMAT2 function, DAT function
and expression, and extracellular dopamine concentration were evaluated as
outcomes of DIO.

Hypothesis: DIO is associated with decreased striatal D2 receptor density,
increased VMAT2 function, decreased DAT function and expression, and
increased extracellular dopamine concentration. The specific aims formulated to
test the hypothesis follow.
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Specific aim 1. Determine striatal D2 receptor density as an outcome of
DIO using saturation analysis of [3H]raclopride binding to striatal membrane
preparations.
Specific aim 2. Determine striatal in vitro VMAT2 and DAT function as
outcomes of DIO using saturation analysis of [3H]dopamine uptake into striatal
vesicular and synaptosomal preparations, respectively.
Specific aim 3. Determine in vitro methamphetamine-induced reverse
transport of DAT as an outcome of DIO using superfused striatal slices.
Specific aim 4. Determine in vitro striatal DAT cellular expression as an
outcome of DIO using biotinylation and Western blot assays.
Specific aim 5. Determine in vivo striatal dopamine uptake and
extracellular dopamine concentration using no net flux microdialysis.

II.

Methods

II a. Materials. Adenosine 5’-triphosphate magnesium salt (ATP-Mg+2),
ascorbate oxidase, chromasolv®, D-glucose, D-methamphetamine, dopamine
hydrochloride, ethylenediaminetetraacetic acid (EDTA), N-[2-hydroxyethyl]
piperazine-N’-[2-ethanesulfonic acid] (HEPES), nomifensine maleate, pargyline
hydrochloride, polyethyleneimine (PEI), (S)-sulpiride and Tris [hydroxyl methyl]
aminomethane hydrochloride (Tris-HCl) were purchased from Sigma-Aldrich (St.
Louis, MO). Perchloric acid (70%) was purchased from Mallinckrodt Baker
(Phillipsburg, NJ). Diazepam and ketamine hydrochloride were purchased from
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N.L.S. Animal Health (Pittsburgh, PA). [3H]Dopamine (3, 4-ethyl-2-[N3

H]dihydroxyphenyl-ethylamine; specific activity, 33.7 Ci/mmol), [3H]raclopride

(methoxy-3H; specific activity, 82.8 Ci/mmol) and tissue solubilizer (TS-2) were
purchased from PerkinElmer Life Sciences (Boston, MA). Phosphate buffered
saline (PBS), polyacrylamide, sodium dodecyl sulfate (SDS), Triton-X 100 buffer
and Tween-20 were purchased from Bio-Rad Laboratories (Hercules, CA).
Immunopure immobilized monomeric avidin gel and sulfosuccinimidobiotin (sulfoNHS-biotin) were purchased from Pierce Chemical (Rockford, IL). Immobilon-P
transfer membranes (0.45 µm pore size) were purchased from Millipore Co
(Bedford, MA). Primary antibodies recognizing rat DAT (C-20; goat polyclonal
antibody), protein phosphatase 2A (PP2A; sc-13601; mouse monoclonal
antibody) and secondary antibodies; donkey anti-goat (sc-2020) and chicken
anti-mouse (sc-2954), were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). β-Actin (A 5441, mouse monoclonal antibody was purchased
from Sigma-Aldrich (St. Louis, MO). All other chemicals were purchased from
Fisher Scientific Co. (Pittsburgh, PA). (2R, 3S, 11bS)-2-Ethyl-3-isobutyl-9,10dimethoxy-2,2,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-ol (Ro4-1284)
was a gift from Hoffman-La Roche Ltd. (Basel, Switzerland). All other chemicals
were purchased from Fisher Scientific Co. (Pittsburgh, PA).

II b. Animals. Outbred adult male Sprague Dawley rats (350-400 g;
Charles River Laboratories Inc., Wilmington, MA) were housed individually in
solid-bottom cages with bedding and received standard rat chow (Teklad
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mouse/rat diet (2018), 18% of calories from fat and total density of 3.1 kcal/g;
Harlan Laboratories Inc., Indianapolis, IN) and water ad libitum. Prior to the
initiation of experimental procedures, rats were fed standard rat chow for one
week during acclimatization to the animal facility. All experimental procedures
were approved by the Institutional Animal Care and Use Committee at University
of Kentucky.

II c. DIO model. A well characterized, naturalistic DIO model employing
outbred rats was used to mimic human obesity (Levin et al., 1997, Boustany et al.,
2004). The model was previously characterized as exhibiting hyperphagia,
increased visceral, epididymal and retroperitoneal adiposity, hypertension,
increased plasma levels of angiotensin peptides, cholesterol and triglycerides,
and defective leptin- and insulin-signaling (Dobrian et al., 2000; Levin and DunnMeynell, 2002; Boustany et al., 2004; Clegg et al., 2005). Rats were fed for 8 wk
either a moderately HF-diet (HF; n = 24; D12266B, 31.8% kcal from fat and total
density of 4.41 kcal/g) or a low-fat diet (LF; n = 6-8; D12489B, 10.6% kcal from fat
and total density of 3.9 kcal/g; Research Diets Inc. New Brunswick, NJ). The
rationale for including the LF group was to parse out the effects of obesity per se
and diet per se. Importantly, the LF group serves as a more appropriate control
than the standard chow group, since unlike standard chow, the protein content
and source of macronutrients is not different between the LF- and HF-diets.
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Food intake was determined daily and body weight determined 3-times
weekly throughout the 8-wk dietary treatment period. During food intake
measurements, the cages were scanned for spillage of any uneaten food particles
in the bedding to determine the exact amount of food consumed. Following the 8wk period, rats fed the HF-diet were segregated into OP and OR groups based on
body weight gain (top and bottom third, respectively; n = 6-8 rats/group; Fig. 5)
(Levin et al., 1997; Boustany et al., 2004). The rats with body weight gain
intermediate to those with maximum and minimum body weight gain (OP and OR
rats, respectively) were not employed for the neurobehavioral assays (Fig. 6: top).
Energy intake was calculated by multiplying daily food intake (g) by total kcal/g of
the respective diet consumed.

II d. Experimental design and procedures. To evaluate the
dopaminergic outcomes of DIO, striatal D2 receptor density, VMAT2 function,
DAT function and expression, and extracellular dopamine concentration were
determined in OP, OR and LF groups. The details of each study follow.

Study 1: As an outcome of DIO, striatal D2 receptor density (B max ) and affinity
(K d ) were evaluated in vitro using [3H]raclopride binding saturation analysis.
Between-subject differences in the kinetic parameters were determined in OP,
OR and LF groups (n = 6 rats/group). Thus, treatment group was a betweensubject factor and [3H]raclopride concentration a within-subject factor. For these
analyses, brains were obtained from OP, OR and LF rats previously employed to
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deteremine other outcomes that included the evaluation of in vivo striatal DAT
function (chapter 2, study 6) and extracellular dopamine concentration (chapter
2, study 6), followed by the evaluation of impulsivity (chapter 3, study 1).

[3H]Raclopride binding. Striatal D2 receptor density was determined
using saturation kinetic analysis of [3H]raclopride binding according to previous
methods (Sun et al., 2003). Rats employed in this study include those anmals
that previously underwent microdialysis (chapter 2, study 6). The alternate
striatum (n = 6 rats/group), that was not implanted with a microdialysis probe
during no net flux microdialysis experiments (chapter 2 study 6) were stored at 80°C for the binding assay. Striata were thawed and homogenized using a
motor-driven glass Teflon homogenizer with 10 up-and-down strokes (500 rpm)
at 0°C in 5 ml of 50 mM Tris-HCl buffer containing 120 mM NaCl, 5 mM KCl, 1.5
mM CaCl 2 , 4 mM MgCl 2 and 1 mM EDTA, pH 7.4. Homogenates were incubated
with [3H]raclopride (0.2-20 nM) in buffer (total volume, 250 μl) for 120 min at
22°C. Nonspecific binding was determined in the presence of (S)-sulpiride (10
μM), a selective D2 receptor antagonist, that displaces [3H]raclopride bound to
D2 receptors (Sun et al., 2003). Thus, [3H]raclopride binding determined in the
presence of (S)-sulpiride (10 μM) enables the detection of [3H]raclopride that is
bound to the entire membrane preparation, except the D2 receptors (nonspecific
binding). Reactions were terminated by filtration onto buffer-soaked Unifilter-96
GF/B filter plates using a Packard Filter Mate Harvester (PerkinElmer Inc.,
Downers Grove, IL). Filter plates were washed 3 times with ice-cold buffer, dried
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for 60 min at 45°C, bottom-sealed and each well filled with 40 μl of scintillation
cocktail (MicroScint 20; Perkin Elmer Inc.). Radioactivity on the filters was
determined by liquid scintillation spectrometry (TopCount NXT; PerkinElmer Inc.).
Protein concentrations were determined with bovine serum albumin as the
standard (Bradford, 1976).

Study 2. As an outcome of DIO, maximal velocity (V max ) and affinity (K m ) of
[3H]dopamine uptake by striatal VMAT2 into synaptic vesicule preparations were
evaluated in vitro using saturation analysis. Between-subject differences in
kinetic parameters were determined in OP, OR and LF groups (n = 6 rats/group).
Thus, treatment group was a between-subject factor and [3H]dopamine
concentration was a within-subject factor. Rats in this study had no prior
experimental manipulations.

In vitro kinetic analysis of [3H]dopamine uptake into VMAT2. VMAT2
function was assessed in striatal synaptic vesicle preparations from separate
groups of OP, OR and LF rats (n = 6 rats/group) using saturation kinetic analysis
of [3H]dopamine uptake, based on previous methods (Nickell et al., 2010).
Vesicles were prepared by homogenizing striata with 10 passes of a Teflon
pestle homogenizer (clearance ~ 0.009”) in 14 ml of ice-cold sucrose solution
(0.32 M sucrose and 5 mM sodium bicarbonate, pH 7.4). Homogenates were
centrifuged at 2,000 g for 10 min at 4°C, and resulting supernatants were
centrifuged at 10,000 g for 30 min at 4°C. Pellets were suspended in 2 ml of 0.32
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M sucrose solution and exposed to osmotic shock via addition of 7 ml of ice cold
water followed by immediate restoration of osmolarity by addition of 900 µl of
0.25 M HEPES and 900 µl of 1 M potassium tartrate solution. Samples were
centrifuged at 20,000 g for 20 min at 4°C. Resulting supernatants were
centrifuged at 55,000 g for 1 h at 4°C, followed by addition of 100 µl of 1.0 M
MgSO 4 , 100 µl of 0.25 M HEPES and 100 µl of 1.0 M potassium tartrate to the
supernatants. Samples were centrifuged at 100,000 g for 45 min at 4°C. Final
pellets were resuspended in 2.4 ml of assay buffer (25 mM HEPES, 100 mM
potassium tartrate, 50 µM EGTA, 100 µM EDTA, 1.7 mM ascorbic acid, 2 mM
ATP-Mg+2, pH 7.4). Nonspecific [3H]dopamine uptake was determined in the
presence of Ro-4-1284 (10 µM), a selective VMAT2 inhibitor (Nickell et al.,
2010). Thus, vesicular [3H]dopamine uptake determined in the presence of Ro-41284 (10 μM) indicates [3H]DA uptake through mechanisms other than VMAT2
(nonspecific uptake). Reactions were initiated by addition of 100 µl of vesicular
preparation to 350 µl assay buffer containing [3H]dopamine (0.1 nM-5 µM) in the
absence or presence of 10 µM Ro4-1284; final assay volume was 500 µl. Assay
tubes were incubated at 34°C for 8 min. [3H]Dopamine uptake was terminated by
placing the samples on ice followed by rapid filtration through Whatman GF/B
glass fiber filters (presoaked with 0.5% PEI in MilliQ water for 3 h). Filters were
washed 3 times with ice-cold assay buffer containing 2 mM MgSO 4 (without 2
mM ATP-Mg+2 ) using a Brandel cell harvester (Model MP-43RS, Biochemical
Research and Development Laboratories Inc., Gaithersburg, MD). Radioactivity
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was determined by liquid scintillation spectrometry (Model B1600TR, Perkin
Elmer Inc.). Protein concentrations were determined as previously described.

Study 3. As an outcome of DIO, maximal velocity (V max ) and affinity (K m ) of
[3H]dopamine uptake by striatal DAT into synaptosomal preparations were
evaluated in vitro using saturation analysis. Between-subject differences in
kinetic parameters were determined in OP, OR and LF groups (n = 6-8
rats/group). Thus, treatment group was a between-subject factor and
[3H]dopamine concentration was a within-subject factor. Rats in this study had no
prior experimental manipulations.

In vitro kinetic analysis of [3H]dopamine uptake at DAT. DAT function
was determined using saturation kinetic analysis of [3H]dopamine uptake into
striatal synaptosomal preparations from separate groups of OP, OR and LF rats
(n = 12-14 rats/group from two separate series of DAT uptake assays), based on
previous methods (Zhu et al., 2003). Striata were homogenized in 20 ml of icecold sucrose solution (0.32 M sucrose and 5 mM sodium bicarbonate, pH 7.4)
with 16 passes of a Teflon pestle homogenizer. Homogenates were centrifuged
at 2,000 g for 10 min at 4°C, and the resulting supernatants were centrifuged at
20,000 g for 15 min at 4°C. Resulting pellets were resuspended in 2.4 ml of icecold assay buffer (125 mM NaCl , 5 mM KCl, 1.5 mM MgSO 4 , 1.25 mM CaCl 2 ,
1.5 mM KH 2 PO 4 , 10 mM D-glucose, 25 mM HEPES, 0.1 mM EDTA, 0.1 mM
pargyline and 0.1 mM L-ascorbic acid, saturated with 95% O 2 /5% CO 2 , pH 7.4).
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Nonspecific [3H]dopamine uptake was determined in the presence of
nomifensine (10 μM), a selective DAT inhibitor (Maragos et al., 2002). Thus,
synaptosomal [3H]dopamine uptake determined in the presence of nomifensine
(10 μM) indicates [3H]DA uptake through mechanisms other than DAT
(nonspecific uptake). Reactions were initiated by the addition of 50 μl of
synaptosomes to 350 µl assay buffer in the absence or presence of nomifensine,
and incubated at 34°C for 5 min followed by addition of [3H]dopamine (0.1 nM-5
µM) in a final volume of 500 µl. Incubation continued for 10 min at 34°C.
Reactions were terminated by the addition of 3 ml of ice-cold assay buffer,
followed by filtration through Whatman GF/B glass fiber filters (presoaked with 1
mM pyrocatechol for 3 h to minimize nonspecific binding of [3H]DA). Filters were
processed, radioactivity and protein concentrations determined as previously
described.

Study 4. As an outcome of DIO, methamphetamine-induced reverse transport of
DAT in superfused striatal slices was determined in vitro in OP, OR and LF
groups (n = 6-8 rats/group). Thus, treatment group was a between-subject factor,
and methamphetamine concentration and time were within-subject factors. Rats
in this study had no prior experimental manipulations.

Methamphetamine-evoked [3H]dopamine overflow assay. Under
normal physiological conditions, DAT translocates dopamine from the
extracellular space into the presynaptic terminal; whereas methamphetamine
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inhibits dopamine uptake and promotes DAT reverse transport, thereby
increasing extracellular dopamine concentrations (Liang and Rutledge, 1982;
Parker and Cubeddu, 1986; Dwoskin et al., 1988; Sulzer et al., 2005). DAT
reverse transport was assessed in striatal slice preparations from separate
groups of OP, OR and LF rats (n = 6-8 rats/group), based on previous methods
(Miller et al., 2001). Coronal slices (500 µm, 6-8 mg) were incubated for 30 min in
Krebs' buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM MgCl 2 , 1 mM NaH 2 PO 4 ,
1.3 mM CaCl 2 , 11.1 mM D-glucose, 25 mM NaHCO 3 , 0.11 mM L-ascorbic acid,
and 0.004 mM EDTA, pH 7.4, saturated with 95% O 2 /5% CO 2 at 34°C), and then
incubated for an additional 30 min in buffer containing 0.1 µM [3H]dopamine.
Each slice was transferred to a superfusion chamber and superfused (1 ml/min)
with Krebs' buffer containing pargyline (10 µM), an MAO inhibitor. After 60 min of
superfusion, three samples (5 ml) were collected to determine basal
[3H]dopamine outflow. Superfusion continued in the absence or presence of
methamphetamine (1-30 µM) for 60 min to determine methamphetamine-evoked
[3H]dopamine overflow as a result of DAT reverse transport. Using a repeatedmeasures design, each chamber containing a single slice was exposed to one
methamphetamine concentration which remained in the buffer until the end of the
experiment. At the end of the experiment, each slice was solubilized in TS-2
tissue solubilizer. Radioactivity in the superfusate samples and striatal slices
were determined by liquid scintillation spectrometry as previously described.
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Study 5. As an outcome of DIO, striatal DAT protein in total, intracellular and
cell-surface fractions was determined in vitro using biotinylation and Western blot
assay in OP, OR and LF groups (n = 8 rats/group). Treatment group was a
between-subject factor, and individual fractions were within-subject factors. Rats
in this study had no prior experimental manipulations.

Biotinylation and Western blot assays. DAT cellular expression was
determined in separate groups of OP, OR and LF groups (n = 8 rats/group) using
biotinylation and Western blot assays, as previously described (Zhu et al., 2005).
β-Actin was used to monitor protein loading within a fraction (total, nonbiotinylated (intracellular) and biotinylated (cell-surface) fraction). To monitor the
integrity of the samples, PP2A was used because this protein is located
predominantly in the intracellular compartment, and should not be biotinylated
since biotin is cell-impermeable. Only cell-surface proteins are expected to be
biotinylated.

Striatal synaptosomes (500 μg protein/sample) were incubated for 1 h at
4°C with continual shaking in 500 μl of 1.5 mg/ml sulfo-NHS-biotin in PBS/Ca/Mg
buffer (138 mM NaCl, 2.7 mM KCl, 1.5 mM KH 2 PO 4 , 9.6 mM Na 2 HPO 4 , 1 mM
MgCl 2 , 0.1 mM CaCl 2 , pH 7.3). After incubation, samples were centrifuged
(8,000 g, 4 min, 4°C). In order to remove the free sulfo-NHS-biotin, the resulting
pellets were resuspended in 1 ml of ice-cold 100 mM glycine in PBS/Ca/Mg
buffer and centrifuged (8,000 g, 4 min, 4°C) and resuspended three times. Final
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pellets were resuspended in 1 ml of ice-cold 100 mM glycine in PBS/Ca/Mg
buffer and incubated with continual shaking for 30 min at 4°C. Samples were
then centrifuged (8,000 g, 4 min, 4°C). Resulting pellets were resuspended in 1
ml of ice-cold PBS/Ca/Mg buffer and centrifuged (8,000 g, 4 min, 4°C) and
resuspended and centrifuged twice more. Final pellets were lysed by sonication
for 2-4 s in 300 μl of Triton X-100 buffer (10 mM Tris, 150 mM NaCl, 1 mM
EDTA, 1% Triton X-100, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μM pepstatin, 250
μM phenylmethysulfonyl fluoride, pH 7.4), followed by incubation and continual
shaking for 20 min at 4°C. Lysates (300 μl) were centrifuged (21,000 g, 20 min,
4°C).

An aliquot of the supernatant fraction (100 μl) was assayed for total DAT
immunoreactivity. The remaining supernatant volume was incubated with
continuous shaking in the presence of monomeric avidin beads in Triton X-100
buffer (100 μl/sample) for 1 h at room temperature followed by centrifugation
(17,000 g, 4 min, 4°C). The resulting supernatant (300 μl; fraction) represented
the non-biotinylated fraction, and was assayed for intracellular immunoreactive
DAT. Laemmli buffer was added to the total synaptosomal and non-biotinylated
fractions before samples were stored at -20°C (1:1 ratio of Laemmli buffer and
respective striatal fraction). Pellets from the previous centrifugations contained
the avidin-adsorbed biotinylated proteins, which were then resuspended in 1 ml
of 1% Triton X-100 buffer and centrifuged (17,000 g, 4 min, 4°C), and this was
repeated twice. Final pellets were incubated with 100 μl of Laemmli buffer (62.5
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mM Tris-HCl, 20% glycerol, 2% SDS, 0.05% β-mercaptoethanol, and 0.05%
bromphenol blue, pH 6.8) for 20 min at room temperature to elute the biotinylated
cell-surface proteins. Following incubation, samples were centrifuged (17,000 g,
4 min, 4°C) and 100 μl of the resulting supernatant (biotinylated fraction) were
stored at -20°C until assay for cell-surface, immunoreactive DAT.

Immunoreactive DAT protein in total, non-biotinylated (intracellular) and
biotinylated (cell-surface) fractions were determined using gel electrophoresis
and Western blot assay. Samples were thawed; proteins were separated by 8%
SDS-polyacrylamide gel electrophoresis for 90 min at 150 V and transferred to
Immobilon-P transfer membranes (0.45-μm pore size; Millipore Corporation,
Billerica, MA) in transfer buffer (50 mM Tris, 250 mM glycine, 3.5 mM SDS) using
a Trans-Blot Electrophoretic semi-dry transfer cell (Bio-Rad) for 60 min at 25 V.
Transfer membranes were incubated with blocking buffer (5% dry milk powder in
PBS containing 0.5% Tween 20) for 1 h at room temperature. DAT and control
protein immunoreactivity were assessed in parallel. Transfer membranes
containing DAT protein (75 kDa mol wt) and control proteins (β-actin: 42 kDa,
PP2A: 34 kDa) were incubated overnight at 4°C with goat polyclonal DAT
antibody (1:500 dilution in blocking buffer) and with mouse monoclonal β-actin
and PP2A antibodies (1:10,000 and 1:500 dilution in blocking buffer,
respectively). Transfer membranes were washed four times with blocking buffer
at room temperature. Transfer membranes containing DAT were incubated for 1
h at 22°C with donkey anti-goat DAT secondary antibody (1:1000 dilution in
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blocking buffer). Transfer membranes containing β-actin and PP2A were
incubated for 1 h at 22°C with chicken anti-mouse secondary antibody (1:5000
dilution in blocking buffer). Chemiluminescence was used to detect the blots by
spraying the membranes with Hy GLOTM chemiluminiscent (CL) horseradish
peroxidase antibody detection reagent (Denville Scientific Inc., Metuchen, NJ)
followed by development using hyblot CL autoradiography film (Denville Scientific
Inc.). Multiple autoradiographs were obtained using different exposure times, and
immunoreactive bands were quantified by densitometric scanning using Image J
software (NIH, Bethedsa, MD).

Study 6. As outcomes of DIO, striatal dopamine uptake (extraction fraction) and
extracellular dopamine concentration were evaluated in vivo using no net flux
microdialysis in OP, OR and LF groups (n = 8 rats/group). Treatment group was
a between-subject factor and dopamine concentration was a within-subject
factor. Rats employed in this study were also used for the behavioral assessment
of impulsivity (chapter 3, study 1) followed by the evaluation of the kinetic
parameters of D2 receptor binding (chapter 2, study 1).

No net flux microdialysis. In vivo striatal DAT function and basal
extracellular dopamine concentration were evaluated using the no net flux
microdialysis method as previously described (Acri et al., 2001). Rats were
anesthetized with ketamine hydrochloride (100 mg/kg, i.p.) and diazepam
(5 mg/kg, i.p.) and placed in a stereotaxic apparatus (Stoelting, Wood Dale, IL).
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An intracerebral guide cannula (MD 2251, Bioanalytical System Inc., West
Lafayette, IN) was implanted. Stereotaxic coordinates were: AP = 1.2 mm,
anterior to bregma: ML = 2.8 mm, lateral to midline and DV = -4 mm ventral to
dura (Paxinos and Watson, 1986). The cannula was fixed to the skull using
stainless steel screws and dental cement. Following surgery, rats were
administered carpofen (5 mg/kg, s.c.) and allowed to recover for 3 days in the
home-cage. Then, a microdialysis probe (MD 2200, Bioanalytical System Inc.)
was inserted into the guide cannula, such that it extended 2 mm beyond the end
of the cannula. The probe tubing was suspended through a swivel spring
assembly attached to the wall of the Plexiglas chamber (25 × 44 × 38 cm), and
connected to a microinfusion pump (KDS250, Holliston, MA). The microdialysis
probe was perfused at 1.2 μl/min for 120 min, and after that at 2.2 μl/min for 90
min with aCSF (145 mM NaCl, 2.7 mM KCl, 1 mM MgCl 2 , 1.2 mM CaCl 2 , 2 mM
sodium phosphate, 0.25 mM ascorbic acid, 5.4 mM D-glucose, pH 7.4, filtered
through a 0.2 μm sterile filter). Probes were perfused (2.2 µl/min) with aCSF
containing 0, 5, 10 and 20 nM dopamine (dopamine in ) in a randomized order of
presentation for 60 min each (20 min for equilibration and 40 min for sample
collection; dopamine out ). Dialysates were collected in tubes containing 5 μl of 0.1
N perchloric acid, frozen on dry ice and stored at −80°C until HPLC analysis.
Dopamine standards were prepared and frozen coincident with dialysate.

Dopamine out was quantified using HPLC with electrochemical (EC)
detection as described previously (Nickell et al., 2010). Dialysates and dopamine
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standards were thawed, ascorbate oxidase (30 μl; 81 U/ml) added to each
sample (30 μl) and the resulting solution analyzed by HPLC-EC. The HPLC-EC
consisted of a model 126 pump and model 508 autosampler (Beckman Coulter
Inc., Fullerton, CA), an ODS Ultrasphere C18 reverse-phase 3 μm column (80
mm × 4.6 mm), a Coulometric-II detector with model 5020 guard cell (+0.60 V)
and a model 5011analytical cell maintained at 50 mV and 350 mV (ESA Inc.,
Chelmsford, MA). HPLC mobile phase was 0.07 M citrate/0.1 M acetate buffer
(175 mg/L octylsulfonic acid-sodium salt, 650 mg/L of NaCl and 7% methanol, pH
4; flow rate, 1.5 ml/min). Separations were performed at room temperature, and 5
to 6 min was required to process each sample. Retention time of dopamine
standards was used to identify dopamine peaks. Peak heights were measured to
quantify the amount of dopamine based on standard curves generated before
and after sample analysis using 32 karat software (Beckman Coulter). Detection
limit for dopamine was 1 pg/100 µl.

Following the behavioral assessment of impulsivity (chapter 3, study 1),
whole brains were obtained and fixed in Chromasolv® for sectioning (Leica
1850 M, Nussloch, Germany) for determination of probe placement.

II e. Data analysis. Data are presented as mean values ± S.E.M., and ‘n’
represents the number of animals tested for each group. Data were analyzed
using GraphPad Prism 4.0 program (GraphPad Software Inc., San Diego, CA)
and SPSS version 9.0 (SPSS Science, Chicago, IL).
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Time dependent differences in body weight and energy intake between
groups were determined by two-way ANOVAs, with OP, OR and LF as a
between-subject factor and time as a within-subject factor. One-way ANOVAs
were used to analyze between-group differences in body weight, energy intake
and % body weight gain after 8 wk of dietary treatment.

Specific [3H]raclopride binding to D2 receptors and specific [3H]dopamine
uptake at VMAT2 and DAT were determined by subtracting nonspecific binding
or uptake from total binding or uptake (Fig. 7). One-way ANOVAs determined
between-group differences in D2 receptor density (B max ) and affinity (log K d ) for
[3H]raclopride binding, and maximal velocity (V max ) and affinity (log K m ) for
[3H]dopamine uptake.

For methamphetamine-evoked [3H]dopamine overflow, each superfusate[3H] was divided by tissue-[3H] at the time of sample collection and expressed as
percentage of tissue-[3H]. Basal [3H]dopamine outflow was determined from the 3
samples collected prior to methamphetamine exposure. To determine betweengroup differences in methamphetamine-evoked [3H]dopamine outflow in striatal
superfusates, a three-way ANOVA was conducted on the time-course data with
treatment group as a between-subject factor and methamphetamine
concentration and time as within-subject factors. Methamphetamine-evoked
[3H]dopamine overflow was calculated by summing increases in superfusate-[3H]
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and subtracting basal [3H]outflow across an equivalent time period. To determine
between-group differences in methamphetamine-evoked [3H]dopamine overflow,
two-way ANOVA was conducted with treatment group as a between-subject
factor and methamphetamine concentration as a within-subject factor.

For Western blot analysis, DAT densitometry values were normalized to
its respective β-actin band to account for variations in loaded protein and
corrected by multiplying by the sum of the volume in each fraction (100 µl total +
300 µl non-biotinylated fraction + 100 µl biotinylated fractions) divided by the
specific fraction volume applied to SDS–polyacrylamide gel (20 µl, total; 40 µl,
non-biotinylated; 10 µl, biotinylated). This value was divided by the ratio of the
fraction volume to the synaptosomal volume (100:300 for total; 200:300 for nonbiotinylated and biotinylated fractions). One-way ANOVAs determined betweengroup DAT density differences within each fraction.

For no net flux microdialysis, the difference between perfusate and
dialysate dopamine concentration [dopamine in -dopamine out ] for each rat was
plotted as a function of perfusion concentration [dopamine in ]. Slope of the linear
regression represents extraction fraction (E d: index of DAT function) and the
regression line x-axis intercept represents the no net flux point (extracellular
dopamine concentration) (Justice, 1993). One-way ANOVAs analyzed betweengroup differences in extraction fraction and extracellular dopamine concentration.
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Post hoc analyses were conducted using Tukey’s or Newman Keul’s test,
as appropriate.

III.

Results

III a. Time course of body weight gain and energy intake during the 8wk exposure to the HF- and LF-diets
Body weight and energy intake for OP, OR and LF groups during the 8-wk
exposure to the HF- and LF-diets are illustrated in Fig. 6. Analysis of the body
weight data revealed a significant group x time interaction (F 14, 1000 = 12.72, p <
0.0001). Prior to diet exposure, body weight did not differ between groups (Fig. 6;
top). At 3 wk of diet exposure, body weight for the OP group was greater than
that for OR and LF groups. At the end of the diet exposure (wk 8), the OP group
exhibited 15% and 12% greater body weight than the OR and LF groups,
respectively. The mean daily energy intake across the 8-wk period was 14%
greater in the OP group compared to the OR group (119 ± 2 and 102 ± 2 kcal per
day, respectively) (F 7, 602 = 7.15, p < 0.0001; Fig. 6; bottom).

III b. In vitro striatal D2 receptor density
Striatal D2 receptor density was evaluated using saturation analysis of
[3H]raclopride binding to striatal membrane preparations (Fig. 8). OP rats
exhibited 42% lower B max compared to OR rats (F 2, 13 = 6.08, p < 0.01; Fig. 8).
No between-group differences in K d were found.
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III c. In vitro striatal VMAT2 function
Striatal VMAT2 function was assessed using kinetic analysis of
[3H]dopamine uptake in isolated striatal synaptic vesicles (Table 3). No betweengroup differences in V max and K m were found.

III d. In vitro striatal DAT function
V max and K m of specific [3H]dopamine uptake into striatal synaptosomes
was evaluated using kinetic analysis (Fig. 9). V max for [3H]dopamine uptake at
DAT was 40% lower in OP compared to OR rats (F 2, 35 = 6.285, p < 0.01), and
not different from LF rats. No between-group differences in K m were found.

III e. Methamphetamine-induced reverse transport of DAT in striatum,
in vitro
Time course of methamphetamine-evoked [3H]dopamine overflow was
assessed using superfused rat striatal slices (Fig. 10). ANOVA of the time course
data revealed a group x concentration x time interaction (F 112, 910 = 1.312, p <
0.05). No differences in basal [3H]dopamine outflow prior to methamphetamine
addition to the buffer were observed among groups. Across the time-course of
the experiment, [3H]dopamine overflow increased following addition of
methamphetamine to the buffer, peaked 10-15 min after methamphetamine
addition, and then over time declined towards basal levels despite the continued
presence of methamphetamine. Although methamphetamine produced a
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concentration-dependent increase in [3H]dopamine, the pattern of the
concentration response was different among OP, OR and LF groups. The
concentration-dependent increase in [3H]dopamine for the OR group reached
plateau at a lower concentration of methamphetamine (3 µM) compared to the
OP and LF groups. The significant three-way interaction from the ANOVA was
evaluated further by a two-way ANOVA at the time point of peak effect for each
group, and a group x concentration interaction was found (F 6, 45 = 3.52; p < 0.05).
Post hoc analysis revealed that only at the highest concentration (30 µM), the
effect of methamphetamine to evoke [3H]dopamine at the peak response was
greater in the OP group compared to OR group. Also, the effect of
methamphetamine (30 µM) to evoke [3H]dopamine at the peak response was
greater in the LF group compared to the OP group .

Collapsed across the time-course, two-way ANOVA on the
methamphetamine-evoked total [3H]dopamine overflow data revealed a group x
concentration interaction (F 8,75 = 6.45, p < 0.0001; Fig. 11). Post hoc analysis
revealed that total [3H]dopamine overflow was greater in the OP group compared
to the OR group at 10 and 30 µM methamphetamine. Also, at these
concentrations, total [3H]dopamine overflow was lower in the OP group
compared to LF.

III f. Striatal DAT cellular expression
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Striatal DAT cellular expression was evaluated using biotinylation and
Western blot analysis. DAT and β-actin immunoreactive bands located at ∼75

and 42 kDa, respectively, were compared among groups for each fraction (Fig.
12). β-Actin levels were not different among groups within a fraction. PP2A
immunoreactive bands located at ∼34 kDa were not detected in the biotinylated

fraction, indicating that biotinylation was performed efficiently. Total striatal DAT
levels were 30% and 48% higher in the OR group compared to OP and LF
groups, respectively (F 2, 17 = 6.143, p < 0.05). No between-group differences in
the biotinylated (F 2, 17 = 3.035, p > 0.05) and non-biotinylated fractions (F 2,
17

= 0.586, p > 0.05) were found.

III g. In vivo striatal DAT function and extracellular dopamine
concentration
In vivo striatal DAT function and basal extracellular dopamine
concentration were determined using the no net flux microdialysis method.
Representative chromatograms of dopamine standards and microdialysates are
illustrated in Fig. 13. The regression line for each group is illustrated in Fig. 14:
top. Striatal extraction fraction (index of DAT function) for the OP group was
about 40% lower than for OR and LF groups (slope = 0.54 ± 0.1, 0.92 ± 0.1, 0.96
± 0.1, respectively; F 2, 16 = 5.313, p < 0.05; Fig. 14: bottom-left). The basal
extracellular dopamine concentration in OP striatum was 45% greater than in OR
striatum (F 2, 16 = 4.767, p < 0.05), but not different from LF striatum (Fig. 14:
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bottom). Schematic representation of microdialysis probe placements in the
dorsal striatum for all groups of rats is provided in Fig. 15.

IV.

Discussion

The current study delineates alterations in striatal dopaminergic function
following the development of DIO. Striatal D2 receptor density was decreased in
the outbred DIO rat model, similar to human obesity (Wang et al., 2001). Strital
VMAT2 function was not altered following the development of DIO; however,
striatal DAT function and expression were decreased and extracellular dopamine
concentration increased following the development of DIO.

Primary reward associated with food intake has been shown to be
mediated by NAc dopamine (Kelley, 2004). Following ingestion of a HF-diet for
12 wk, NAc dopamine turnover in rats with free-access (obese) or restrictedaccess (non-obese) to a HF-diet was decreased compared to rats with freeaccess to standard chow (Davis et al., 2008), suggesting alterations in either
dopamine release, uptake and/or metabolism. In contrast, extracellular NAc
dopamine was decreased in inbred adult obese rats compared to rats inbred for
resistance to obesity and fed standard chow (Geiger et al., 2008). A caveat of
both these latter studies is that NAc was not dissected into shell and core, which
are functionally distinct regions and subserve primary reward and habitual
behavior, respectively (Bassareo and Di Chiara, 1999; Kelley, 1999; Kelley,
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2004). Dopamine release from NAc shell, striatum and mPFC slices was shown
to be decreased in inbred obese rats compared to inbred obesity-resistant rats
(Geiger et al., 2008). Further, a decrease in expression of mRNA for VMAT2,
tyrosine hydroxylase, DAT and D2 was found in cultured VTA neurons from
inbred obesity-prone compared to inbred obesity-resistant rats (Geiger et al.,
2008). Collectively, deficient dopamine function in NAc appears to contribute to
decreased primary reward and to the development of the obesity phenotype.
While decreased mesolimbic dopamine function is suggested to promote
compensatory hyperphagia leading to obesity, the current study focused on
striatal dopaminergic mechanisms.

A shift in underlying dopaminergic control from NAc to dorsal striatum
coincides with the development of habitual behaviors (Ito et al, 2002; Kelley,
2004; Everitt and Robbins, 2005; Koob and Volkow, 2010). A decrease in dorsal
striatal postsynaptic D2 receptors was found in the current study using an
outbred-DIO model, consistent with results from obese humans (Wang et al.,
2001). Decreased D2 receptor density may have preceded the development of
obesity or resulted from pre-existing decreases in DAT function and/or increased
extracellular dopamine levels associated with repeated food reward. Further,
alterations in VMAT2 and DAT function following the development of DIO was
investigated since these transporters regulate extracellular dopamine
concentrations. Increased VMAT2 function in DIO may contribute towards
increased extracellular dopamine levels such that VMAT2-mediated uptake of
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cytosolic dopamine into synaptic vesicles will facilitate dopamine storage for
subsequent release. In contrast to this proposed hypothesis, no between-group
differences in striatal VMAT2 function were found suggesting that striatal VMAT2
function is not altered following the development of DIO.

Both in vitro and in vivo studies demonstrated decreased striatal DAT
function and increased extracellular dopamine concentration in the OP compared
to the OR group. Importantly, obesity (not the diet per se) decreased DAT
function since OP and OR rats received the same HF-diet. Furthermore, the
ability of the OR phenotype to resist the development of obesity, despite
receiving ad libitum access to the HF-diet, may be due to compensatory
increases in DAT function and decreases in extracellular dopamine
concentration. Overall, decreases in striatal DAT function as a result of obesity
may be important for the maintenance of obesity.

Clearance of extracellular dopamine is primarily regulated by DAT
localized at the cell-surface (Zahniser and Sorkin, 2004). A possible explanation
for the decrease in DAT function in DIO is a decrease in cell-surface DAT
expression. Thus, in DIO, the effect of methamphetamine was anticipated to be
decreased as a result of diminished cell-surface DAT expression. Surprisingly,
methamphetamine-induced DAT reverse transport was increased in OP relative
to OR. In contrast, dopamine uptake was decreased in OP compared to OR.
Differential effect of obesity on DAT uptake and reverse transport may be
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explained by differential regulation of dopamine uptake via DAT and dopamine
release via DAT reverse transport. Uptake is regulated by D2 autoreceptors and
DAT interacting proteins like, PICK1 and synaptogyrin-3 (Cass and Gerhardt,
1994; Torres et al., 2001, Egana et al., 2009). Reverse transport is dependent on
PKC and CaMKII, whereas uptake is not (Kantor and Gnegy, 1998; Fog et al.,
2006). Thus, obesity may differentially alter the bidirectional function of DAT, i.e.,
dopamine uptake and dopamine reverse transport, by modulating distinct
signaling mechanisms.

DAT cellular localization was evaluated as a potential mechanism
underlying altered DAT function in OP and OR. Previous studies showed
reduced DAT density in striatum from rats fed a HF-diet for 20 days compared
with chow-fed controls (South and Huang, 2008). The current study extends
previous work showing a decrease in total DAT protein in OP compared to OR
striatum, also consistent with decreased striatal dopamine uptake in OP
compared to OR. However, no differences in cell-surface or intracellular DAT
expression were found, suggesting that regulation of DAT function in DIO is
trafficking-independent. Alternative mechanisms underlying decreased DAT
function and expression in OP striatum may include differential regulation of DAT
synthesis, degradation and recycling.

Overall, the current study demonstrates decreased striatal DAT function
and increased extracellular dopamine concentration following the development of
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DIO. Further, these striatal alterations may be responsible for the compensatory
decrease in post-synaptic D2 receptors. Importantly, the reported striatal
dopaminergic mechanisms in DIO may lead to an increase in reward threshold
that maintains excessive and habitual food intake in obesity.
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Table 3

Group

V max (fmol/min/mg protein)

K m (μM)

LF

318 ± 26.3a

0.15 ± 0.05a

OP

300 ± 28.3

0.16 ± 0.06

OR

285 ± 24.6

0.15 ± 0.05
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Table 3: Kinetic analysis of [3H]dopamine uptake at striatal VMAT2. aData are
expressed as mean ± S.E.M; n = 6 rats/group.
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Figure 5
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Figure 5: Development of the DIO model for the evaluation of dopaminergic
outcomes. Adult male Sprague Dawley rats received the HF- or LF- diet for 8 wk.
Following the 8-wk diet exposure, rats fed the HF-diet were segregated into OP
and OR groups based on body weight gain (top third and bottom third,
respectively). Neurochemical assays were conducted in OP, OR and LF groups
(Picture courtesy of Victoria English, Dr. Cassis’ Laboratory).
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Figure 6: Time course of body weight gain and energy intake during the 8-wk
exposure to the HF- and LF-diets. Top: Representative scatter plot that illustrates
the body weight gain in rats (n = 22) following the 8-wk HF-diet exposure. The
dots in red and blue represent the body weight gain in rats that were segregated
as OP and OR phentotypes, respectively. The dots in black represent the body
weight gain in rats that were intermediate to that of OP and OR. These rats were
not employed for the neurobehavioral assays. Bottom: DIO is associated with
increased body weight and energy intake. Since mean body weight and mean
energy intake for OP, OR and LF groups were not different between assays, data
for each group were collapsed across the different assays conducted. The
number of rats per group employed for the different assays was: in vitro VMAT2
function, n = 6/group; in vitro DAT function, n = 12-14/group (two separate series
of DAT uptake assays); methamphetamine (METH)-induced DAT reverse
transport, n = 6-8/group; DAT cellular localization, n = 8/group; in vivo DAT
function and extracellular dopamine concentration, n = 8/group. The group of rats
used to determine in vivo striatal DAT function was employed also to determine
impulsivity and striatal D2 receptor density. Top: OP rats exhibited greater body
weight compared to OR and LF rats from wk 3-8 of diet exposure. Data are
pooled from groups that were employed in studies 1-6 (methods section) and
expressed as the mean (SEM are smaller than the size of the symbol); n = 40-44
rats/group; *p < 0.001, indicates OP different from OR and LF. OP rats had
greater energy intake compared to OR rats across the 8-wk period of diet
exposure. Data are pooled from groups that were employed in studies 1-6
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(methods section) and expressed as the mean (SEM are smaller than the size of
the symbol); n = 40-44 rats/group; #p < 0.001, indicates OP different from OR.
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Figure 7: Typical saturation kinetic analysis curves for binding ([3H]raclopride)
and uptake ([3H]dopamine uptake) assays. Striatal D2 receptor density was
assessed using saturation analysis of [3H]raclopride binding to striatal
membranes. Striatal VMAT2 function and DAT function were assessed using
saturation kinetic analysis of [3H]dopamine (DA) uptake into striatal vesicular and
synaptosomal preparations, respectively. Specific [3H]raclopride binding to D2
receptors and specific [3H]DA uptake at VMAT2 and DAT were determined by
subtracting nonspecific binding or uptake from total binding or uptake. B max
represents D2 receptor density and K d represents affinity: concentration of
[3H]raclopride that binds to 50% of the maximal number of DA D2 receptors. V max
represents the maximal velocity of [3H]DA uptake at VMAT2/ DAT and K m
represents the affinity of [3H]DA for VMAT2/ DAT (concentration of [3H]DA
transported at ½ V max ).
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Figure 8
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Figure 8: Saturation analysis of [3H]raclopride binding to striatal membranes
from OP, OR and LF groups. DIO is associated with decreased striatal D2
receptor density. Striatal D2 receptor density was assessed using saturation
analysis of [3H]raclopride binding to striatal membranes. Nonspecific binding was
determined in the presence of (S)-sulpiride (10 μM). Specific [3H]raclopride
binding to striatal D2 receptors in OP, OR and LF groups (top). B max of the OP
group was lower compared to the OR group (bottom-left). No between-group
differences in K d were found (bottom-right). Data are expressed as pmol/g
protein (mean + SEM) for specific [3H]raclopride binding and B max and as nM
(mean + SEM) for K d ; n = 4-5 rats/group; *p < 0.05, indicates OP different from
OR.
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Figure 9
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Figure 9: Kinetic analysis of [3H]DA uptake at striatal DAT from OP, OR and LF
groups. DIO is associated with decreased in vitro striatal DAT function. Kinetic
analysis of [3H]DA uptake was conducted in the presence of nomifensine (10
µM). Specific [3H]DA uptake at striatal DAT of OP, OR and LF groups (top). V max
of striatal [3H]DA uptake at DAT was lower in the OP group compared to the OR
group (bottom-left). No between-group differences in K m were found (bottomright). Data are expressed as pmol/min/mg protein (mean + SEM) for specific
[3H]DA uptake at striatal DAT and V max and as µM (mean + SEM) for K m ; n = 1013 rats/group; *p < 0.05, indicates OR different from OP and LF.
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Figure 10
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Figure 10: Time course of methamphetamine-evoked [3H]DA in striatal
superfusates from OP (top), OR (middle) and LF (bottom) groups. DIO is
associated with increased methamphetamine-evoked [3H]DA (% tissue) in striatal
superfusates. Time course of methamphetamine-evoked [3H]DA overflow was
assessed using superfused rat striatal slices. Superfusion buffer contained 10 µM
pargyline. Striatal slices were superfused in the absence (control) or presence of
methamphetamine (1-30 µM) for 60 min. Arrow indicates time point at which
methamphetamine (METH: 1-30 μM) was added to the buffer. Also,
methamphetamine remained in the buffer until the end of the experiment. Data
are expressed as mean ± S.E.M; n = 5-7 rats/group; *p < 0.01, indicates OP
different from OR and LF.
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Figure 11
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Figure 11: Methamphetamine-evoked striatal [3H]DA overflow from OP, OR and
LF groups. DIO is associated with increased methamphetamine-evoked striatal
[3H]DA overflow. In response to methamphetamine (10 or 30 µM), striatal [3H]DA
overflow was higher in the OP group compared to the OR group, but lower
compared to the LF group. Also methamphetamine-induced striatal [3H]DA
overflow was lower in the OR group compared to the LF group. Data are
expressed as mean ± S.E.M; n = 5-7 rats/group; *p < 0.01, indicates OP different
from OR and LF.
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Figure 12
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Figure 12: Striatal DAT cellular expression in OP, OR and LF groups. DIO is
associated with decreased total striatal DAT expression. Biotinylation was
conducted in striatal synaptosomes obtained from OP, OR and LF groups. Total
striatal DAT levels were higher in the OR group compared to that of OP and LF
groups. No between-group differences in striatal DAT levels in the nonbiotinylated and biotinylated fractions were found. Representative immunoblot
(top). Mean DAT immunoreactivity in total, non-biotinylated and biotinylated
fractions from LF, OP and OR groups (bottom). Data are mean ± SEM; n = 6
rats/group; *p < 0.05, indicates OR different from OP and LF.
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Figure 13
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Figure 13: Representative HPLC chromatograms. Top: Representative
chromatogram of dopamine standards; 5, 10, 20 and 40 nM. Bottom:
Representative chromatogram of a microdialysis sample. Retention time of
dopamine: 4-5 min.
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Figure 14
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Figure 14: In vivo striatal DAT function and basal extracellular DA concentration
in OP, OR and LF groups. DIO is associated with decreased in vivo striatal DAT
function and increased basal extracellular DA concentration. No net flux in vivo
microdialysis was conducted in the dorsal striatum of OP, OR and LF groups.
The slope of the regression line represents the extraction fraction (E d ) and the
intersection of the regression line with x-axis represents the no net flux point i.e.
extracellular DA concentration (top). Striatal extraction fraction for the OP group
was lower than for OR and LF groups (p < 0.05; bottom left). The basal
extracellular DA concentration in OP striatum was greater than in OR striatum (p
< 0.05; bottom right). Data are expressed as nM (mean ± SEM) for DA exchange
and basal extracellular DA and as mean ± SEM for E d ; n = 5-6 rats/group; *p <
0.05, indicates OP different from OR and LF; #p < 0.05, indicates OP different
from OR.
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Figure 15
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Figure 15: Schematic representation of probe placement within the dorsal
striatum. Lines indicate the the 2mm microdialysis membrane (n = 5-6/ group).
Numbers to the right indicate distance from bregma. (Adapted from Paxinos and
Watson, 1986)
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Chapter Three
Evaluation of impulsivity and food-motivated behavior as outcomes of DIO

I.

Introduction

Obesity is a neurobehavioral disorder which involves excessive intake of
palatable foods that persists despite the threat of fatal health consequences
(Volkow and Wise, 2005). Increased preference for palatable, HF-foods is
attributed to favorable orosensory properties and post-ingestive effects of HFdiets (Warcik and Weingarten, 1995; Lucas et al., 1998; Sclafani et al., 2001;
Gaillard et al., 2008). Importantly, the reinforcing effects of palatable foods are
shown to be mediated by activation of striatal dopaminergic systems (Martel and
Fantino, 1996; Small et al., 2003). Furthermore, decreased striatal D2 receptor
availability in obese humans compared to control supports a role for striatal
dopaminergic system involvement in obesity (Wang et al., 2001). Striatal D2deficency in obesity is hypothesized to trigger motivational processes that
increase food consumption, and thereby, compensate for an understimulated
dopaminergic system (Wang et al., 2009).

In addition to the involvement of striatal dopamine pathways that regulate
reward and motivation, brain circuits that regulate inhibitory control (impulsivity),
salience attribution and decision making have also been implicated in obesity. In
obesity, enhanced sensitivity to palatable foods is evident from higher than
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normal baseline metabolism of [18F]fluoro-deoxyglucose (marker of brain
function) in the somatosensory cortex of obese subjects compared to control
(Wang et al., 2002a). Decreased striatal D2 receptor availability in obese humans
was shown to be associated with decreased metabolic activity in DLPFC, medial
OFC and anterior cingulate gyrus (Volkow et al., 2008). The reported association
between striatal D2 receptor availability and prefrontal metabolism suggests
dopaminergic modulation of prefrontal cortical function that regulate inhibition,
salience attribution and decision making processes (Volkow et al., 2008).

Obese individuals exhibit greater preference for diets high in fat and
carbohydrates, compared to lean individuals (Drewnowski et al., 1992).
Reinforcing effects of palatable foods are shown to be greater in obese
compared to non-obese humans, as demonstrated in studies conducted using
the PR schedule of reinforcement (Epstein et al., 2007). While food
reinforcement is an important determinant of motivation to eat, it may also
interact with other psychological variables that influence food intake. Importantly,
sensitivity to palatable food reward was shown to drive overeating only when
accompanied by insufficient inhibitory control (Appelhans et al., 2011). In
overweight and obese women, sensitivity to palatable food reward and inhibitory
control was assessed using the power of food scale and delay discounting task
for monetary rewards, respectively (Appelhans et al., 2011). Higher food reward
sensitivity predicted greater palatable food intake in overweight and obese
women, only at low levels of inhibitory control. Further, women with a binge-
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eating disorder were shown to exhibit increased impulsivity compared to control,
as measured using an impulsivity and novelty seeking scale (Claes et al., 2002;
Vervaet et al., 2003). Higher disinhibition scores was found in obese compared to
non-obese individuals, based on a three factor eating questionnaire, that assess
hunger, restraint and inhibition (Boschi et al., 2001). Another study demonstrated
a positive correlation between impulsivity, assessed using the delay discounting
procedure and dietary disinhibition (Yeomans et al., 2008). Thus, coincident with
increased motivation for palatable foods, increased impulsivity, a multifaceted
behavioral construct, also plays a role in obesity (Whiteside and Lynam, 2001;
Mobbs et al., 2010).

Overall, nonhomeostatic food intake in obesity appears to be regulated by
lack of inhibitory control and increased motivation. The current study investigated
impulsivity and food-motivated behavior as behavioral outcomes of DIO.

Hypothesis: DIO will be associated with increased impulsivity and increased
food-motivated behavior. The specific aims that were formulated to test the
proposed hypothesis follow.
Specific aim 1. As an outcome of DIO, impulsivity will be evaluated using
the delay discounting task.
Specific aim 2. As outcomes of DIO, food-motivated behavior and
persistence of food-seeking behavior will be evaluated using the PR schedule of
reinforcement and extinction procedures, respectively.
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II.

Methods

II a. Animals. Outbred adult male Sprague Dawley rats (350-400 g;
Charles River Laboratories Inc., Wilmington, MA) were housed individually in
solid-bottom cages with bedding and received standard rat chow and water ad
libitum. Prior to the initiation of experimental procedures, rats were fed standard
chow for one week during acclimatization to the animal facility. Experimental
procedures were approved by the Institutional Animal Care and Use Committee
at University of Kentucky.

Following acclimatization, rats were randomly assigned to groups fed for 8
wk either a HF-diet (n = 24) or a LF-diet (n = 8). Food intake was determined
daily and body weight determined 3 times weekly. Energy intake was derived by
multiplying the daily food intake (g) by the total kcal/g of the respective diet
consumed. Following an 8-wk HF-diet exposure, rats were segregated into OP
and OR groups as previously described in chapter two (n = 8/group) (Fig. 16).

II b. Behavioral apparatus. Behavioral experiments were conducted in
operant conditioning chambers (28 cm × 24 cm × 25 cm; ENV-001; MED
Associates, St. Albans, VT) enclosed within sound-attenuating chambers (ENV018M; MED Associates). Operant chambers had a metal rod floor, Plexiglas front
and back walls and aluminum side walls. A house light (28 V) was centered on
the left side wall 2.5 cm from the ceiling and illuminated the chamber. Food
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pellets were dispensed from a food hopper (ENV-203M-45; MED Associates) into
a recessed food tray (5 cm × 5 cm × 3 cm), which was centered on the right side
wall 2 cm above the floor. Retractable levers (4.5 cm) were located on the right
side wall 6 cm above the floor on either side of the recessed food tray. White
stimulus lights (28 V; 3 cm in diameter) were located 3 cm above each lever.
Chambers were connected to a personal computer interface and controlled using
MED-PC software (SG-502). Behavioral procedures were carried out during the
light cycle.

II c. Experimental design and procedures. Impulsivity, motivation for
HF- and LF- food reinforcement, and extinction to food-reinforced responding
were evaluated as behavioral outcomes of DIO. The details of each study follow.

Study 1. As an outcome of DIO, impulsivity was evaluated using the delay
discounting task in OP, OR and LF groups (n = 6-8/group). Treatment group was
a between-subject factor and session was a within-subject factor. Rats employed
in this study were previously used to evaluate striatal DAT function and
extracellular dopamine concentration in vivo (chapter 2, study 6).

Delay discounting task. Impulsivity was evaluated as an outcome of
DIO, using the delay discounting task (Marusich and Bardo, 2009). To facilitate
lever responding, rats received all of their daily food allowance during a 3-h
period after each operant session; OP and OR groups received the HF-diet and

143

the LF group received the LF-diet. Each delay discounting session consisted of
15 blocks, and each block consisted of 4 trials, such that 60 trials were
administered across a 2-h session. Each trial lasted for 60 s including an
adjusted inter-trial interval (ITI). During ITIs, both cue lights and house light were
off and lever presses had no programmed consequences. The first 2 trials of
each block were forced trials; only one of the two levers was extended into the
chamber and the stimulus light above the extended lever was illuminated.
Presses on the extended lever during the forced trials resulted in immediate
retraction of the lever, followed by delivery of either one or three sucrose-based
45 mg pellets (F0021 dustless precision pellets, Bio-Serv Inc., Frenchtown, NJ).
In subsequent free-choice trials, both levers were extended and both stimulus
lights were illuminated. One lever delivered one sucrose pellet immediately
following a response. A response on the other lever delivered three sucrose
pellets following a delay. The position of the lever delivering one reinforcer vs.
three reinforcers alternated daily. The initial delay for the delivery of the three
pellets was 0 s. The delay was adjusted depending on which lever was chosen
subsequently. If the lever delivering three pellets was chosen, then a 1-s
increase in the delay resulted upon reinforcement of the next response on this
lever. Alternatively, if the lever delivering one pellet was chosen, then a 1-s
decrease in the delay resulted following a response on the lever delivering three
pellets. A minimum delay of 0 s and a maximum delay of 45 s was imposed
between the response and the delivery of the three-pellet reinforcer. During the
delay, the stimulus lights were off and the house light remained illuminated. The
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delay imposed during the last free choice trial for each session was employed as
the initial delay on the next session.

Study 2. As outcomes of DIO, motivation for food reinforcement and persistence
of food-seeking behavior were evaluated in OP, OR and LF rats (n = 8
rats/group). To evaluate motivation for food reinforcement, rats were initially
trained on a FR schedule followed by a PR schedule of reinforcement. Rats in
this study experienced no prior experimental manipulations. Persistence of foodseeking behavior was evaluated using extinction procedures that were conducted
in the same groups of rats employed for the FR and PR schedules of
reinforcement. For FR, PR schedules of reinforcement and during extinction
procedures, treatment group was a between-subject factor and session was a
within-subject factor.

Food-reinforced operant behavior during FR and PR schedules of
reinforcement. Food-reinforced operant behavior was assessed in separate
groups of naïve OP, OR and LF rats using a FR and PR schedule of
reinforcement. To facilitate lever responding, rats received all of their daily food
allowance during a 3-h period after each operant session; OP and OR groups
received the HF-diet and the LF group received the LF-diet. For the operant
conditioning studies, rats received custom made HF and LF dustless 45 mg
pellet reinforcers (F06378 HF precision pellets with 31.2% Kcal from fat; F06379
LF precision pellets with 10.6% Kcal from fat; Bio-Serv Inc.). Operant procedures
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were employed as described previously (Green et al., 2002), with minor
modifications. Initially, rats were introduced to the chambers with the levers
retracted, and non-contingent food pellets became available in the food tray at
~45 s intervals for 12 min. Subsequently, two daily 1-h autoshaping sessions
occurred during which both levers were extended into the chamber for 100 s.
Cue light above the active lever was illuminated only during the period when the
levers were extended into the chamber. Following 100 s, both levers retracted
immediately followed by delivery of a food pellet reinforcer. If a response
occurred on the active lever prior to the elapse of 100-s lever extensions, the
levers were retracted and a food pellet was delivered. Inactive lever responses
were recorded, but had no programmed consequence. The position of the active
lever was counterbalanced across sessions. Following autoshaping, rats were
reinforced on a FR-1 schedule for. The duration of each FR schedule was one
hour session per day for three days, during which one lever press resulted in the
delivery of one food pellet with no illumination of the cue light. Lever response
requirements were gradually increased from FR-2 to FR-3 to FR-5 to FR-10, the
terminal schedule. During this phase of training, OP and OR groups received the
HF pellet reinforcers, and the LF group received the LF pellet reinforcers. For
each incremental FR schedule, requirements for stable responding was defined
as less than 20% variability in the number of responses across 3 consecutive
sessions and a minimum of a 2:1 ratio of active to inactive lever responses.
Stable responding was attained for each schedule within the three FR 1-h
sessions that were conducted across there days.
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Subsequently, the groups were switched to a PR schedule of
reinforcement and the session duration was increased to 3 h. During the PR
sessions, both levers were extended; however, responses on only active lever
resulted in reinforcer delivery. Responding on the other lever (inactive lever) had
no programmed consequence. Following delivery of each reinforcer, the
response requirement for the next reinforcer delivery was increased based on the
following equation: [5e (response numberX0.2)]-5 (1, 2, 4, 6, 12, 15, 20, 25, 32, 40, 50,
62, 77, 95, 118, 145, 178, 219, 268, 328, 402, 492, 603 …; number of active
lever responses required to obtain a single reinforcer) (Richardson and Roberts,
1996). For 3 PR sessions, OP and OR groups received the HF pellet reinforcers,
and the LF group received the LF pellet reinforcers. For the next 3 PR sessions,
OP and OR groups received the LF pellet reinforcers, and the LF group received
the HF pellet reinforcers. The last ratio completed at the end of the 3-h session
was defined as the PR breakpoint, and served as an index of motivation.

Extinction of food-reinforced operant behavior. Following the PR
schedule of reinforcement, the same groups of rats underwent extinction for daily
1-h sessions for ten consecutive days to determine the effect of DIO on
persistence of food-seeking behavior. During extinction, responses on either
lever did not result in the delivery of food pellets. After each extinction session,
OP and OR groups were given 3 h access to the HF-diet in the home-cage and
the LF group given 3-h access to the LF-diet in the home-cage.
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II d. Data analysis. Data are presented as mean values ± S.E.M., and ‘n’
represents the number of animals tested for each group. Data were analyzed
using GraphPad Prism 4.0 program (GraphPad Software Inc., San Diego, CA)
and SPSS version 9.0 (SPSS Science, Chicago, IL).

Time dependent differences in body weight and energy intake between
groups were determined by two-way ANOVA, with OP, OR and LF as a betweensubject factor and time as a within-subject factor. One-way ANOVAs analyzed
between-group differences in body weight, energy intake and % body weight gain
after 8 wk of dietary treatment. The level of caloric restriction imposed by the 3-h
access to daily food allowance was dervied based on the food intake during the
3-h access, expressed as a percentage of daily food intake during the 8-wk ad
libitum access.

Mean adjusted delay was obtained from the delay discounting task as a
measure of impulsivity. Rats with mean adjusted delay (averaged for the last 5
sessions of free choice trials) below the median split were categorized as highimpulsive, and those with mean adjusted delay above the median were
categorized as low-impulsive. Two-way ANOVAs with OP, OR and LF as a
between-subject factor and FR schedule and extinction session as within-subject
factors analyzed between groups differences in number of reinforcers earned
and lever responses. One-way ANOVAs on mean adjusted delay and PR
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breakpoint determined between-group differences. Post hoc analyses were
conducted by Tukey’s test to compare between two groups.

III.

Results

III a. Time course of body weight gain and energy intake during the 8wk exposure to the HF- and LF-diet
Body weight and energy intake for OP, OR and LF groups during the 8-wk
exposure to the HF- or LF-diets are illustrated in Fig.17. Analysis of the body
weight data revealed a significant group x time interaction (F 14, 147 = 20.19, p <
0.0001). Prior to diet exposure, body weight did not differ between groups (Fig.
17; top). At 3 wk of diet exposure, body weight for the OP group was greater than
that for OR and LF groups. At the end of the diet exposure (wk 8), the OP group
exhibited 18% and 11% greater body weight than the OR and LF groups,
respectively. Determination of energy intake for OP and OR groups revealed that
OP rats had greater energy intake (14%) than OR rats across the 8-wk period
(F 7, 98 = 6.5, p < 0.0001; Fig. 17; bottom). Interestingly, despite increases in body
weight rats across the 8-wk period, energy intake remained relatively constant
across this period.

III b. Impulsivity
The level of caloric restriction imposed by the 3-h access to daily food
allowance during the behavioral assays was not different between OP and OR
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groups (58% and 54%, respectively). Rats from the OP, OR and LF groups were
evaluated in the delay discounting task and the mean adjusted delay was
averaged across the last five sessions (Fig. 18). The mean adjusted delay for
each group varied by less than 5 s across the last 5 sessions of testing. The
median for all of the animals tested was 10.5 s. Rats with a mean adjusted delay
below and above the median were categorized as high-impulsive and lowimpulsive, respectively. OP rats exhibited 30% greater mean adjusted delay
compared to OR rats (F 2, 14 = 4.219, p < 0.05), indicating that OP rats were less
impulsive than OR rats.

III c. Food-reinforced operant behavior
Food-reinforced operant behavior in OP, OR and LF rats was determined
using FR and PR schedules of reinforcement. During the FR schedule, number
of reinforcers earned and number of active and inactive lever presses for OP, OR
and LF groups are illustrated in Fig. 19. The number of reinforcers earned was
relatively constant across the incremental increases in the FR schedule
requirement (Fig. 19; top), and the number of response on the active lever (Fig
19; bottom left), but not the inactive lever (Fig 19; bottom right), increased
correspondingly. ANOVA on the number of reinforcers earned revealed a
significant interaction of group x FR schedule (F 8, 84 = 2.751, p < 0.05). Post hoc
analysis showed that at FR-10, the number of reinforcers earned by OP and OR
groups was lower than that for the LF group (p < 0.05). Parallel results were
obtained for the number of active lever responses, in that a significant interaction
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of group x FR schedule (F 8, 84 = 4.068, p < 0.001) was revealed. The number of
active lever responses during the FR 10 schedule was lower in OP and OR
groups compared to the LF group (p < 0.001). Inactive lever responses were not
different between groups across FR schedules (F 8, 84 = 0.91, p > 0.05).

Following completion of the FR schedule of responding, the PR schedule
was initiated to determine the breakpoint (motivation) for food reinforcement for
each group (Fig. 20). During PR sessions 1-3, OP and OR groups earned HFreinforcers and the LF group earned LF-reinforcers. Main effects of group (F 2, 21
= 4.14, p < 0.01) and session (F 2, 42 = 8.09, p < 0.01) were found; however, the
group x session interaction was not significant (F 2, 42 = 0.41, p > 0.05). During PR
sessions 4-6, OP and OR groups earned LF-reinforcers, and the LF group
earned HF-reinforcers. A main effect of group (F 2, 20 = 5.35, p < 0.01) was found;
there was no main effect of session (F 2, 40 = 0.1, p > 0.05) and no group x
session interaction (F 4, 40 = 2.32, p > 0.05). The mean breakpoint for OP rats was
greater than that for OR rats, when responding was for either HF (F 2, 22 = 3.655,
p < 0.05) or LF reinforcers (F 2, 18 = 4.639, p < 0.05).

III d. Extinction of food-reinfoced operant responding
The persistence of operant responding during extinction, a time period in
which responding did not result in delivery of reinforcers, was determined for OP,
OR and LF groups (Fig. 21). A main effect of extinction session was found (F 9, 189
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= 69.8, p < 0.0001); however, there was no main effect of group (F 2, 21 = 0.27, p
> 0.05) and no group x session interaction (F 18, 189 = 1.35, p > 0.05).

IV.

Discussion

The current study demonstrates decreased impulsivity and increased
motivation for food reinforcers following the development of DIO, in the outbred
rat model. Decreased impulsivity in obesity reported in the current study is not
consistent with previous findings that obese humans are impulsive (Weller et al.,
2008). Nonetheless, increased motivation for HF-reinforcers following the
development of DIO is consistent with the observation that the orosensory
properties and post-ingestive effects of HF-dengender overeating of HF-foods
(Kern et al., 1993; Warwick and Weingarten, 1995).

Obesity and drug addiction are hypothesized to share common underlying
neurobehavioral mechanisms (Robinson and Berridge, 2003; Volkow et al., 2008;
Kenny, 2011). Personality traits including high sensation seeking and high
impulsivity (lack of inhibition, premeditation and perseverance) predispose and
are affected by drug addiction (Ersche et al., 2010). Furthermore, drug addiction
is shown to be associated with increased impulsive choice, assessed using the
delay discounting procedure in human addicts and rats following repeated drug
exposure (Coffey et al., 2003; Gipson and Bardo, 2009; Setlow et al., 2009). In
the current study, impulsivity also measured using delay discounting was

152

decreased following development of DIO, which contrasts with a report showing
increased impulsivity in obese women as measured by delay discounting (Weller
et al., 2008). Different outcomes between the animal model and the human
studies regarding impulsivity may be due to differences in species, sex or
reinforcers employed. Importantly, both studies employed delay discounting
which measures only one facet of impulsivity. Impulsivity is a multidimensional
behavioral trait that involves urgent actions, lack of premeditation, lack of
perseverance, and an increase in sensation seeking behaviors (Whiteside and
Lynam, 2001). Therefore, interpretation of current and previous studies is limited
somewhat by delay discounting, which measures only one facet of the construct
of impulsivity, i.e impulsive choice. Impulsivity consists of both reward seeking
and lack of inhibition personality factors. Since OP rats exhibited increased
responding for the larger delayed reward as opposed to the smaller immediate
reward, it is likely that reward-based motivational processes may have overcome
impulsive choice in the animal model, but not in the human study.

OP and OR rats did not differ in acquisition of FR responding for HFreinforcers suggesting that between group-differences in learning were not found.
However, PR breakpoint was greater in OP than OR rats. Further, PR breakpoint
was higher in OP rats regardless of whether the reinforcer was HF or LF,
indicating that caloric density was not a factor in food motivation. Also, OP rats
exhibited a greater number of active lever responses during extinction sessions,
compared to OR and LF rats. However, one caveat of the extinction results is
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that extinction training was conducted following the PR sessions. Evaluation of
PR breakpoint prior to the extinction procedure may have diminished the food
seeking behavior at higher response ratios during the PR schedule.
Compulsivity is typically charecterized by persistence of responding when the
reinforcer is no longer available (extinction), increased PR breakpoints
(motivation), and increased resistance to punishment (Belin et al., 2011). The
observation that the OP group exhibits a greater level of motivation for both HFand LF-reinforcers compared to the OR group suggests the development of
compulsive behavior in DIO (Belin et al., 2011).

Controversy exists regarding the effect of obesity on motivation for food
across studies using different animal models of obesity. In contrast to the current
results, PR breakpoint for HF-reinforcers did not differ between DIO-prone
Osborne-Mendel and the DIO-resistant S5B\PI inbred rats fed standard chow in
the home-cage (Thanos et al., 2011). Similarly, no differences in PR breakpoint
for sucrose pellets were found between out-bred Sprague Dawley rats with 12-wk
free-access (obese) or restricted-access (non-obese) to a HF-diet in the homecage (Davis et al., 2008). However, both groups receiving the HF-diet in the
home-cage had decreased PR breakpoint for sucrose pellets compared to
another group with free-access to standard-chow in the home-cage, suggesting
that the reward value of sucrose was decreased following long-term access to
HF-diet. Interestingly, a decreased PR breakpoint for sucrose reinforcement was
found in Sprague Dawley rats selectively inbred for obesity compared to those
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inbred for resistance to obesity and fed standard chow in the home-cage (Davis
et al., 2008). Discrepancies between these previous results and those of the
current study showing an increase in PR breakpoint and motivation for HF-food
in the OP group may be due to differences in the animal model of obesity, the
reinforcer type (sucrose vs. HF), and/or the home-cage diet. Importantly, sucrose
and HF-diets exhibit differences in orosensory properties and satiety
mechanisms (Warwick and Weingarten, 1995; Gaillard et al., 2008; Avena et al.,
2009). However, it is unlikely that the HF home-cage diet is responsible for the
increased PR breakpoint in OP rats in the current study, since PR breakpoint for
HF- or LF-reinforcers was not different between OR and LF rats, even though
they received different home-cage diets.

Consistent with the current results, CCK-1 receptor-deficient OLETF rats
and leptin-receptor deficient Zucker rats fed standard chow in the home-cage
exhibited increased PR breakpoints for sucrose reinforcers compared to lean
controls (Glass et al., 1999; Hajnal et al., 2007). Similarly, outbred Wistar rats fed
a HF/high-sugar home-cage diet demonstrated increased PR breakpoint for
sucrose reinforcers compared to chow-fed rats (Fleur et al., 2007). The current
study is consistent with and extends these findings by showing increased
motivation for HF- and LF-reinforcers in the OP group compared to the OR
group, both of which received ad libitum access to the HF-diet in the home cage.
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Interestingly, the LF group was not differentially motivated to obtain the LF
vs. HF reinforcers during the PR schedule. One explanation for the lack of an
increase in responding (breakpoint) is that the LF rats did not find the novel HF
reinforcers more rewarding than the LF reinforcers, such that both types of
reinforcers were similarly rewarding. Alternatively, it is possible that an extended
training would have revealed group differences based on the palatability of the
pellet reinforcer. However, during acquisition of operant responding under the FR
schedule, the LF rats responded more for LF reinforcers than OP and OR rats for
HF reinforcers, but only under the FR-10 schedule of responding. This may be
explained by the lower caloric density and lower satiation associated with LF
reinforcers compared to HF reinforcers.

In summary, the current results reveal decreased impulsivity and
increased motivation for food reinforcement following the development of DIO.
Decreased impulsivity in DIO was an unanticipated outcome. Nonetheless,
increased food-motivated behavior may underlie the maintenance of habitual and
excessive food intake in obesity.
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Figure 16

HF-diet (31.8% Kcal fat)
or
LF-diet (10.6% Kcal fat )

Week 1

Segregation
into
OP and OR

Week Week
2-7 6

Week
Week88

Behavioral
assays

EVALUATION OF OUTCOMES

Monitor body weight and food intake

Obesity Resistant
group (OR):
minimum body
weight gain

OR

OP

157

Obesity Prone
group (OP):
maximum body
weight gain

Figure 16: Development of the DIO model for the evaluation of behavioral
outcomes. Adult male Sprague Dawley rats received the HF- or LF- diet for 8 wk.
Following the 8-wk diet exposure, rats fed the HF-diet were segregated into OP
and OR groups based on body weight gain (top third and bottom third,
respectively). Behavioral assays were conducted in OP, OR and LF groups
(Picture courtesy of Victoria English, Dr. Cassis’ Laboratory).
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Figure 17
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Figure 17: Time course of body weight gain and energy intake during the 8-wk
exposure to the HF- and LF-diets. DIO is associated with increased body weight
and energy intake. Top: OP rats exhibited greater body weight compared to OR
and LF rats from wk 3-8 of diet exposure. Data are pooled from groups that
were employed in studies 1 and 2 (methods section) and expressed as the
mean (SEM are smaller than the size of the symbol); n = 16 rats/group; *p <
0.001, indicates OP different from OR and LF. Bottom: OP rats had greater
energy intake compared to OR rats across the 8-wk period of diet exposure.
Data are pooled from groups that were employed in studies 1 and 2 (methods
section) and expressed as the mean (SEM are smaller than the size of the
symbol); n = 16 rats/group; #p < 0.001, indicates OP different from OR.
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Figure 18
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Figure 18: Mean adjusted delay of OP, OR and LF groups. OP rats exhibited a
greater mean adjusted delay compared to OR rats. Rats were trained on a delay
discounting task for 28 consecutive sessions. One lever delivered one sucrose
pellet immediately following a response. Response on the other lever delivered
three sucrose pellets following an adjusted delay. Mean adjusted delay to obtain
the larger delayed food reinforcer was calculated at the end of each session by
averaging the delays on free choice trials. Data are expressed as mean ± SEM of
adjusted delay across the last 5 sessions; n = 5 rats/group; *p < 0.05, indicates
OP different from OR.
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Figure 19
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Figure 19: Reinforcers earned and lever responses during FR schedule of
reinforcement in OP, OR and LF groups. During the FR-10 schedule of
reinforcement, the number of reinforcers earned and the number of active lever
responses emitted was lower in OP and OR groups compared to the LF group.
No between-group differences in inactive lever responses were found. OP, OR
and LF groups were reinforced on FR-1 schedule for three 1-h sessions, during
which one active lever press resulted in delivery of one food pellet reinforcer.
Lever response requirements were gradually increased from FR-2 to FR-3 to FR5, until FR-10. For each FR response requirement, OP and OR groups pressed
the active lever to obtain HF-reinforcers; LF groups pressed the active lever to
obtain LF-reinforcers. Data are expressed as number of food reinforcers earned
(top) and number of active and inactive lever presses (bottom) and are presented
as mean ± SEM; n = 8 rats/group; *p < 0.001, indicates OP and OR different from
LF.
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Figure 20
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Figure 20: PR breakpoint of OP, OR and LF groups. The OP group exhibited a
higher PR breakpoint for both HF- and LF-reinforcers compared to the OR group.
During sessions 1-3 of the PR schedule, OP and OR groups earned HFreinforcers and LF group earned LF-reinforcers. During sessions 4-6, OP and OR
groups earned LF-reinforcers; LF received HF-reinforcers. PR breakpoint of OP,
OR and LF groups for each PR session (top). Mean PR breakpoint for the HFand LF-reinforcers (bottom). Data are expressed as mean ± SEM; n = 5-8
rats/group; *p < 0.05, indicates OP different from OR.
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Figure 21: Extinction of operant responding in OP, OR and LF groups. No
between-group differences in activel lever responses were found during
extinction. Data are expressed as mean ± SEM; n = 7-8 rats/group.
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Chapter Four
Evaluation of behavioral and dopaminergic predictors of the development
of DIO

I.

Introduction

Obesity is shown to be associated with increased motivation for palatable
foods and increased impulsivity, a multifaceted behavioral construct (Whiteside
and Lynam, 2001; Weller et al., 2008; Appelhans et al., 2011). Increased
sensitivity to palatable food reward in obesity has been shown to drive overeating
only when accompanied by insufficient inhibitory control (Appelhans et al., 2011).
Personality traits that include high sensation seeking and high impulsivity (lack of
inhibition, premeditation and perseverance) are not only affected by drug
addiction, but also serve as behavioral predictors of drug addiction (Ersche et al.,
2010). To the extent that obesity and drug addiction share common underlying
neurobehavioral mechanisms (Kenny, 2011), an individual’s level of motivation
and impulsivity may also serve as behavioral predictors of obesity.

Ingestion of palatable foods activates striatal dopaminergic systems and
the resulting dopaminergic activation is suggested to influence hedonic and
nonhomeostatic food intake in obesity (Berthoud, 2011; Wise, 2006). Decreased
striatal D2 receptors are reported in obese humans compared to control (Wang
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et al., 2001). However, it is not clear whether decreases in striatal D2 levels
preceded the development of obesity.

Activation of D2 autoreceptors is shown to increase DAT function (Cass
and Gerhardt, 1994). Given that decreases in striatal D2 levels may precede the
development of obesity, it is likely that corresponding alterations in DAT function
may exist prior to the development of obesity. The role of DAT is implicated in
obesity based on previous reports that DAT-deficient mice exhibit increased
extracellular dopamine concentration and greater food intake, compared to
wildtype-mice (Pecina et al., 2003). Furthermore, the current results described in
chapter 2 demonstrate decreases in striatal DAT function and increases in
extracellular dopamine levels following the development of DIO. Taken together,
these striatal dopaminergic mechanisms may be consequences of obesity or
may have preceded the development of obesity.

Identification of predictors of obesity will facilitate better pharmacological
and behavioral intervention. Evaluation of predictors of obesity is difficult in
humans, but can be investigated in controlled studies using animal models, such
as the outbred DIO rat model. In the current study, impulsivity, food-motivated
behavior and striatal dopamine function were evaluated as neurobehavioral
predictors of DIO.
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Hypothesis: Pre-existing individual differences in the levels of impulsivity,
motivation, striatal DAT function and extracellular dopamine concentration will
predict the development of DIO in a rat model. The specific aims formulated to
test the proposed hypothesis follow.

Specific aim 1. As predictors of DIO, impulsivity and motivation for HF
food reinforcers will be evaluated using the delay discounting task and PR
schedule of reinforcement, respectively.
Specific aim 2. As predictors of DIO, striatal DAT function and extracellular
dopamine concentration will be evaluated using in vivo no net flux microdialysis.

II.

Methods

II a. Materials. Ascorbate oxidase, Chromasolv®, D-glucose and
dopamine hydrochloride were purchased from Sigma-Aldrich (St. Louis, MO).
Perchloric acid (70%) was purchased from Mallinckrodt Baker (Phillipsburg, NJ).
Diazepam and ketamine hydrochloride were purchased from N.L.S. Animal
Health (Pittsburgh, PA). All other chemicals were purchased from Fisher
Scientific Co. (Pittsburgh, PA).

II b. Animals. Outbred adult male Sprague Dawley rats (350-400 g;
Charles River Laboratories Inc., Wilmington, MA) were housed individually and
received standard rat chow and water ad libitum. Rats were maintained on
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standard chow during acclimatization to the environment and assessment of
neurobehavioral predictors. Behavioral procedures were carried out in operant
chambers during the light cycle. All experimental procedures were approved by
the Institutional Animal Care and Use Committee at the University of Kentucky.

II c. Experimental design and procedures. Impulsivity, motivation for
HF-reinforcers, striatal DAT function and extracellular dopamine concentration
were evaluated as neurobehavioral predictors of DIO. Following the evaluation of
predictors using behavioral and neurochemical assays, rats were fed the HF-diet
for 8 wk. Following the 8-wk HF-diet exposure, rats were segregated into OP and
OR groups as previously described in chapter two (methods section) (Fig. 22).
The LF group was not employed in the evaluation of the predictors of obesity,
because the LF-diet does not result in obesity. The details of each experiment
follow.

Study 1. As a predictor of DIO, impulsivity was determined using the delay
discounting task that was conducted exactly as described previously in the
methods section of chapter three. An experimentally naïve group of rats (n = 22
rats) was used for this study. Session was a within-subject factor. To facilitate
lever responding, rats were provided with 15 g of standard chow following each
operant session. Following the delay discounting task, this group was used to
evaluate motivation for food reinforcement (Study 2).
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Study 2. As a predictor of DIO, motivation for HF food reinforcement was
determined using the PR schedule of reinforcement that was conducted for daily
3-h sessions for 6 consecutive days. The PR schedule was conducted exactly as
described previously in the methods section of chapter three. Session was a
within-subject factor. To increase hunger and thereby facilitate lever responding,
rats were provided with 15 g of standard chow following each operant session.
Subsequently, this group of rats was used to evaluate in vivo striatal DAT
function and extracellular dopamine concentration (Study 3).

Study 3. As predictors of DIO, striatal DAT function and extracellular dopamine
concentration in vivo were determined using the no net flux microdialysis assay
that was conducted exactly as described in the methods section of chapter two.
Dopamine concentration was a within-subject factor. Rats employed in this study
were previously used to evaluate impulsivity and motivation for food
reinforcement (Studies 1 and 2).

Following microdialysis, rats were fed the HF-diet for 8 wk. Body weight
and food intake were monitored across the 8-wk period, as described previously.
Following the 8-wk HF-diet exposure, rats were segregated into OP and OR
groups. Whole brains were obtained and fixed in Chromasolv® for sectioning
(Leica 1850 M, Nussloch, Germany) for determination of probe placement.

173

II e. Data analysis. Data are presented as mean values ± S.E.M., and ‘n’
represents the number of animals tested for each group. Data were analyzed
using GraphPad Prism 4.0 program (GraphPad Software Inc., San Diego, CA).

Time dependent differences in body weight and energy intake between
groups were determined by two-way ANOVA, with OP and OR as a betweensubject factor and time as a within-subject factor. Student’s unpaired t-test was
used to determine between-group differences in body weight, energy intake and
% body weight gain after 8 wk of dietary treatment. Mean adjusted delay was
obtained from the delay discounting task as a measure of impulsivity. Rats with
mean adjusted delay (averaged for the last 5 sessions of free choice trials) below
the median were categorized as high-impulsive and rats with mean adjusted
delay above the median were categorized as low-impuslive. For no net flux
microdialysis, the difference between perfusate and dialysate dopamine
concentration [dopamine in -dopamine out ] for each rat was plotted as a function of
perfusion concentration [dopamine in ]. Slope of the linear regression represents
extraction fraction (E d: index of DAT function) and the regression line x-axis
intersect represents the no net flux point (extracellular dopamine concentration)
(Justice, 1993). Pearson’s correlation coefficients determined relationships
between % body weight gain and each behavioral and neurochemical measure
that include mean adjusted delay, PR breakpoint, extraction fraction and
extracellular dopamine concentration.
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III.

Results

III a. Development of DIO
Body weight and energy intake for OP and OR groups during the 8-wk
exposure to the HF-diet are illustrated in Fig. 23. Analysis of the body weight
data revealed a group x time interaction (F 7, 77 = 17.2, p < 0.0001). Prior to diet
exposure, body weight did not differ between groups (Fig. 23: top). At 3 wk of diet
exposure, body weight for the OP group was greater than that for the OR group.
At the end of the 8-wk HF-diet exposure, the OP group exhibited 20% greater
body weight than the OR group. Also, the OP group exhibited 17% greater
energy intake than the OR group, across 8 wk (F 7, 77 = 2.21, p < 0.05; Fig. 23:
bottom).

III b. Impulsivity does not predict the development of DIO
To determine if impulsivity predicts the development of DIO, the delay to
obtain the larger sucrose reinforcer was determined prior to an 8-wk exposure to
the HF-diet. As illustrated in the scatter plot (Fig. 24), both OP and OR groups
included rats that exhibited low mean adjusted delay. The mean adjusted delay
varied by less than 5 s across the last 5 days of testing all of the animals. The
median of the group was 7.5 s. Rats with mean adjusted delay below and above
7.5 s were categorized as high- and low-impulsive groups, respectively. Linear
regression analysis of the data showed no correlation between mean adjusted
delay and % body weight gain (Pearson r = 0.227, p = 0.35).
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III c. Motivation to obtain HF-reinforcers predicts the development of
DIO
To determine if motivation to obtain HF-food predicts the development of
DIO, PR breakpoint for HF-reinforcers was determined prior to an 8-wk HF-diet
exposure. Linear regression analysis of the data showed a positive correlation
between PR breakpoint for HF-reinforcers and % body weight gain (Pearson r =
0.51, p < 0.05, Fig. 25; top). Mean PR breakpoint for HF-reinforcers across the 6
sessions was greater in OP compared to OR rats (p < 0.01; Fig. 25; bottom).

III d. In vivo striatal DAT function and basal extracellular dopamine
concentration do not predict the development of DIO
To determine if striatal DAT function and basal extracellular dopamine
concentration predicts the development of DIO, in vivo microdialysis, using the
no net flux microdialysis method, was conducted prior to an 8-wk HF-diet
exposure. Linear regression analysis of the data showed no correlation between
extraction fraction (index of DAT function) and % body weight gain (Pearson r =
0.275, p = 0.3, Fig. 26; top). Also, no correlation was found between striatal basal
extracellular dopamine concentration and % body weight gain (Pearson r = 0.291, p = 0.275, Fig. 26; bottom).

IV.

Discussion
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The current study provides novel findings that motivation to obtain HFfood predicts the development of obesity in an outbred animal model of DIO,
whereas surprisingly, impulsivity does not predict DIO. A pre-existing dopamine
reward deficiency has been suggested to contribute to compensatory overeating
of carbohydrates leading to human obesity (Blum et al., 2006). The current
results indicate that striatal DAT function and extracellular dopamine do not
predict DIO. Thus, deficiency in striatal DAT function does not underlie obesity
resulting from consumption of a HF-diet.

Personality traits including reward-seeking and high impulsivity (inability to
resist cravings, lack of premeditation and perseverance) are known to regulate
drug addiction in humans (Whiteside and Lynam, 2001). Given that common
neurobehavioral mechanisms underlie obesity and drug addiction (Volkow et al.,
2008; Kenny, 2011), hallmarks of drug addiction including impulsivity and
motivation were evaluated in the DIO model. Impulsivity evaluated using delay
discounting is shown to predict psychostimulant intake in animal models (Perry
and Caroll, 2008; Marusich and Bardo, 2009). In the current study, impulsivity did
not predict DIO, suggesting that distinct mechanisms underlie the predisposition
for drug addiction and obesity. Nonetheless, interpretation of the current study is
limited somewhat by the delay discounting task, which measures only one facet
of the construct of impulsivity. Therefore, evaluation of other facets of impulsivity
might provide a broader perspective in highlighting the role of impulsivity in the
development of obesity.
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Lack of correlation between mean adjusted delay and body weight gain
suggests that impulsivity does not predict the development of DIO. Unlike
impulsivity, motivation for HF-reinforcers predicted the development of DIO, as
indicated by a positive correlation between PR breakpoint for HF-reinforcers and
body weight gain. The current results are consistent with previous studies in
which PR responding for sucrose pellets were determined in Wistar rats that
were subsequently exposed to a high-fat high-sucrose (HFHS) diet or a chowdiet for 4 wk (Fleur et al., 2007). In contrast to the chow-fed control, a positive
correlation was found between PR responding for sucrose pellets and abdominal
fat stores in rats fed the HFHS-diet. However, unlike the current study, rats fed
the HFHS-diet were not segregated into OP and OR phenotypes. Although both
current and previous studies report pre-exisiting increases in food-motivated
behavior, the two studies differ with respect to reinforcers, home-cage diet,
duration of diet exposure and obesity model employed. In the previous study,
pre-exisiting increases in motivation for sucrose reinforcers did not translate into
increased energy intake upon 4-wk exposure to the HFHS diet. Conversely, in
the current study, a pre-exisiting increase in PR breakpoint for HF-reinforcers
was consistent with increased energy intake in the OP phenotype throughout the
8-wk exposure to the HF-diet. This discrepancy may be attributed to distinct
postingestive mechanisms associated with HF- and sucrose-reinforcers/diets
(Warwick and Weingarten, 1995; Avena et al., 2009; Gaillard et al., 2008). While
preference for high-fat was not determined in the current study, previous studies
have demonstrated increased choice for fat compared to carbohydrate and
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protein diets in inbred obesity-prone (Osborne-Mendel) compared to obesityresistant (S5B\PI) rats during a macronutrient choice procedure (Okada et al.,
1992). Similar increases in fat preference may underlie increased motivation for
HF-reinforcers in the current outbred DIO model.

Reward associated with food intake is known to be mediated by NAc
dopamine; however, the development of habitual behavior appears to involve a
shift in underlying dopaminergic control from NAc to dorsal striatum (Ito et al.,
2002; Kelley, 2004; Everitt and Robbins, 2005; Koob and Volkow, 2010). In the
current study, striatal DAT function and extracellular dopamine concentration did
not predict obesity that developed following an 8-wk HF-diet exposure, leading to
large body-weight differences of 150 g. Decreased extracellular dopamine in
NAc-shell has been reported to predict obesity, and excessive food intake was
interpreted as a compensation for low basal dopamine in NAc-shell (Rada et al.,
2010). However, these results were obtained only after 5 days of HF-diet, the
between-group body-weight differences were only 20 g, and the lower dopamine
levels may have resulted from transient exposure to the HF-diet per se. In
contrast, in the current study, striatal dopamine did not predict obesity when
evaluated prior to the HF-diet exposure. That is, individual differences in striatal
dopamine prior to the HF-diet exposure did not correlate with long-term bodyweight gain.

179

The lack of pre-exisiting individual differences in striatal dopamine function
between OP and OR phenotypes is supported by previous reports that suggest
dorsal striatal mechanisms to be recruited only upon development of habitual and
compulsive behaviors (Ito et al., 2002; Everitt et al., 2008; Wise, 2009).
Therefore, prior to repeated exposure to the HF-diet, alternate neural
mechanisms that mediate reward sensitivity and associative learning may
regulate the susceptibility to DIO. Further studies evaluating NAc dopamine as a
predictor of obesity are needed.

In summary, motivation for HF-food, but not impulsive behavior, predicts
the development of DIO. Both striatal DAT function and basal extracellular
dopamine concentration did not predict the development of obesity. Nonetheless,
motivation for HF-food likely promotes excessive food intake associated with the
development of obesity.
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Figure 22
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Figure 22: Evaluation of neurobehavioral predictors of DIO. Adult male Sprague
Dawley rats were fed standard chow during the evaluation of neurobehavioral
predictors and were subsequently exposed to the HF-diet for 8 wk. Food intake
was determined daily and body weight determined 3 times weekly. Following the
8-wk exposure to the HF-diet, rats were segregated into OP and OR groups
based on body weight gain (top third and bottom third, respectively). (Picture
courtesy of Victoria English).
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Figure 23
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Figure 23: Development of DIO in rats employed to evaluate the
neurobehavioral predictors. Rats were maintained on standard chow during
assessment of neurobehavioral predictors of DIO and were subsequently
exposed to a HF-diet for 8 wk. Rats were segregated into OP and OR groups
based on body weight gain. Top: OP rats exhibited greater body weight
compared to OR rats from wk 3-8 of the dietary treatment. Bottom: OP rats
exhibited greater energy intake compared to OR rats from wk 1-6. Data are
expressed as the mean (SEM are smaller than the size of the symbol); n = 6
rats/group; *p < 0.05, indicates OP different from OR.
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Figure 24
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Figure 24: Lack of correlation between mean adjusted delay and % body weight
gain. Mean adjusted delay was determined prior to an 8-wk exposure to the HFdiet. No correlation between mean adjusted delay and % body weight gain was
found. Data points represent individual rats (n = 19; Pearson r = 0.227, p = 0.35).
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Figure 25
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Figure 25: Positive correlation between PR breakpoint for HF-reinforcers and %
body weight gain. Mean PR breakpoint for HF-reinforcers across the 6 sessions
was determined prior to an 8-wk exposure to the HF-diet. Top: A positive
correlation between PR breakpoint for HF-reinforcers and % body weight gain
was found. Data points represent individual rats (n = 19; Pearson r = 0.51, p <
0.05). Bottom: In the same group of rats, the OP group exhibited a greater PR
breakpoint for HF-reinforcers compared to the OR group. Data are expressed as
mean ± SEM; n = 6 rats/group; *p < 0.01, indicates OP different from OR.
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Figure 26
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Figure 26: Lack of correlation between in vivo striatal dopamine function and %
body weight gain. No net flux in vivo microdialysis was conducted prior to an 8wk exposure to the HF-diet. Data points represent individual rats. Linear
regression of the data shows no correlation between striatal extraction fraction
and % body weight gain (top). Also, no correlation between striatal basal
extracellular DA concentration and % body weight gain was found (bottom).
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Chapter Five
Overall Discussion

I.

Review

Obesity has emerged as a major worldwide health concern. Latest reports
from the IOTF indicate that around 475 million adults and 40-50 million children
in the world are obese (IASO, 2012). The dramatic rise in obesity rates has been
attributed to multiple factors that include; genetic susceptibility, increased ease of
access to diets rich in fat, sugar and salt, and a sedentary lifestyle lacking
adequate physical activity (Deedwania, 2004; Farooqi and O’Rahilly, 2006;
Valentino et al., 2010). Obesity is also associated with several metabolic
disorders, cardiovascular complications and certain types of cancer (IASO,
2012). Evidently, escalating obesity rates have serious health and economic
consequences. Thus, there is a critical need for the development of safe and
effective strategies to treat this medical condition, and prevent further escalation
of the obesity epidemic.

Obesity results from a long-term positive energy balance such that energy
intake exceeds energy expenditure. Obesity research over the past few decades
has unveiled potential central and peripheral anti-obesity molecular targets
(Valentino et al., 2010). In particular, comprehensive understanding of
hypothalamic mechanisms that regulate energy homeostasis has increased over
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the past few decades. The homeostatic system comprises of hunger, satiety and
adiposity hormones which act on hypothalamic and brainstem circuits to regulate
food intake and energy expenditure (Hommel et al., 2006; Morton et al., 2006).
Importantly, dysfunction in one or more components of the homeostatic system
has been implicated in the development of obesity (Druce et al., 2005; Meyers et
al., 2008). While homeostatic systems regulate energy homeostasis under
normal physiological conditions, persistent indulgence in palatable HF foods is
believed to involve the higher brain reward systems (Palmiter, 2007).
Furthermore, hormonal regulators of energy homeostasis that include leptin,
insulin and ghrelin are shown to act on the brain reward system, specifically the
mesoaccumbens dopamine system (Kenny, 2011).

Obesity is associated with increased preference and excessive
consumption of palatable HF foods (Sclafani et al., 2001; Gaillard et al., 2008).
Importantly, activation of the mesolimbic and the striatal dopamine reward
systems are implicated in the reinforcing and motivational effects of palatable
foods (Martel and Fantino, 1996; Small et al., 2003; Olausson et al., 2006).
Further, a shift in control from dopamine pathways in the NAc to striatum is
believed to occur coincident with the development of habitual behaviors (Wise,
2009; Koob and Volkow, 2010). The involvement of striatum in motivation for
food is supported by findings that rats over-expressing striatal delta Fos B exhibit
high PR breakpoints for food reinforcement (Olausson et al., 2006). Human brain
imaging studies demonstrate an inverse relationship between BMI and striatal D2
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receptor density, suggesting striatal dopaminergic dysregulation in obesity (Wang
et al., 2001; Volkow et al., 2008). Furthermore, obese rats are shown to exhibit
increased thresholds for electrical brain stimulation reward, increased resistance
to aversive stimuli-induced disruption of food consumption, and decreased
striatal D2 receptors (Johnson and Kenny, 2010). Thus, dysregulated striatal
dopaminergic function may underlie excessive food intake in obesity.

Extracellular dopamine levels are primarily regulated by DAT, which
translocates dopamine back into the neuron, thereby terminating activation of
presynaptic and postsynaptic dopamine receptors (Sulzer et al., 2005).
Implication of DAT in food reward is suggested by results from DAT knockout
studies in which DAT deficient mice exhibited increased extracellular dopamine
and greater food intake, compared to wild-type mice (Pecina et al., 2003).
Furthermore, genetic linkage analysis revealed that DAT polymorphism is
associated with binge-eating (Shinohara et al., 2004). Thus, elevated dopamine
as a result of dysregulated DAT function may contribute to alterations in food
intake and the development of obesity. Furthermore, motivation for palatable
foods and impulsivity also play an important role in obesity (Weller et al., 2008;
Mobbs et al., 2010).

Current pharmacotherapies for obesity remain limited with respect to
weight loss, amelioration of metabolic abnormalities, safety and tolerance
(Cawthrone, 2007; Kushner, 2012). Further investigation of the role of higher
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brain reward systems and behavioral mechanisms in obesity may facilitate
pharmacological and behavioral interventions for the treatment and prevention of
obesity. Thus, the purpose of this dissertation was to investigate the role of the
striatal dopamine reward system, impulsivity and motivation in obesity.
Importantly, striatal dopaminergic and behavioral mechanisms were evaluated as
both outcomes and predictors of obesity using a rat model of DIO.

Neurobehavioral outcomes of DIO. Evaluation of the neurochemical
and behavioral outcomes of DIO are detailed in chapters 2 and 3, respectively.
As neurochemical outcomes of DIO, striatal D2 receptor density, VMAT2
function, DAT function and expression, methamphetamine-induced DAT reverse
transport, and extracellular dopamine concentration were evaluated in the
outbred DIO rat model. Striatal D2 receptor density was decreased in OP relative
to OR rats, consisitent with human obesity (Wang et al., 2001). Decreases in
striatal D2 receptor density may be compensatory to increased VMAT2 function,
decreased striatal DAT function and increased extracellular dopamine
concentration. No between-group differences in striatal VMAT2 function were
found suggesting that VMAT2 function is not altered following the development of
DIO. However, OP rats exhibited decreased striatal DAT function (in vitro and in
vivo) and increased extracellular dopamine concentration compared to OR rats.
In contrast with the decrease in DAT function, an increased effect of
methamphetamine to induce DAT reverse transport was found in OP relative to
OR striatum. DAT cellular localization was evaluated as a potential mechanism

194

underlying altered DAT function in DIO. Total DAT protein was decreased in OP
relative to OR striatum; however, no differences in cell-surface or intracellular
DAT expression were found. These results suggest that regulation of DAT
function in DIO is trafficking-independent.

Impulsivity and food motivated behavior were evaluated as behavioral
outcomes of DIO. The OP rats exhibited decreased impulsivity in the delay
discounting task, compared to the OR rats. These results are in contrast to a
study showing increased impulsive choice exhibited by obese women in a delay
discounting task (Weller et al., 2008). Importantly, motivation for both HF and LF
reinforcement was greater in OP compared to OR rats.

Neurobehavioral predictors of DIO. Human studies are limited by their
ability to determine if impulsivity, motivation, DAT function and extracellular
dopamine concentration serve as predictors of DIO. In the current study, these
neurobehavioral factors were evaluated in an outbred rat model, prior to an 8-wk
HF-diet exposure. Results demonstrated that motivation to obtain HF-food
predicts the development of obesity, whereas impulsivity does not predict DIO.
Also, striatal DAT function and extracellular dopamine concentration did not
predict DIO.

Collectively, results from the outcome and predictor studies demonstrate
that as a predictor, motivation for HF-reinforcers was greater in rats which
subsequently became obese upon the 8-wk exposure to the HF-diet, compared
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to those that did not become obese when exposed to the same diet for the same
period of time. The greater level of motivation continued to be observed in the
OP rats, compared with OR rats, once DIO was established, indicating that this
factor is involved in both the initiation and maintenance of obesity. In contrast,
impulsivity, DAT function and extracellular striatal dopamine levels did not predict
the development of obesity upon exposure to the HF- diet. A pre-existing
dopamine reward deficiency has been suggested to contribute to compensatory
overeating of carbohydrates leading to human obesity (Blum et al., 2006). The
current results indicate that a deficiency in striatal DAT function is an outcome of
DIO, but does not underlie obesity resulting from consumption of a HF-diet.
Once DIO was established, the level of impulsivity decreased, DAT function
decreased and extracellular striatal dopamine concentration increased in OP rats
relative to OR rats, indicating that obesity has an impact on activation of the
striatal dopamine system and on impulsive behavior. Although the impact on the
dopaminergic system was expected, the decrease in impulsivity was an
unanticipated outcome. A working model of dopaminergic outcomes in OP and
OR phenotypes are illustrated in Fig. 27.

II.

Mechanisms underlying decreased DAT function and increased

methamphetamine-induced DAT reverse transport in DIO

Extracellular levels of dopamine are primarily regulated by DAT function
(Sulzer et al., 2005). Importantly, DAT-deficient mice exhibit increased
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extracellular dopamine and greater food intake compared to wildtype-mice
(Pecina et al., 2003). Based on these prior observations, the hypothesis of the
current study was that striatal DAT function will be decreased and extracellular
dopamine levels will be increased in obesity. Consistent with this hypothesis,
both our current in vitro and in vivo results demonstrate decreased striatal DAT
function and increased extracellular dopamine levels following the development
of DIO. Since clearance of extracellular dopamine is primarily regulated by DAT
localized at the cell-surface of dopaminergic neurons (Zahniser and Sorkin,
2004), one explanation for the decrease in DAT function is a decrease in cellsurface DAT expression. Thus, the expectation was that obesity will be
associated with diminished impact of methamphetamine as a result of diminished
cell-surface DAT expression available for methamphetamine-induced reverse
transport.

Refuting the proposed hypothesis, the current results revealed increased
methamphetamine-induced DAT reverse transport in OP relative to OR striatum.
Obesity may differentially alter DAT functions, i.e., dopamine uptake and
dopamine reverse transport, by modulating the specific signaling mechanisms
that regulate these functions. In the current study, striatal dopamine uptake was
decreased in OP compared to OR, which could be explained by a decrease in D2
autoreceptor function in OP, considering previous observations that D2
autoreceptors regulate DAT function (Cass and Gerhardt, 1994).
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The decreased DAT function in OP relative to OR could be alternatively
explained by activation of PKC, which has been previously shown to decrease
dopamine uptake at hDAT expressed in Xenopus oocytes (Zhu et al., 1997). With
respect to DAT reverse transport, PKC activation is shown to increase
amphetamine-induced dopamine reverse transport in both striatal slices and HEK
293 cells transfected with DAT (Kantor and Gnegy, 1998; Khoshbouei et al.,
2004; Robertson and Galli, 2009). Thus, PKC activation may underlie the
unanticipated increase in methamphetamine-induced reverse transport of DAT in
the current study.

Another explanation for the decreased dopamine uptake and increased
methamphetamine-induced DAT reverse transport is differential partitioning of
membrane DAT into lipid-raft and non-raft micro-domains. Previous studies
suggest that cell-surface DAT can be fractionated into at least two different
micro-domains (i.e., raft and non-raft membrane compartments; Foster et al.,
2008). Rafts are composed of a greater percentage of lipids than the non-raft
compartments. DAT distribution was reported to be 35% in raft and 65% in nonraft striatal membranes from standard housed rats. Importantly, phosphorylation
of DAT by PKC is shown to occur to a greater extent in the lipid raft compartment
of the membrane, compared with the non-raft compartment (Foster et al., 2008).
Thus, DAT partitioning between lipid-raft and non-raft membrane compartments
may underlie the decrease in dopamine uptake and increase in
methamphetamine-induced reverse transport in obesity.
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III.

Pattern of neurobehavioral responses between OP, OR and LF

groups

The design of the current studies included the LF group only for the
evaluation of the outcomes of obesity, not for the evaluation of the predictors of
obesity. Since the LF-diet does not result in obesity; including the LF group in the
predictor studies simply would not have provided information about predictors of
obesity.

Generally, the pattern of response between OP and OR was consistent,
i.e., there was a difference between these groups and the direction depended on
the outcome measured. However, comparisons between OP and LF vs. OR and
LF were not always consistent in the studies that evaluated the neurobehavioral
outcomes of DIO. For several neurochemical outcome measures, including
dopamine uptake, DAT expression and extracellular dopamine concentration, no
differences were found between OP and LF groups. Also, no differences were
found between OR and LF groups on behavioral outcome measures of
impulsivity, nor for motivation for food. Thus, OP and OR rats were fed the HFdiet, and LF rats were fed the LF-diet, yet neither the OP nor the OR groups were
different from the LF group with respect to these neurobehavioral outcomes. An
interpretation of this result is that these outcome measures are not altered by the
diet per se, but instead, altered by the neurobiological mechanisms underlying
obesity.
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A different pattern emerged when comparisons were made between the
OP and LF groups for methamphetamine-induced reverse transport of DAT. The
effect of methamphetamine was lower in the OP group than in the LF group;
further, the effect of methamphetamine was lower in the OR group compared
with the OP group. Thus, an outcome of prolonged exposure to the HF-diet per
se may be a downregulation of the signaling mechanisms that regulate the
interaction of methamphetamine with DAT, resulting in decreased dopamine
release into the extracellular space in both OP and OR groups relative to the LF
group. Importantly, since the OP group exhibited a greater effect of
methamphetamine compared to the OR group, it appears that obesity mitigated
the effect of the diet per se on this specific outcome measure. Thus, both the
development of obesity and effects of the diet per se contribute to the observed
differential between-group effects of methamphetamine.

A somewhat different pattern emerged in the no net flux microdialysis
studies evaluating in vivo DAT function. In contrast to the pattern of effect for
methamphetamine, the OP group exhibited lower DAT function in vivo compared
with the LF group; however, the OR group was not different from the LF group,
indicating that the diet per se does not affect this outcome measure. Importantly,
the OP group exhibited a lower DAT function in vivo compared to the OR group
and this effect is not dependent on the diet since both OP and OR groups were
fed the HF-diet. Thus, obesity alone appears to contribute to differential in vivo
DAT function between the OP and OR groups.
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Overall, the LF group is comprised of an unknown distribution of both OP
and OR phenotypes. Based on sampling distribution, the pattern of response
might vary across experiments. Thus, cross-experiment direct statistical
comparisons to LF are inappropriate and were not conducted.

IV.

Alternate explanations for decreased impulsivity and increased food-

motivated behavior following the development of DIO

Increased sensitivity to palatable-food reward in obese humans is shown
to drive overeating only when accompanied by insufficient inhibitory control
(Appelhans et al., 2011). Based on prior reports, the hypothesis of the current
study was that high impulsivity may underlie the inability to resist excessive
eating in obesity. In contrast, OP rats demonstrated decreased impulsivity i.e.
increased choice for the larger delayed reward in the delay discounting task,
compared to OR rats. Consistent with the current results, decreased impulsivity
in a delay discounting task was reported in rats with excitotoxic lesions of the
OFC (Winstanley et al., 2004). Despite increases in the delay to the larger
reward, OFC-lesioned rats did not shift preference for the smaller immediate
reward, suggesting that the delay failed to devalue the large reward. Thus,
dysregulated OFC function may underlie decreased impulsivity in OP compared
to OR rats.
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In humans, self-reported impulsivity is shown to negatively correlate with
activation in different cortical areas that mediate inhibitory control that includes;
superior medial frontal gyrus, bilateral ventral PFC, dorsal amygdala, and right
dorsolateral PFC (Horn et al., 2003; Asahi et al., 2004; Brown et al., 2006).
Interestingly, higher BMI is shown to be associated with lower baseline
metabolism in PFC and cingulate gyrus, along with associated impairments in
inhibitory control processes (Volkow et al., 2009). Furthermore, a structural MRI
study reported lower gray matter density in the medial frontal gyrus of the PFC in
obese versus lean individuals, suggesting dysregulated inhibitory control in
obesity (Pannacciulli et al., 2006). Thus, impairments in neural systems that
mediate inhibitory control and executive functions may increase the vulnerability
to indulge in excessive eating behaviors (Wang et al., 2009). Mesocorticolimbic
function was not investigated in the current DIO model. Insight into these
alternate mechanisms may provide additional explanation for the observed
decrease in impulsivity following the development of DIO.

In the current study, sucrose reinforcers were employed during the delay
discounting task. Previous studies have investigated the influence of the quality
and quantity of the delayed reinforcer on the rate of discounting food rewards
(Calvert et al., 2010). The amount and quality of the delayed reinforcer employed
i.e., precision food pellets vs. cellulose; saccharin vs. quinine were varied across
experimental conditions (Calvert et al., 2010). Rate of discounting was derived as
a function of the amount and type of the reinforcer employed as well as the delay
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until the receipt of the food reinforcer (Myerson and Green, 1995). Despite
increased preference for precision food pellets over cellulose and for saccharin
over quinine, no differences in the rate of discounting for the different types of
reinforcer were found. These results suggest that the quantity and quality of the
reinforcer type do not influence discounting of the delayed reward. Thus, despite
increased preference for fat over carbohydrate diets (Okada et al., 1992),
employment of HF-reinforcers over sucrose pellets in the current study may not
have yielded different results with respect to impulsivity measured using the
delay discounting task.

In contrast to decreased impulsivity following the development of DIO,
increased food-motivated behavior was found in OP relative to OR rats. In the
current study, motivation for HF-reinforcers was determined as opposed to
sucrose reinforcers, since obesity is known to result from excessive consumption
of HF-diets. Decreased DAT function and increased extracellular striatal
dopamine levels may underlie increased food-motivated behavior in OP rats.
Dopamine is implicated in incentive motivation for food reinforcement (Wise,
2004). DAT-deficient mice that exhibit elevated extracellular striatal dopamine
levels also demonstrate enhanced PR responding for palatable foods, compared
to wildtype control (Caignard et al., 2006). Delta FosB is a transcription factor
that accumulates in dynorphin-expressing medium spiny neurons of both the NAc
and dorsal striatum upon repeated exposure to natural rewards or drugs of abuse
(Nestler, 2008; Perroti et al., 2008). DAT-deficient mice also exhibited increased
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delta FosB expression in the NAc-core and dorsal srtriatum, consistent with
previous reports that suggest upregulation of delta FosB expression upon chronic
dopaminergic stimulation (Nestler, 2008). Importantly, over expression of striatal
delta Fos B is shown to increase PR responding for palatable foods indicating
that delta FosB expression increases food-motivated behavior (Olausson et al.,
2006). Furthermore, increased striatal delta FosB expression was detected in
adult mice that had access to palatable HF or sucrose diets, and this effect was
associated with enhanced motivation for palatable foods (Wallace et al., 2008). In
addition to striatal delta FosB expression, additional intracellular signaling
cascades are implicated in modulating incentive motivation for food (Kenny,
2011). Dopamine receptor signaling in the striatum is shown to increase
motivational properties of food via inhibition of cyclin-dependent kinase 5 and
also via dephosphorylation of protein phosphotase 1 regulatory subunit 1B
(Benavides et al., 2007; Stipanovich et al., 2008). Taken together, activation of
transcriptional mechanisms as a result of decerased striatal DAT function,
increased extracellular dopamine levels and increased dopaminergic signaling
may underlie increased motivation for food reinforcement in DIO. On the other
hand, increased DAT function in OR relative to OP rats may enable the OR
phenotype to resist transcriptional modulation of food-motivated behavior,
despite exposure to the HF-diet.

V.

Neurobehavioral predictors of DIO
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Motivation for HF-reinforcers predicted the development of DIO; however,
impulsivity was not a predictive factor. Thus, neural systems that regulate
impulsivity may not regulate predisposition to DIO. Also, striatal DAT function and
extracellular dopamine concentration did not serve as predictors of DIO. Given
the role of striatal dopamine in food motivated behavior, motivation for HFreinforcers was not associated with corresponding increases in extracellular
striatal dopamine levels for the predictor study. A possible explanation for this
observation is that the dorsal striatum does not play a major role in primary
reward but appears to be recruited only during the development of compulsive
and habitual behaviors (Everitt et al., 2008). Importantly, striatal dopaminergic
mechanisms were recruited only after the development of DIO in the current
study, suggesting that these mechanisms facilitate the maintenance of habitual
and excessive food intake in obesity. Prior to an 8-wk exposure to the HF-diet,
alternate reward systems may modulate incentive motivational properties of HFreinforcers. NAc dopamine mediates primary reward and incentive motivation for
food reinforcers (Bassareo and Di Chiara, 1999). Thus, dopamine function in
alternate reward systems, that includes the mesocorticolimbic system, may serve
as predictors of DIO.

VI.

Neuroendocrine regulation of the striatal dopamine reward system

Given the interaction between homeostatic and reward systems, sustained
stimulation of dopamine reward circuits by adiposity hormones may underlie
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increased food-motivated behavior following DIO. Previous studies have
demonstrated defective central leptin- and insulin-signaling relative in OP relative
OR rats (Levin and Dunn-Meynell, 2002; Clegg et al., 2005). Metabolic hormones
that regulate energy homesostasis also have been shown to modulate the
activity of the dopamine reward system (Palmiter, 2007). Double-label studies
have demonstrated the co-expression of leptin and insulin receptors with tyrosine
hydroxylase, a marker of dopamine neurons (Figlewicz et al., 2003). Leptin
inhibits dopamine neuron firing rate and decreases extracellular NAc dopamine
levels (Krugel et al., 2003; Hommel et al., 2006). Intraventricular insulin
administration has been shown to increase DAT mRNA in rat VTA/substantia
nigra, suggesting insulin-mediated decreases in extracellular dopamine
concentration (Figlewicz et al., 1994). Also, local application of insulin to VTA
slice preparations revealed inhibition of evoked somatodendritic dopamine via
PI3K and mTOR activation (Mebel et al., 2012). Furthermore, this effect was
abolished in the presence of a selective DAT inhibitor, GBR 12909, as well as in
VTA slices of DAT knockout mice, suggesting that insulin regulates DAT function
(Mebel et al., 2012). Intracerebroventricular leptin and insulin infusion has been
shown to decrease sucrose self-administration and reverse CPP for HF-food
(Figlewicz et al., 2004, 2006). Knockdown of midbrain leptin receptors in rats has
been shown to increase PR responding for sucrose reinforcers (Davis et al.,
2011). Taken together, development of DIO and increased food intake may lead
to increased adiposity hormones stimulation of the reward circuitry, including
decreased DAT function and increased extracellular dopamine.
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VII.

Implications

The results from the current dissertation research imply that alterations in
striatal DAT function and extracellular dopamine concentration occur as a result
of DIO. Motivation for HF-food reinforcers predicted the development of DIO and
the greater level of motivation persisted following the development of DIO.
Decreased DAT function, increased extracellular dopamine concentration and
decreased striatal D2 receptors following the development of DIO may contribute
towards an increase in reward threshold in the OP phenotype. Overall, these
striatal dopaminergic alterations may underlie the maintenance of nonhomeostatic food intake in obesity.

VIII.

Limitations

In the current study, decreased striatal D2 receptor density was found
following the development of DIO. Striatal D2 receptor availability is known to
modulate reinforcing properties of food and govern vulnerability to addictive
behaviors (Volkow et al., 2003). Reduced striatal D2 receptors is believed to
produce a reward deficit such that this deficiency predisposes an individual to a
high risk of rewarding, compulsive addictive behaviors, like excessive indulgence
in palatable foods, in order to compensate for the understimulated dopaminergic
system (Blum et al., 2006; Volkow et al., 2008). Thus, decreased striatal D2
levels may have preceded the development of DIO and hence may serve as a
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predictor of DIO, which was not investigated in the current study. As a predictor
of DIO, striatal D2 receptor density can be evaluated prior to the 8-wk HF-diet
exposure, using positron emission tomography scanning. Also, the role of D1
receptors in obesity is not clear. Thus, in addition to D2 receptors, further studies
that investigate the expression and function of striatal D1 receptors in obesity are
needed.

The effect of methamphetamine on DAT reverse transport was evaluated
in the current DIO model. In addition to DAT reverse transport,
methamphetamine also decreases vesicular dopamine uptake and promotes
dopamine release from the vesicles (Sulzer et al., 2005). Striatal VMAT2 function
was not altered following the development of DIO. However, the effect of
methamphetamine on VMAT2 function following the development of DIO was not
investigated. Thus the current study provides limited understanding of the role of
striatal VMAT2 in DIO.

Extracellular striatal dopamine levels were evaluated as a function of
dopamine uptake mechanisms. Synthesis, metabolism and release mechanisms
also contribute towards extracellular dopamine levels; however these
mechanisms were not investigated in the current study. Importantly, D2
autoreceptor-stimulation exerts a negative feedback on dopamine
neurotransmission by inhibition of dopamine synthesis and release and increases
in DAT function (Dwoskin and Zahniser, 1986; Meiergerd et al., 1993; Cass and
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Gerhadt, 1994). Further studies investigating D2 autoreceptor function in the DIO
model are needed to provide better understanding of mechanisms that contribute
towards decreased DAT function and increased extracellular DA levels in
obesity.

Given that total DAT protein levels were decreased in OP relative to OR
rats, this effect was not localized to either the cell-surface or the intracellular
locus using the biotinylation assay. The biotinylation assay enables the isolation
of a relatively purified cell-surface fraction as opposed to the intracellular fraction.
As such, lack of corresponding alterations in intracellular DAT levels may have
been overlooked during the biotinylation assay due to technical limitations.

Altertations in E d values obtained in the no net flux microdialysis assay
reflect changes in tissue resistance mechanisms that include tortuosity and
uptake mechanisms (Bungay et al., 1990; Chefer et al, 2009). Considerable
evidence demonstrates the influence of uptake mechanisms on E d (Bungay et
al., 2003). However, it is also likely that tissue lipid content may have contributed
towards alteration in tissue tortuosity thereby resulting in corresponding
alterations in E d values in the current study (e.g., decrease in tortuosity will
increase E d values and vice-versa). The influence of tissue tortuosity on
alterations in E d is unclear. Also, theoretically, as E d approaches 1 the source of
resistance to diffusion may switch to the membrane (Bungay et al., 1990). Thus,
alterations in E d may not reflect resistance mechanisms in the tissue alone.
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However, it is not clear when this switch occurs. Therefore, it is likely that E d
values closer to or greater than 1 may represent a ceiling effect under the
experimental conditions employed.

In the current study, extinction procedures were conducted following the
PR schedule of reinforcement which complicates the interpretation of the
extinction results. Importantly, OP and OR rats exhibited different levels of
responding during the PR schedule such that extinction training started at
different levels for these groups. Alternatively, rats can be trained on a FR
schedule (eg. FR5) that would first equlaize responding between the two groups,
following which extinction procedures can be conducted.

IX.

Future directions

Future studies may include experiments that elucidate alternate
mechanisms that underlie altered DAT function following the development of
DIO. Cell-surface DATs are distributed into lipid-raft and non-raft microdomains
(Foster et al., 2008). Greater phosphorylation of DAT by PKC occurs in the lipidraft compared to the non-raft compartment. Importantly, PKC activation
decreases DA uptake and increases amphetamine-induced DA reverse transport
(Zhu et al., 1997; Khoshbouei et al., 2004). Taken together, an alternate
interpretation of decreased DA uptake and increased methamphetamine-induced
DA reverse transport in DIO is that cell-surface DAT in the OP striatum may be
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localized to the lipid raft, relative to the non-raft microdomain. DAT localization in
lipid raft and non-raft microdomains could be investigated in the DIO model,
using discontinuous sucrose density centrifugation of striatal synaptosomal
preparations (Foster et al., 2008). Different gradient fractions obtained could be
assayed for DAT protein by Western blot analysis. Lipid composition of intact
striatal tissue and isolated membrane rafts could be determined using mass
spectrometry to further elucidate the effects of HF- and LF-diets on DAT function
and localization.

To the extent that the dopamine reward system is malleable, interventions
that increase striatal DAT function and thereby normalize dopaminergic
transmission may be efficacious in the treatment of obesity. Drugs that increase
DAT function, for example, D2 agonists (Meiergerd et al.1993; Cass and
Gerhadt, 1994), may serve as potential treatment options for obesity. Importantly,
acute administration of bromocriptine, a D2 receptor agonist, is shown to
normalize obesity-associated metabolic profile abnormalities through
mechanisms independent of body weight and food intake (Kok et al., 2006).
Based on current results, D2-agonists can be evaluated for their ability to
normalize DAT function, extracellular dopamine concentration and foodmotivated behavior in DIO. Presynaptic D2 receptors are high affinity receptors
compared to postsynaptic receptors. In order to achieve selective stimulation of
D2 autoreceptors lower doses of D2 agonists can be evaluated.
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In addition to decreases in food intake, increases in energy expenditure is
also critical for obesity intervention. There is considerable evidence that suggests
environmental enrichment as a potential behavioral intervention for the
prevention and treatment of obesity. Novel stimuli provided in an enriched
environment are shown to increase physical activity and dopamine release in
reward-relevant pathways (Rebec et al., 1997). Furthermore, environmental
enrichment is shown to decrease body weight and produce alterations in DAT
function in rats fed standard chow. Also, rats exposed to environmental
enrichment during development are shown to be protected against the rewarding
effects of stimulant drugs of abuse (Bardo et al., 2001; Zhu et al., 2004, 2005).
Enrichment-induced protection may result directly from increases in physical
activity and/or alterations in the dopamine reward system. Considering the
common dopamine reward circuitries underlying drug addiction and obesity,
environmental enrichment can be evaluated as a potential preventive and
treatment strategy for obesity.

X.

Final comments

The current dissertation research delineates striatal dopaminergic and
behavioral mechanisms as outcomes and predictors of obesity. Results
demonstrate that motivation for high-fat food, but not impulsive behavior, predicts
DIO and that a higher level of motivation for food persists after the development
of obesity. Interestingly, obesity results in decreased striatal DAT function, which
may underlie the maintenance of habitual, compulsive food intake associated
212

with obesity. Pharmacological and behavioral interventions counteracting the
alterations in striatal dopaminergic function may prove efficacious in the
treatment of obesity.
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Figure 27
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Figure 27: Schematic of DIO effects on striatal DA. Striatal D2 receptor density
and DAT function were decreased and extracellular DA concentration increased
in OP compared to OR. Cell-surface DAT expression and VMAT2 function were
not different between OP and OR. Closed dots represent DA.
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